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 Abstract  
To determine the effect rotational correlation time (τR) has on relaxivity, peptides of 
different lengths were investigated. Extending the length of the peptide had a negligible 
impact on folding, stability and inner-sphere water coordination. The relaxivity was found to 
be the same indicating that τR is not the limiting factor in this class of contrast agent.  
A peptide was designed with the potential to increase secondary sphere water 
coordination to the peptide exterior. No change in relaxivity was observed, compared to MB1-
2, due secondary sphere H2O being located at too far from the paramagnetic Gd(III).  
Secondary sphere water coordination was further investigated when a water channel 
was identified. The channel allows water to come within close proximity of Gd(III), with the 
potential to increase relaxivity. D-amino acids were introduced in an attempt to block the 
water channel, but this had little impact.  
Finally, the biological activity of the peptides in biological systems was investigated. It 
was found that increased transmetalation occurred when the Gd(III) binding site was located 
at the N-terminus of the coiled coil. Cell lines were treated with Gd(MB1-1)3 at MRI relevant 
concentrations and cell death occurred when treated with clinically relevant concentrations 
of the metallo peptide. 
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Chapter 1: Literature Review 
1.1 Introduction 
 Magnetic resonance imaging (MRI) is a technique at the forefront of medical 
diagnosis.1 MRI was developed in the 1950’s as an in vivo imaging technique, building on 
nuclear magnetic resonance (NMR) methodology.2 MRI uses radio frequency waves as a 
source of excitation; this is a non-invasive technique that has been shown to have no 
detrimental effects on the patient.3 This makes it more attractive than other imaging 
techniques, for example, computed tomography (CT) which uses X-rays, and positron emission 
tomography (PET) which uses radioactive markers.4 This chapter will introduce and review 
MRI contrast agents (CAs), with specific focus on lanthanide metallopeptides.  
1.2 The Lanthanides  
The lanthanides are becoming more and more popular in biomedical research because 
of their interesting chemical, magnetic and photo-physical properties, which have led to uses 
in medical imaging. They are most stable in their +3 oxidation state.5 Because of the poor 
shielding of the nucleus by 4f electrons, as the atomic number increases across the series, the 
distance between outer electrons decreases and the atomic radii decreases. This is known as 
lanthanide contraction.5–7  
Despite their differences in size across the series, the lanthanides have comparable 
chemical properties, because of the 5s and 5p shielding of the outer 4f electrons. This allows 
a general lanthanide binding site to be developed. An ideal binding site will have a 
coordination number of more than six, be made of hard oxygen and nitrogen atoms, and will 
facilitate electrostatic bonding.5,7  
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The photo-physical properties of the lanthanides are due to electronic transitions and 
results in luminescence. Due to the Laporte Rule, f-f transitions are spin forbidden, resulting 
in weak emission. In order to overcome this, a sensitiser can be used. A sensitiser works by 
transferring energy from a strongly absorbing chromophore to the lanthanide, resulting in 
increased emission.8 The sensitiser often contains an aromatic ring, as this will have a high 
extinction coefficient for absorption in the UV region.8 In order for sensitisation to take place 
the sensitiser and lanthanide must have an overlap in energy emission and absorption. 
Organic fluorophores such as the amino acid tryptophan, shown in Figure 1.1, are often used 
and can be characterised by a high molar absorption, short lived excited state, and a neutral 
charge.9  
 
Figure 1.1: The amino acid tryptophan. 
Ln(III) emission is long lived (millisecond) due to Laporte forbidden transitions. This is 
advantageous in biological samples as it leads to better signal to noise and resolution. Tb(III) 
emission is most commonly studied as its low lying excited states lead to emission in the visible 
region.10 Gd(III) has a high energy excited state which results in emission in the UV region. 
Tb(III) is often used as a model for Gd(III) luminescence as it is hard to find sensitisers with 
excited states of a high enough energy to allow for energy transfer to Gd(III).6,7  
1.3 Relaxation Theory in MRI 
NMR was first discovered in 1946 (Bloch, Hansen, Packard and Purcell, Torrey, Pound), 
and led to Bloch and Purcell sharing the Nobel Prize in physics for their work in 1952.11,12 To 
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understand the process of how MR images are formed, a basic understanding of the theory of 
NMR is required.13 See Chapter 2 for further information.  
Most commonly, MRI uses NMR to image 1H nuclei in water and organic molecules, 
such as lipids and proteins, inside the body.3 Contrast in MRI is related to the relaxation times 
(longitudinal relaxation time (T1) and transverse relaxation time (T2)) of in vivo protons, proton 
density and instrument parameters.3 T1 describes the process by which net magnetisation 
returns to its initial maximum value.13 T2 describes the process by which the transverse 
components of magnetisation decay.13 Relaxivity is defined as the change in relaxation rate of 
bulk water protons upon addition of a CA; this is normalised to the concentration of the CA 
and reported as r1 and r2, respectively. T1 and T2 vary depending on the type of tissue being 
studied. For example, fat has a short T1 and T2 compared to water. Metal complexes can 
enhance contrast by shortening the T1 and T2 relaxation times of water through electron-
proton dipolar coupling. Contrast agents that primarily reduce T1 are called positive, whereas 
those that mostly affect T2 are called negative.3  
The Solomon-Bloembergen-Morgan (SBM) equations, established in the 1960’s, define 
the interaction of paramagnetic metals with bulk water in MRI.14 The equations consist of a 
number parameters, three of which can be synthetically modified when designing a CA: the 
hydration of the metal ion (q), the rotational correlation time (τR)  and the mean residence 
time of water (τm).15,16  
In the SBM equations, water interactions can be divided into two mechanisms. The 
inner-sphere relaxation mechanism (𝑟𝑖
𝐼𝑆)  takes advantage of interactions between the Gd(III) 
ion and the water molecules directly coordinated to the ion.17 The outer sphere mechanism 
(𝑟𝑖
𝑂𝑆)  uses the interactions between the water located in the second and outer sphere which 
is diffusing in proximity to the CA construct, these interactions are shown in Figure 1.2.18  
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Figure 1.2: Factors influencing solvent water relaxation based on [Gd(DOTA)]. The metal complex has 
one coordinated water molecule distance r away from Gd(III). Primary water exchange occurs with 
the bulk water at a rate of 1/τm and the rotational correlation time is indicated by τR. Properties of 
the Gd(III) ion such as the primary and secondary electronic relaxation time (T1e, T2e) also influence 
relaxivity. Secondary sphere effects also influence relaxivity such as secondary water exchange 
(1/τ’m) and the Gd(III) H2O’ distance (r’). 
The inner-sphere relaxivity (𝑟𝑖
𝐼𝑆) of a CA is controlled using the inner-sphere relaxation 
mechanism. This takes into account the number of bound water molecules (q), the molar 
concentration of bulk water ([H2O]), the longitudinal relaxation time of bound water (Tim), and 
the water residence time (τm),19 as given in Equation 1.1. 
Equation 1.1:     𝑟𝑖
𝐼𝑆 =
𝑞/[𝐻2𝑂]
𝑇𝑖𝑚+𝜏𝑚 
 𝑖 = 1,2 
When considering the longitudinal relaxation time (T1m) at fields higher than 1.5 T, the 
dipolar relaxation mechanism (𝑇1
𝐷𝐷) will dominate for Gd(III) contrast agents (GdCAs).20,21 This 
is represented in Equation 1.2, where μ0 is the permittivity of the vacuum, γH is the 
magnetogyric ratio of a proton, ge is the electronic G-factor (2 for Gd(III)), μB is the Bohr 
magneton, S is the spin quantum number, rMH is the ion-proton distance, τC is given in Equation 
1.7, and ωH is the Larmor frequency of a proton.       
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Equation 1.2:   
1
𝑇1
𝐷𝐷 =
2
15
(
𝜇0
4𝜋
)
𝛾𝐻
2 𝑔𝑒
2𝜇𝐵
2 𝑆(𝑆+1)
𝑟𝑀𝐻
6 [
3𝜏𝐶
1+𝜔𝐻
2 𝜏𝑐
2] 
The SBM theory failed to accurately describe the transverse relaxation time (T2m) so 
the SBM equations were adapted by Gueron and the mechanism of Curie spin relaxation (T2CS) 
was introduced.22 Three mechanisms contribute to T2m and 1 𝑇2𝑚⁄
= 1
𝑇2
𝐷𝐷⁄ + 1 𝑇2
𝑆𝐶⁄ + 1 𝑇2
𝐶𝑆⁄ , 
shown further in Equations 1.3 – 1.10, where τSC  is the scalar coupling correlation time, τCS is 
the Curie spin correlation time, τR is the rotational correlation time, τm is the water residency 
time, τie is the electronic relaxation time, (A/ ℏ) is the hyperfine coupling constant, Δ is 
determined from crystal field effects, ωS is the Larmor frequency of an electron and τV is the 
correlation time related to the zero field splitting. A detailed review of the explanation of these 
factors has been published by Aime and co-workers.16 
Equation 1.3:   
1
𝑇2
𝐷𝐷 =
1
15
(
𝜇0
4𝜋
)
𝛾𝐻
2 𝑔𝑒
2𝜇𝐵
2 𝑆(𝑆+1)
𝑟𝑀𝐻
6 [4𝜏𝑐 +
3𝜏𝑐
1+𝜔𝐻
2 𝜏𝑐
2] 
Equation 1.4:    
1
𝑇2
𝑆𝐶 =
1
3
(
𝐴
ℏ
) 𝑆(𝑆 + 1)(𝜏𝑆𝐶) 
Equation 1.5:               
1
𝑇2
𝐶𝑆 =
1
5
(
𝜇0
4𝜋
)
2 𝜔𝐻
2 𝑔𝑒
4𝜇𝐵
4 𝑆2(𝑆+1)2
(3𝑘𝐵𝑇)2𝑟𝑀𝐻
6 (4𝜏𝐶𝑆) 
Where: 
Equation 1.6:     
1
𝜏𝐶
=
1
𝜏𝑅
+
1
𝜏𝑚
 
Equation 1.7:           
1
𝜏𝑆𝐶
=
1
𝜏𝑚
+
1
𝜏𝑖𝑒
 𝑖 = 1,2 
Equation 1.8:    
1
𝜏𝐶𝑆
=
1
𝜏𝑅
+
1
𝜏𝑚
 
Equation 1.9:   
1
𝑇1𝑒
=
Δ2(4𝑆(𝑠+1)−3)
25
(
𝜏𝑉
1+𝜔𝑆
2𝜏𝑣
2 +
4𝜏𝑉
1+𝜔𝑆
2𝜏𝑣
2) 
Equation 1.10:   
1
𝑇2𝑒
=
Δ2(4𝑆(𝑠+1)−3)
50
(
5𝜏𝑉
1+𝜔𝑆
2𝜏𝑣
2 +
2𝜏𝑉
1+4𝜔𝑆
2𝜏𝑣
2 + 3) 
~ 6 ~ 
 
CAs are able to enhance relaxivity when q = 0, therefore, outer sphere water 
coordination must be important.23 This can take two forms (1) second sphere water relaxation, 
described in Equation 1.11, with prime indicating second sphere, and (2) outer sphere water 
relaxation, i.e. bulk water.15,16  
Equation 1.11:    𝑟𝑖
𝑆𝑆 =
𝑞′/[𝐻2𝑂]
𝑇𝑖𝑚
′ +𝜏′𝑚 
 𝑖 = 1,2 
Outer sphere relaxivity is estimated using the equations proposed by Freed,24 and is 
dictated by water exchange and the distance between Gd(III) and the water molecule.15,16 A 
thorough explanation of outer sphere contributions can be found in the works of Freed,24 
Aime16 and Caravan.15 
1.3.1 T1 Specific Contrast Agents  
Magnevist was first designed in the 1980’s as a T1 specific CA. It is made up of 
diethylenetriaminepentaacetic acid (DTPA) as a chelate around Gd(III), 25,26 shown in Figure 
1.3(a). By using eight of the available donating sites of DTPA to coordinate to Gd(III), a single 
site remains, allowing for primary water coordination and exchange. This exchangeable water 
is used to transfer T1 relaxation of Gd(III) to the bulk water. Gd(III) has the ability to reduce T1 
of 1H nuclei substantially because of the large magnetic moment of the seven unpaired 
electrons.25,26  
The acquisition of a T1 weighted image is enhanced by GdCAs due to the shortening of 
the T1 relaxation rate of the water that interacts with the GdCA. Water located in different 
tissues will not interact with a GdCA in the same way due to different compositions of tissue 
and concentrations of water, and so relaxation times will differ. A MRI pulse sequence can be 
designed to image only the fast relaxing nuclei, allowing for specific tissue imaging.27  
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1.3.2 T2 Specific Contrast Agents  
T2 based CAs are most typically based on superparamagnetic iron oxide (SPIO) 
particles. The field inhomogeneity of SPIOs alters the magnetic field, dephasing the water 
signal and altering the T2 of associated water.28,29 All SPIO CA have been removed from the 
clinics due to concerns regarding toxicity.  
In this work, the focus is on new Ln(III) based CAs for use as T2 CA. Gd(III) can be used 
for T2 contrast, in addition to those Ln(III) that produce a hyperfine shift, such as Dy(III), Tm(III) 
or Tb(III). A hyperfine shift is the difference in chemical shift between the nucleus of a 
paramagnetic molecule and that in a diamagnetic analogue. For example, primary sphere 
water that has been influenced by the paramagnetic Ln(III) and bulk water. The large 
difference in frequency between bound and bulk water creates a powerful T2 CA because of 
the dephasing which occurs during water exchange.29 
1.4 Current Gd(III) Contrast Agents 
 
Figure 1.3: Structures of the MRI CAs, (a) [Gd(DTPA)]2- and (b) [Gd(DOTA)]. 
Commercial CAs consist of a Gd(III) metal centre with an octadentate heteroatom 
organic chelator. The octadentate structure allows for q = 1. There are currently nine CAs on 
the market, listed in Table 1.1, all based on Gd(III) with slight structural differences of the 
(a) (b) 
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ligand. These approved CAs are injected at hundred millimolar concentrations, required due 
to their low efficiencies.30 
Table 1.1: The 9 clinically approved GdCAs currently on the UK market  
Contrast Agents Clinical Name 
Gadoterate Dotarem 
Gadodiamide Omniscan 
Gadobenate MultiHance 
Gadopentetate Magnevist 
Gadoteridol ProHance 
Gadoversetamide OptiMARK 
Gadobutrol Gadovist [EU] / Gadavist [US] 
Gadopentetic acid dimeglumine Magnetol 
Gadofosveset  Ablavar / Vasovist 
 
The negatively charged [Gd(DTPA)]2- (Magnevist) and [Gd(DOTA)] (Dotarem) were the 
first GdCAs to be used in the clinics; their structures are shown in Figure 1.3.31 The DPTA ligand 
is commercially available, however, the preparation of DOTA is time consuming.32 These first 
generation CAs are extremely useful in medical diagnostics and have accounted for the 
increased use of MRI. They distribute in the intravascular space and are non-specific, however, 
they can concentrate in the kidneys due to the elimination process of glomerular filtration.28 
1.5 Approaches to Enhanced Contrast  
Since the introduction of a range of different imaging techniques during the twentieth 
century, medical applications have been of high importance in imaging research. Different 
techniques have been optimised for various uses, for example, increasing the resolution of CT, 
increasing depth penetration of optical imaging and improving the sensitivity of MRI.33 
Ultimately all imaging modalities have turned to CAs, to increase  the effectiveness of the 
technique in the clinics.4  
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A MRI CA is most effective when it has a high relaxivity and a high kinetic and 
thermodynamic stability. This means that a lower dose can be administered and the CA safely 
excreted, intact after imaging.30 It has proven difficult to find a CA with all of these 
properties.34 Many CAs have problems with solubility in blood, which is a challenging obstacle 
for administration.  
Gd(III) is highly toxic in its aqueous form5 and is similar in size to Ca(II), allowing Gd(III) 
to move easily through Ca(II) channels in cell membranes and disturbing Ca(II) pathways and 
cell messaging. Gd(III) toxicity is linked to Nephrogenic Systemic Fibrosis (NSF).35,36 This is a 
disease of fibrosis of the skin and internal organs and is caused by Gd(III) exposure in patients 
who have renal failure. NSF can occur due to imaging with a GdCA, therefore, Gd(III) must 
remain coordinated to a ligand to avoid toxicity.37 
The ability of a CA to influence magnetic resonance relaxation times is categorised by 
its corresponding relaxivities, r1 and r2. The aim of optimising a new CA is to maximise these 
values. This can be achieved by modifying the parameters defined in the SBM equations: water 
coordination (q), water residence time (τm) and rotational correlation time (τR).14,15,38  
1.5.1 Water Coordination 
There are three water spheres that can be defined in a GdCA.39 The inner, or primary, 
sphere comprises of water which is directly coordinated to Gd(III). The secondary sphere 
contains water hydrogen bonded to the CA construct or primary water, where the residency 
time is longer than the diffusional correlation time of bulk water. The outer sphere is less 
organised and water freely diffuses.40  
The importance of q has previously been highlighted through the analysis of a complex, 
based on DTPA, with the ability to conjugate to human serum albumin (HSA) through a 
~ 10 ~ 
 
diphenyl phosphate group. In the absence of HSA, the metallo complex had q = 1. When HSA 
bound to the complex, water coordination was blocked leading to q = 0. This reduction in q 
was accompanied by a reduction in r1 from 6 to 2 mM-1 s-1.41 The difference in rotational 
correlation time, due to the binding of a large protein, was shown to have no impact on 
relaxivity in this example. 
Many of the CA’s currently on the market have q = 1.14 It was proposed that when 
more water is located in the inner-sphere, relaxivity would increase and the CA would be less 
stable. Additionally Gd(III) would become less shielded and more likely to transmetalate.15 
There have been examples of stable CAs with q = 2, attractive as the coordination of more 
inner-sphere water molecules enables the relaxivity of the CA to be enhanced.16 By using hexa- 
or hepta-coordinate ligands, complexes with q = 2 or 3 can be developed, this is often 
associated with a decrease in thermodynamic and kinetic stability. In one example, a 
derivative of DOTA, [Gd(DO3A)] with three pendant arms and q = 2, led to a r1 of twice that of 
[Gd(DOTA)] (where r1 = 4.74 mM-1 s-1) whilst maintaining a high stability constant.42 Another 
example is a q = 3 complex of hydroxypyridinone (HOPO) ligands capped with triazacyclonane 
groups. The r1 was found to be three times higher (9.9 compared to 3.3 mM-1 s-1) than that of 
[Gd(DTPA)]2-. This can be attributed to fast water exchange and a high q. In comparison, r2 was 
found to be four times higher (16.0 compared to 3.5 mM-1 s-1) due to the additional influence 
of outer sphere effects. In this example, despite the increase in q, the stability constant 
remains high enough for clinical use.43  
Secondary sphere water also plays a significant role in relaxivity. Secondary sphere 
water effects arise from water which can interact with inner-sphere water or the CA scaffold. 
Secondary sphere water is influenced by the paramagnetic effect of the Ln(III), and its 
contribution is predominantly due to the exchange rate of secondary sphere water and its 
~ 11 ~ 
 
distance from Gd(III).20,21 Using an analogue of [Gd(DTPA)]2- with q = 0, [Gd(TTHA)]3-,39 it was 
determined that a third of the relaxivity at low fields and a quarter of the relaxivity at high 
fields could be attributed to secondary sphere water.44  
Botta and co-workers found that through the careful selection of hydrogen bond 
acceptor groups on a GdCA it is possible to: promote the formation of a strong interactions; 
increase the number of water molecules in the second hydration shell; and decrease their 
average distance from the paramagnetic metal centre.45 They concluded that despite 
secondary sphere water playing only a small role in determining the relaxivity of GdCA, it is 
important to consider for a more realistic interpretation of relaxation data and for a better 
understanding of the structure-relaxivity relationship.45 Large increases in relaxation are 
possible due to secondary sphere water interactions and can be optimised through exploiting 
strong interactions with suitable side chains such as phosphonate and carboxoamide lignds.45  
Botta and co-workers also concluded that secondary sphere water effects play an 
important role when small GdCA interact with macromolecules, such as BSA, which results in 
an increase in relaxivity. The increase could not be attributed to inner or outer sphere water 
spheres but was instead attributed to the exchangeable protons close to the interaction site 
of the complex and from a network of hydrogen bonded water molecules in the second sphere 
of the GdCA.45 This contribution is only detected in the presence of the protein because of the 
reduced mobility of its well-structured hydration layer. 
1.5.2 Water Residency Time and Exchange 
Water residency time (τm) is defined as the average time an individual water molecule 
is coordinated to the metal centre before it exchanges with the bulk.40,46 τm directly impacts τC 
and determines the total number of water molecules that are influenced by the metal centre. 
If τm is too long, there will only be a small effect on the bulk water. If τm is too short, water 
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molecules will not be sufficiently relaxed before they exchange, with both scenarios leading 
to poor relaxivity. Therefore, there is an optimum τm window which changes with τR, as shown 
in Figure 1.4. At high fields, relaxivity is largest when τm is equal to the inverse of the Larmor 
frequency.  
 
Figure 1.4: An optimum window for water residency time occurs for varying rotational correlation 
times. Figure reproduced with permission from Caravan, P. Chem. Soc. Rev. 2006, 3, 512–523.   
τm is dependent on complex charge and solvent accessibility. This was demonstrated 
by replacing acetate oxygen ligands with amine groups to decrease τm, or in another example, 
using phosphate oxygens to increase τm.39 By using hydrophilic or hydrophobic side chains, or 
conjugating proteins to the CA, τm can be slowed due to hydrogen bonding of water to the 
complex, or sterically blocking water access.47,48 This was also demonstrated in the work by 
Lukes and co-workers, where a carboxylic acid group was substituted with a phenyl containing 
a phosphate group on one arm of DTPA.49 This reduced τm from 303 to 90 ns. The same was 
observed when a monophosphonic acid group was introduced into a macrocyclic DOTA 
complex. This reduced τm from 37 to 14 ns. In this example, the decrease in water residency 
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time was thought to be due to the steric conformation of the ligand forcing the DOTA analogue 
into a conformer which allowed better solvent access to the metal centre.50,51 
The direct observation of water exchange at a Cd(II) binding site within a de novo 
designed coiled-coil has recently been performed by Hemmingsen and co-workers, using 113Cd 
NMR spectroscopy.52 The water residency time was calculated to be on the scale of 10 ns and 
was the first direct experimental observation of the residence time of water coordinated to 
Cd(II) in any system.52 It was found that a substitution of leucine for alanine, 10 Å below the 
metal binding site, resulted in a change in the equilibrium constant and the water residence 
time, despite the metal binding site remaining unchanged. By using de novo designed proteins 
and NMR, it was established that nanosecond water exchange times can be determined for 
water binding to metals within coiled coils and that these exchange reactions can be 
controlled by amino acid substitutions that occur several residues away from the metal 
binding site.52 
1.5.3 Rotational Correlation Time 
Large CAs normally exhibit slow rotational correlation times (τR), which can increase 
inner-sphere relaxivity. This has been observed when large Gd(III) complexes are used, with a 
τR of 10 ns, compared to τR of 0.1 ns for [Gd(DOTA)], and an increase in relaxivity is observed.40 
The rotation of a molecule is defined by its size and shape. For a spherical molecule τR can be 
determined by considering viscosity (η), radius (r3), the Boltzmann constant (KB) and 
temperature (T), as shown in Equation 1.12. 
Equation 1.12: 𝜏𝑅 = 4𝜋𝜂𝑟
3/3𝑘𝐵𝑇 
τR is increased by increasing the size of the molecule, for example through the 
conjugation of a macromolecule. Examples of such work include dendrimers,48 proteins53 and 
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nanoparticles.54 The addition of such macromolecules provides a large degree of synthetic 
versatility which can be taken advantage of for multimodal imaging, drug delivery and 
therapeutics.55  
When used in biological applications, dendrimers often have functionalised terminal 
groups such as hydroxyl groups which allow for increased solubility,56 Raymond and co-
workers described a Gd(hydroxypyridinone)-based chelate coordinated to a dendrimer which 
contained 12 hydroxyl groups, allowing for adequate solubility.57 A relaxivity three times 
higher than commercial agents was reported. The dendrimer based CA was most efficient at 
a field strength of 90 MHz, which makes it one of the first published CAs which features fast 
water exchange and high relaxivity when used at higher magnetic fields. 
A significant amount of research has been conducted using [Gd(DTPA)]2- derivatives 
conjugated to HSA.15 There are a number of examples of small molecule contrast agents that 
bind to HSA, resulting in an increase of the rotational correlation time and an increase in 
relaxivity, for example, MS-325 (7 times increase in relaxivity on binding) and MP-2269 (3 
times increase in relaxivity on binding), structures shown in Figure 1.5.15 When using MP-2269 
it was calculated that the rotational correlation time was 1 ns, 7 times longer than the 
unbound complex and that the water residence time did not change upon binding. It has also 
been shown that increasing the number of benzyloxymethyl (BOM) groups onto DTPA in the 
presence of HSA increases relaxation. Two derivatives of [Gd(DTPA)]2-, one with one BOM 
group and the other with three, both showed an increase in relaxivity. The derivative with 
three BOM groups had a higher relaxivity and was more rigidly bound; reducing internal 
motion. Additionally, on binding to HSA the relaxivity of the complex increased from 8 mM-1 
s-1 to 54 mM-1 s-1.  
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Figure 1.5: (a) MS-325 and (b) MP-2269 ligands. 
When increasing τR, for example by coordination to a polymer, dendrimer, or 
macromolecule, there may be fast internal motion, for example, side chain rotation, coupled 
with the overall rotation of the macromolecule.58 In the SBM equations, τC is a function of the 
overall motion of the macromolecule and the internal motion.15 This may be approximated 
using a model free approach where a second spectral density term is added to account for the 
fast motion. 
Magnetic field strength impacts the effect of changing τR. At low field slowing the 
rotation increases relaxivity, however, at higher fields r1 and r2 are impacted differently. This 
was demonstrated by Uppal and co-workers who simulated the effects of different τR at 
different field strengths, as shown in Figure 1.6. It was found that r2 was consistent over a 
range of field strengths (1 - 15 T), and a dramatic decrease in r1 was demonstrated when τR 
was slow.40  
(a) 
(b) 
~ 16 ~ 
 
 
Figure 1.6: The change in (A) r1 and (B,C) r2 as a function of field strength. r2 is highly dependent on 
water residence times, due to a scalar contribution, but there is no effect on r1. Rotational 
correlation times of 0.1 ns (dashed), 1.0 ns (grey line) and 10 ns (black line) with a water residency 
time of (B) 5 ns or (C) 100 ns. Figure reproduced with permission from Caravan, P.; Farrar, C. T.; 
Frullano, L.; Uppal, R. Contrast Media Mol. Imaging 2009, 4 (2), 89–100. 
1.6 Lanthanides as MRI Contrast Agents 
Gd(III) is the most common Ln(III) used in MRI, however some of the other Ln(III)’s also 
have the ability to enhance signal. In one example, the magnetic field dependence of r1 and r2 
was investigated in Dy(III) analogues of Gd(III) complexes.59–61 Dy(III) has a highly efficient 
transverse relaxivity at high field strengths.62 Clinical MRI is constantly using higher magnetic 
fields, therefore new CAs need to be developed and optimised for higher field strengths where 
current GdCAs may fail. Dy(III) based complexes are becoming more popular as they display 
long water residence times resulting in an increase in relaxivity.62  
Dy(III) is not the only Ln(III) which has the potential to be used in MRI, however, the 
mechanism by which contrast occurs is different. For Gd(III), T1 and T2 are due to water 
exchange between the CA and bulk water, described in the inner-sphere relaxation. The inner-
sphere mechanism is also responsible for T1 of Dy(III), Ho(III), Er(III) and Tb(III).63 However, T2 
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is caused by the diffusion of water in the field inhomogeneities created by the CA, described 
in the outer-sphere relaxation mechanism.63  
The T1 relaxation induced by Dy(III), Ho(III), Er(III) and Tb(III) is almost 100 times less 
efficient than for Gd(III).63 This is due to the different electron relaxation times of the ions: 
long for Gd(III), 176 ps, and short for the remaining lanthanides (<<20 ps).63 As the inner-
sphere relaxation rate is proportional, at low field, to the shortest correlation time, which is 
the electronic relaxation time for Dy(III), Ho(III), Er(III) and Tb(III), the r1 is negligible. This can 
be compared to Gd(III)  which has r1 of 4 - 40 s-1 mM-1 at 1.5 T.64 
Gd(III) has a high T2 relaxation rate, where the inner-sphere water mechanism is the 
dominant process.63 However, for Dy(III), Ho(III), Er(III) and Tb(III) T2 relaxation is due to the 
outer sphere mechanism. When using the outer sphere mechanism, r2 increases quadratically 
with increasing field strength, making these lanthanides most efficient at high fields.63 
Additionally, the outer sphere mechanism for T2 is proportional to the square of the radius; 
very small CAs (radius <5 nm) containing Dy(III), Ho(III), Er(III) and Tb(III) will be inefficient, (r2 
< 20 s-1 mM-1) even at high fields.  
It is thought that the outer sphere mechanism dominates for T2 of Dy(III), Ho(III), Er(III) 
and Tb(III) because of the difference in the electron relaxation times, which cause negligible 
inner-sphere relaxation rates for these compounds compared to the outer-sphere 
contribution, due to the mean magnetic moment of the CA. One major drawback of using 
these Ln(III) is their toxicity. Without strong binding, the Ln(III) could be released in vivo 
causing a toxic response.65 A summary of the properties of the lanthanides of interest is shown 
in Table 1.2 
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Table 1.2: A summary of the properties of a number of different lanthanide salts relevant for MRI 
Ln(III) Gd Tb Dy Ho Er 
Atomic radius / 
pm 
233 225 228 226 226 
Electronic 
relaxation time / 
ps 
176 << 20 
Number of 
unpaired 
electrons 
7 6 5 4 3 
Magnetic 
moment 
7.9 9.6 10.4 10.7 9.5 
Relaxivity 
mechanism 
T1 and T2 
are 
dominated 
by the 
inner-
sphere 
mechanism 
T1 is negligible and T2 is dominated by the outer sphere 
mechanism 
 
1.7 The Use of Manganese(II) in MRI Contrast Agents 
Due to the toxicity attributed to GdCA, especially in patients with renal failure, 
manganese(II) contrast agents (MnCAs) can be used as an alternative. MnSO4 was first 
reported as a potential MRI CA in 1973.3 Mn(II) features all the physical attributes that make 
Gd(III) highly effective as an MRI CA, especially in T1 imaging. Both ions have long longitudinal 
electronic relaxation times, high spin quantum numbers and fast water exchange.66 Mn(II) 
complexes can be cleared from the body through biliary excretion which is extremely 
attractive for patients suffering from renal failure.   
 [Mn(DPDP)]3− (Telescan) is the only Mn(II) CA to have been approved for clinical use. 
It was designed by Lissner and co-workers and was approved in the 1990s, with the structure 
shown in Figure 1.7.67,68 It was used as a liver imaging agent and was found to undergo partial 
dechelation in plasma, with Mn(II) being taken up rapidly by surrounding cells.69,70 
~ 19 ~ 
 
[Mn(DPDP)]3− has q = 0 which gives rise to low relaxivity.3 However, a large enhancement of 
T1 was observed in the liver and was thought to be due to free Mn(II) interacting with 
proteins.3 The use of [Mn(DPDP)]3− demonstrated both the success and weaknesses attributed 
to using MnCAs; the complex was highly efficient yet the lability of Mn(II) highlights the 
challenge of designing a stable MnCA.  
 
Figure 1.7: Structure of [Mn(DPDP)]3−, clinical name Telescan. 
 Caravan and co-workers66 developed a series of Mn(II) complexes to be used as MRI 
CAs and replace current GdCAs. The most successful featured a PyC3A chelator which formed 
a stable, inert complex with Mn(II), as shown in Figure 1.8. It has been reported that 
[Mn(PyC3A)]− is one of the most stable Mn(II) complexes at physiological pH.66,71 The stability 
was further investigated by a transmetalation study with Zn(II). On addition of 25 molar 
equivalences of Zn(II) to comparable solutions of [Mn(PyC3A)]− and [Gd(DTPA)]2−, the MnCA 
was found to be 20 times more resistant to dissociation than the GdCA.66 When comparing 
relaxivity, [Mn(PyC3A)]− was found to be comparable to commercial GdCAs. In further work, a 
bi-functional analogue of the chelator allowed for the development of a targeted probe for 
molecular imaging of thrombosis.66 Such Mn(II) complexes have optimal thermodynamic 
stability and kinetic inertness whilst still achieving high relaxivity.66  
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Figure 1.8: Structure of Manganese contrast agent [Mn(PyC3A)]−. 
1.8 Peptide-Based Contrast Agents  
Macromolecular CAs have the potential for high relaxivity, due to their slow rotational 
correlation time in solution.72 Because of their large size, it is possible to optimise the water 
coordination time and water exchange to generate even higher relaxivities.73 Macromolecules 
can be adapted for ideal biodistribution and localisation, through chemical modifications to 
their exterior.73 
Peptides can be used as scaffolds for MRI CAs due to their wide variety of structures, 
bioavailability and non-toxicity. They are most commonly used for localisation into a specific 
tissue, for example a tumour. An example of this is the work by Sherry and co-workers where 
a short peptide was used to provide greater binding specificity.74 A DOTA chelate, coupled to 
the N-terminus of a 12 amino acid peptide (G80BP), was designed to bind to the yeast 
transcription factor Gal80. The DOTA-peptide complex had a two fold increase in r1 ( at 20 
MHz) compared to [Gd(DOTA)] due to reduced tumbling.74 
Self-assembling peptides can be used to conjugate to Gd(III). Upon addition of Gd(III), 
the peptide self-assembles into a larger structure. This allows for an enhancement of relaxivity 
because of the slower rotational correlation time. Meade and co-workers demonstrated this 
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through the development of a poly-Lys3-Ala3 peptide, which they conjugated to DOTA. In this 
example, nanofibres were formed upon self-assembly and a relaxivity three times higher than 
[Gd(DOTA)] was observed.75  
1.9 De Novo Design and Coiled-Coil Peptides  
De novo design76,77 continues to become more and more popular as a method of 
designing novel proteins.78 De novo is defined as “from first-principles” and involves the 
careful selection of a linear sequence of amino acids which will yield a peptide with the desired 
secondary and tertiary structure.79 These designs are most frequently based on the α-helix.80 
Previous work has involved using coiled-coil structures which consist of two or more ⍺-helices 
that wrap around each other in a left handed super helix.81 Coiled coils created by de novo 
design have the advantage of combining the simplicity of an α-helix with the complexity of a 
cooperatively stabilised structure. The complex, assembled from short polypeptide chains, 
exhibits globular protein characteristics such as inter-chain interactions that promote coiled-
coil folding.80 
Three-stranded coiled-coils are well understood structures that are common in nature. 
They occur in fibrous proteins and cell-surface receptors,78 with the most well-known example 
being keratin.82 The structural principles that dictate the folding of coiled coils have been 
discovered through biophysical characterisation and crystallographic studies of both natural 
and designed peptides.83–85  
The trimeric coiled-coil structure features a seven-residue repeat, allowing for a full 
turn of the α-helix, termed a heptad, where the residues are labelled a-g. Apolar residues at 
the a and d position stabilise the coiled coil by packing their hydrophobic side chains into the 
centre of the structure. Charged side chains at the interfacial e and g positions have the ability 
to shield the hydrophobic core with their side chains and form stabilising electrostatic and 
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hydrogen bonding interactions. Positions b and c are normally occupied by hydrophilic 
residues which aid with solubility and the f position accommodates highly polar and charged 
residues.78  
The formation of a three-stranded coiled-coil, in comparison to different oligomeric 
states, is dependent on the position and nature of hydrophobic residues.86,87 For a trimeric 
structure these residues must be restricted to the a and d position.84,88,89 A single residue 
change has the ability to change the oligomeric state of the coiled coil. For example, an 
asparagine residue at a single a position of a coiled coil can change the structure from a 
trimeric to dimeric coiled coil.84,85 Three-stranded coiled-coils are versatile scaffolds for 
protein design. They can be exploited for the introduction of functional sites: the hydrophobic 
core can bind small ligands or contain metal binding sites. The exterior can also be modified 
to bind transition metals or complex organic ligands.78  
1.10 Metal Binding in Coiled-Coil Peptides  
Metals are commonplace in biology and are found in a third of all naturally occurring 
proteins.90 They are important for functions such as enzyme catalysis, electron transfer and 
structure stabilisation.79,91 The incorporation of a metal binding site is useful for enhancing 
peptide stability, folding and function.80 Metal binding is attractive for the construction of de 
novo designed peptides because metal ions can play an important role in determining protein 
structure and can also be used in the catalytic centres of proteins. As such, many coiled-coil 
peptides have been designed with the ability to bind transition metals.  
Of the 20 naturally occurring amino acids, a number can be used for metal binding. 
The most common are the carboxylate groups of aspartic acid (Asp) and glutamic acid (Glu), 
the imidazole of Histidine (His) and the thiolate group of cysteine (Cys). Each functional group 
has the ability to bind to a number of biologically relevant metals.90,92 The hard oxygen donors 
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of Asp and Glu prefer binding to hard metals such as Ca(II) and Mg(II), whereas the soft thiolate 
groups of Cys will bind to softer metals such as Cd(II) preferentially. His shows little preference 
and can bind to either hard or soft metals.92 
Dieckmann and co-workers used coiled-coil peptides to investigate metal binding site 
geometry.93 Metal binding sites can be identified as structural or functional. Structural sites 
fulfil the coordination of the metal; they have a common geometry and are well defined in 
crystal structures. Here, the metal can act as a template around which the peptide will fold. In 
comparison, functional metal binding sites can have a more unusual geometry which are 
enforced in folded coiled coils.78 Dieckmann and co-workers used a trimeric coiled-coil to 
investigate the structure of a cysteine Hg(II) binding site.93 A cysteine residue was located at 
position a of the coiled coil. Metal binding was examined using spectroscopic and physical 
methods. In the apo peptide a dimeric structure formed at low pH, but became a trimer above 
pH 7. At low pH the peptide bound Hg(II) in a two coordinate complex. Upon increasing pH a 
trigonal geometry was formed when peptide was in excess.  
1.11 Lanthanide Binding Coiled-Coil Peptides  
Except for one rare example,94 lanthanides are not bound in native proteins. Due to 
the similarities between Ca(II) and Ln(III) coordination chemistry, Ln(III) binding sites can be 
developed using natural Ca(II) binding sites as a motif. Resulting Ln(III) metallopeptides have 
a variety of applications such as optical imaging agents, MRI CAs and catalysts.  
Ln(III) binding requires hard oxygen or nitrogen donor groups. These are often 
attached to hydrophilic amino acids with negative charges such as Asn, Asp, Glu and Gln. The 
introduction of these groups in the hydrophobic core can be highly destabilising.  
Hodges and co-workers designed the first Ln(III) coiled-coil, which consisted of a 
disulphide bridged, two-stranded coiled-coil, capable of binding La(III) and Ca(II) at the helical 
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interface. The coiled coil used the non-natural amino acid (γ-carboxyglutamic acid) which has 
two carboxylate groups in its side chain, structure shown in Figure 1.9. These two negative 
groups repel each other, however, on the addition of a metal, a transition occurred leading to 
a folded two-stranded coiled-coil.80 Kashiwada and co-workers built upon this work through 
the design of a three-stranded coiled-coil which has the ability to selectively bind Ln(III) over 
other metals. The peptide featured a trigonal planar binding site located within the 
hydrophobic core of the coiled coil, made up of γ-carboxyglutamic acid.95 Upon addition of a 
Ln(III) a trimeric structure forms.81,96 Non-natural amino acids can be expensive and their use 
is limited to peptides that can be readily synthesised. Therefore, the de novo design of coiled 
coils using natural amino acids to create a Ln(III) binding site would be much more desirable. 
 
Figure 1.9: The non-natural amino acid, γ-carboxyglutamic acid. 
In de novo designed coiled coils, each amino acid is selected for its structural or 
functional contribution to the overall peptide. Peptides developed previously in the Peacock 
group include the MB1 series designed by Berwick and co-workers.97 The peptides incorporate 
a lanthanide binding site, with the ability to bind gadolinium. This was the first example of a 
Gd(III) coiled-coil to be reported. The coiled coil uses the sequence Ac-G-(IaAbAcIdEeQfKg)x-G-
NH2.97  
By changing the residues in the a and d positions of a heptad, a Ln(III) binding site is 
formed. This was achieved by inserting asparagine at position d of the second heptad and 
aspartate at position a of the third heptad. This generated a hard oxygen binding site to bind 
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Ln(III) ions.97 Tryptophan was introduced into the f position of the second heptad, next to the 
lanthanide binding site. Tryptophan has two main advantages; the first is its ability to absorb 
light at 280 nm so that the peptide concentration can be calculated using UV-Vis spectroscopy. 
The second is its ability to sensitise lanthanide luminescence allowing the binding site to be 
probed. This sequence of amino acids creates a metal binding site with a possible 9 
coordination using the oxygen atoms from three asparagine residues and three aspartate 
residues on the internal core of the coiled coil.97  
1.12 De Novo Designed Lanthanide Coiled-Coils for MRI 
 The MB1 series of coiled-coil peptides are shown in Figure 1.10 and have been 
optimised for use in MRI by changing q. The relaxivity of the MB1 peptides was investigated 
at 7 T due to the trend towards the use of high field instruments in clinical MRI.  
The four peptides in the MB1 series contain the same Ln(III) binding site, but differ in 
its linear translation along the coiled coil. The most apparent difference between the four MB1 
peptides is their difference in folding, measured using CD spectroscopy, in the absence and 
presence of Ln(III), with the data shown in Table 1.3. When the Ln(III) binding site is located 
towards either termini of the peptide, an increase in folding is observed compared to when it 
is located in the centre of the peptide, suggesting the destabilising binding site is better 
tolerated when the core heptads remain unchanged.95 
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Figure 1.10: Pymol figures of the MB1 series of peptides A) Ln(MB1-1)3, B) Ln(MB1-2)3, C) Ln(MB1-3)3 
and D) Ln(MB1-4)3. Peptide backbone is represented as a cartoon, the metal binding site and Trp 
sensitiser represented as sticks and the Ln(III) ion as a sphere. Reproduced with permission from 
 Berwick, M. R.; Slope, L. N.; Smith, C. F.; King, S. M.; Newton, S. L.; Gillis, R. B.; Adams, G. G.; 
Rowe, A. J.; Harding, S. E.; Britton, M. M.; Peacock, A. F. A. Chem. Sci. 2016, 7, 2207–2216. - 
Published by The Royal Society of Chemistry. 
  An increase in folding was observed for each peptide on addition of Ln(III) in a 1:3 
Ln(III) to peptide monomer ratio, indicating that binding is possible despite the position of the 
Ln(III) binding site.95 This was confirmed using luminescence studies where addition of one 
equivalent of Tb(III) per trimer showed characteristic Tb(III) emission peaks with the emission 
enhancement attributed to the sensitisation of Tb(III) by the tryptophan sensitiser. A binding 
constant for each peptide was extrapolated, with the log Ka values given in Table 1.3. The 
binding constants were shown to be the same within the experimental error, despite the 
differences in peptide folding and stability.95 The stability of the metallo coiled coils displayed 
the same trend as folding, with the free energy of folding given in Table 1.3.  
Luminescence lifetime decay experiments were used in order to determine q for each 
peptide in the MB1 series. q was found to be zero when the Ln(III) binding site was located in 
the centre of the coiled coil but increased when the binding site was positioned at either 
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terminus, due to water being unable to penetrate the hydrophobic core of the coiled coil. 
When q = 0, in the MB1-2 and MB1-3 peptides, the r1 relaxivity was found to be comparable 
to that of [Gd(DOTA)], compared to r2 which was found to be significantly higher.97 This was 
thought to be due to an outer sphere water mechanism, involving the coordination of water 
to the exterior of the peptide construct, in addition to the proposed reduction in rotational 
correlation time compared to [Gd(DOTA)].  
 By translating the Ln(III) binding site towards the C-terminus of the coiled coil and 
increasing the inner-sphere water coordination, q = 2, the relaxivities (both r1 and r2) were 
shown to increase significantly. By increasing the inner-sphere even more, q = 3, by translating 
the binding site to the N-terminus of the coiled coil, maximum relaxivities for the MB1 series 
of peptides was observed, data given in Table 1.3.95 
 These results demonstrate the control that can be accomplished through the 
translation of a Ln(III) binding site along a de novo designed coiled coil and that the location 
of the Ln(III) binding site can enhance the relaxivity of the MRI CA through the use of inner-
sphere and outer sphere water coordination and dynamics.  
Table 1.3: Data collected through analysis by CD, luminescence and MRI by Berwick and co-workers.95 
 
 
% Folding 
Apo 
% Folding 
Metallo 
Metallo-
ΔGºH2O /  
kcal mol-1 
log Ka q 
r1 / 
mM-1 s-1 
r2 / 
mM-1 s-1 
MB1-1 80 ± 6 83 ± 7 22.4 ± 1.5 5.3 ± 0.2 3.1 ± 0.2 9.9 ± 1.5 88.3 ± 16.8 
MB1-2 21 ± 3 62 ± 3 15.3 ± 2.0 5.5 ± 0.2 0.0 ± 0.1 4.1 ± 1.2 24.4 ± 2.6 
MB1-3 15 ± 1 41 ± 4 16.7 ±  3.9 5.2 ± 0.3 0.0 ± 0.1 4.0 ± 1.0 20.9 ± 1.0 
MB1-4 55 ± 6 70 ± 5 19.3 ± 4.8 5.3 ± 0.4 1.8 ± 0.4 7.5 ±  4.1 37.6 ± 4.0 
1.13 Project Aims 
The coiled coil is a common peptide motif and has been extensively used as a scaffold 
for metal binding. Through the design of the MB1 series of peptides, it has been observed that 
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metal hydration can be tuned through translation of the Gd(III) binding site. This has allowed 
for the first steps into the optimisation of this class of peptides for use as MR imaging probes.  
In this thesis the MB1 peptides will be further investigated, and optimised for use as 
MRI CAs. This will involve the principles of the SBM equations, which provide important 
information allowing for the optimisation of a CA. This work will include investigation into 
rotational correlation time, water coordination and water residence time in order to provide 
further insight into CA optimisation.  
Rotational correlation time, in comparison to MB1-1, will be investigated through the 
synthesis and characterisation of two new peptides of differing length (4, and 6 heptads). 
Increasing peptide length from 5 to 6 heptads was proposed to slow the rotational correlation 
time and increase relaxivity. The effect of rotational correlation time and the MRI efficiency 
will be discussed in Chapter Three.  
Secondary sphere water interactions, in comparison to MB1-2, will be analysed 
through the synthesis of a new peptide with side chains predicted to coordinate more water 
to the peptide exterior. Increasing secondary sphere water coordination was proposed to 
cause an increase in MRI relaxivity. This will be discussed in Chapter Four.  
The presence of a water channel in the MB1-2 peptide will be investigated in Chapter 
Five. This will be achieved through the design, synthesis and characterisation of two new 
peptides containing D-amino acids which were proposed to block water access to the 
hydrophobic core of the coiled coil, thereby decreasing secondary sphere water interactions 
and decreasing relaxivity. This will allow for a proof of concept and greater understanding into 
secondary sphere water interactions in the MB1 peptides. 
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Finally, the toxicity and biological effects of the MB1-1 and MB1-2 peptides will be 
investigated in Chapter Six. Here, transmetalation studies were undertaken, using 
luminescence spectroscopy, and two cell types were incubated with Gd(MB1-1)3 in order to 
assess the toxicity of the CA within biological systems.  
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Chapter 2: Experimental Techniques 
2.1 Peptide Synthesis and Purification 
Solid-phase peptide synthesis (SPPS) was introduced by Merrifield in 196398 and is 
used to synthesise a peptide on a resin. Normally, the C-terminus of the peptide is coupled to 
the resin through a carboxyl group and the N-terminus is protected to avoid polymerisation 
reactions. This protective group can be selectively removed to allow for the next amino acid 
to couple, forming a peptide bond. An excess of amino acid is used to drive the synthesis to 
completion and any unreacted reagent can be washed away. An amino acid with a protecting 
group at the N-terminus is then added to the solution with an activator for the carboxyl group. 
The amino acid couples with the amine on the N-terminus of the amino acid currently attached 
to the support. Any unreacted amino acid is washed away. The deprotection and coupling 
procedures can be repeated until the desired sequence is produced. This method of peptide 
synthesis can lead to incomplete reactions and there is a chance that side reactions may take 
place. There is also the possibility of reagent impurities residing on the resin. This can lead to 
a lower yield of peptide and, therefore, this method is generally used for peptides up to 50 
amino acids in length, depending on the sequence.9,98,99 A diagram showing the peptide 
synthesis cycle is shown in Figure 2.1. Deprotection and coupling can be assisted by the use of 
a microwave. Microwave irradiation allows more complex sequences to be constructed, as it 
prevents aggregation and secondary structure formation.100,101  
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Figure 2.1: A schematic diagram of Fmoc SPPS illustrating the coupling procedure for the first amino 
acid on  the solid support, the deprotection and coupling cycle and the final deprotection and 
cleavage to form the desired peptide. 
Fluorenylmethoxycarbonyl (Fmoc) is commonly used to protect the N-terminus of an 
amino acid during SPPS and is readily removed using an organic base, for example, piperidine. 
Amino acid side chains often need to be protected to avoid side reactions during synthesis. A 
wide selection of reagents and resins can be used in SPPS; the following were used in this 
work. A rink amide 4-methylbenzhydrylamine (MBHA) resin was used as a solid support, (O-
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(benzotriazol-1-yl)- N,N,N’,N’,-tetramethyluronium) hexafluorophosphate (HBTU) and 
diisopropylethylamine (DIPEA) activate the carboxyl and amine groups allowing for the 
formation of amide bonds. The final amino acid in the desired peptide sequence is acetylated, 
using acetic acid and DIPEA, at the N-terminus to prevent any further reactions taking place. 
The peptide is cleaved from the resin, and the amino acid protecting groups removed using a 
mixture of TFA, TIPS and H2O.9,99,102 The resulting peptide can then be dissolved in a mix of 
acetic acid and water, and purified using HPLC. 
2.2 High Performance Liquid Chromatography  
Liquid chromatography (LC) separates molecules by charge, mass and 
hydrophobicity.103,104 The sample is injected onto a stationary phase and the chosen mobile 
phase is passed over, causing the sample to flow through the stationary phase, with a rate 
determined by the sample’s affinity for the two phases.  Separation of the mixture will occur 
due to the different chemical properties of the components of the sample.105 When using 
HPLC, the polar stationary phase is contained in a tightly packed column and the mobile phase 
is pumped through under high pressure. This allows for better separation and better 
resolution of the chromatogram.103 Reversed phase HPLC differs in that the stationary phase 
is non-polar.103,104 The non-polar stationary phase is frequently formed of aliphatic carbon 
chains, for example C18, as used in this work, which are secured onto a silica support. The 
mobile phase is made up of a mixture of solvents, for example, acetonitrile and water, and the 
polarity of the mobile phase is controlled by changing the ratio of the two solvents as a 
function of time. Ion pairing reagents such as TFA can be added to the solvents in order to aid 
solubility and create an acidic pH, which increases hydrophobic interactions between the 
peptide and the column, allowing for an improvement in resolution. The polarity of the mobile 
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phase can be changed in order to separate the peptide species by size and hydrophobicity. 
Peptides, or peptide fragments, with a low molecular weight commonly elute first.102–104  
2.3 Mass Spectrometry 
Mass spectrometry is a commonly used gas-phase technique where a sample is ionised 
and separated by a magnetic field, based on its mass to charge ratio (m/z). Many different 
ionisation techniques, separation methods and detection methods are possible and are 
selected depending on the properties of the sample. The most common ionisation methods 
for the analysis of peptide samples are electrospray ionisation (ESI) and matrix assisted laser 
desorption ionisation (MALDI). This is because a high energy focused beam of electrons, such 
as in electron impact, can be too harsh for biological samples.103,106,107  
In ESI, a liquid containing the sample of interest travels through a charged capillary at 
high pressure and enters a vacuum. This results in a fine spray of charged droplets which 
evaporate to give ionised molecules. This is a soft ionisation method as it does not cause 
fragmentation. ESI produces a range of charged species, giving the species of interest a 
characteristic charge envelope.103,106,107 
MALDI is a soft ionisation technique which uses a matrix to form a co-crystal with the 
sample of interest. The matrix must be able to absorb in the UV region, as it is through the 
crystals being irradiated with a high energy laser beam, that the matrix absorbs energy and 
transfers it to the sample, generating single charged ions of the sample of interest.106,107  
Time of flight detectors, which can be coupled with both of these ionisation 
techniques, measure the time taken for the ions of interest to travel along the drift tube, 
determining the mass to charge ratio.106,107  
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2.4 Ultra Violet-Visible Spectroscopy 
Certain molecules have the ability to absorb energy; this is most commonly observed 
as electromagnetic radiation. In a given chemical system, this has the potential to result in  an 
electronic transition, occurring between the ground and excited state.108 The difference in 
energy between these two levels (ΔE) is related to the frequency (ν) and wavelength (λ) of the 
absorbed electromagnetic radiation, where h is Planck’s constant and c is the speed of light in 
a vacuum, as given in Equation 2.1. When considering biological molecules, such as peptides, 
absorption often occurs in the UV region.103,108 
Equation 2.1:                                       Δ𝐸 = ℎ𝜐 =
ℎ𝑐
𝜆
     
  In UV-Visible spectroscopy, the transmittance of light travelling through a sample of 
interest is measured.103 This is the ratio between the intensity of light measured and that of a 
blank. This can be converted to absorbance (A), which is related to the extinction coefficient 
(ε), concentration of the peptide (c) and the path length of the cuvette (l), as identified by the 
Beer Lambert law, as given in Equation 2.2.  
Equation 2.2:             𝐴 = 𝜀𝑐𝑙 
The amino acid tryptophan absorbs at 280 nm with an extinction coefficient of 5690 
M-1 cm-1.108 By using the intensity of absorbance at this wavelength, the exact concentration 
of tryptophan in solution, and therefore the peptide concentration, can be calculated.   
2.5 Circular Dichroism 
Circular dichroism (CD) measures the optical activity of asymmetric molecules using 
the basic principles of absorption spectroscopy.109 Differently oriented circularly polarised 
light (AL and AR) is passed through a sample of interest and the difference in absorbance, 
(𝜃𝑜𝑏𝑠), is recorded as a function of wavelength, reported in milidegrees. For peptides this can 
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then be converted to molar ellipticity per residue, which is calculated from the number of 
amino acids in the peptide of interest (n), the peptide concentration (c) and the cuvette 
pathlength (l), as shown in Equations 2.3 – 2.4.110 
Equation 2.3:     𝜃𝑜𝑏𝑠 = 𝐴𝐿 − 𝐴𝑅 
Equation 2.4:    [𝜃] =
𝜃𝑜𝑏𝑠
𝑛 ×𝑐 ×𝑙 ×10
 
Peptides are characterised using CD as they consist of chiral amino acids and fold to 
generate chiral secondary structures. The emission of the peptide backbone gives rise to a CD 
signal which can then be assigned to a specific secondary structure, for example, α-helix or β-
sheet, as shown in Figure 2.2.108 For coiled-coil peptides, a minimum is observed at 208 and 
222 nm and a 1:1 ratio of the two minima is representative of an α-helical structure. The 
minimum at 208 nm is indicative of a single stranded helix, with a decrease in this band 
representing a more coiled structure.  
 
Figure 2.2: CD spectra illustrating different secondary structures of proteins.111 
The minimum at 222 nm can be used to calculate the percentage folding of a coiled 
coil, with 100% folding being representative of every amino acid being in its preferred position 
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in the helix.80,112–114 This can be calculated using Equation 2.5, based on the molar ellipticity 
per residue at 222 nm, ([𝜃]222 𝑛𝑚), and the number of amino acids in the peptide sequence 
(n).110  
Equation 2.5:  𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑓𝑜𝑙𝑑𝑒𝑑 =  
([𝜃]222 𝑛𝑚−640)
((−42500 ×(1−
3
𝑛
))−640)
× 100 
2.6 Emission Spectroscopy 
The electromagnetic radiation which is emitted from a sample can be measured, and 
categorised as either fluorescence or phosphorescence. During the process of fluorescence, 
emission will occur from an excited singlet state. Here, the electrons in the excited and ground 
states are spin paired. The transition is spin allowed and has a short lifetime. In 
phosphorescence emission occurs from an excited triplet state. An electron in the excited 
state will be in the same spin orientation as the electron in the ground state. This means that 
the transition is spin forbidden and the emission rate is slower. In the case of emissive metal 
complexes, emission can often occur from both singlet and triplet excited states, and is 
referred to as luminescence.108,115  
An excited electron can follow a number of non-radiative decay pathways, as shown 
in Figure 2.3. Non-radiative intersystem crossing (ISC) can occur, followed by relaxation to the 
lowest vibrational level. Here, an electron can transfer from a singlet to a triplet state, allowing 
phosphorescence to take place. Quenching can also occur through non-radiative pathways 
involving collisions or interactions with other molecules. Importantly for lanthanides, water 
has the ability to quench luminescence by transferring high energy vibrations from OH 
bonds.116 
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Figure 2.3: Jablonski diagram showing excitation from the ground to excited state. Energy is 
transferred between different energy levels through internal conversion and intersystem crossing. 
This leads to fluorescence or phosphorescence.  
Terbium emission is commonly studied due to its low lying excited state which leads 
to emission at a wavelength located in the visible spectrum.5 The amino acid tryptophan is 
often used as a sensitiser for terbium emission as it has a large molar absorptivity and a short 
excited state. The tryptophan sensitiser can be excited to a higher energy singlet state. From 
here, the energy can be transferred through intersystem crossing to an excited triplet state. 
The excited triplet state can then pass energy to the 5D4 excited terbium state, leading to 
luminescence emission to the 7FJ ground state.5 
2.7 Nuclear Magnetic Resonance  
NMR can be used to measure the intrinsic magnetic properties of nuclei with a spin 
quantum number (I) that does not equal zero. This nucleus will possess intrinsic angular 
momentum which, in turn, imparts a magnetic moment (μ). When located in a static magnetic 
field (B0), the magnetic moment will align with the magnetic field, shown in Figure 2.4(a). For 
a nucleus of spin = I there are 2I + 1 available orientations, represented by the magnetic 
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quantum numbers (m), with the lowest energy state being preferred, shown in Figure 
2.4(b).13,117 
Figure 2.4: Schematic to show (a) a nucleus and magnetic moment, (b) energy levels of an I = ½ 
nucleus and (c) the Boltzmann distribution of spins leading to macroscopic magnetisation. 
For hydrogen nuclei, the spins will orientate in the lowest energy state, m = +½, where 
the spin direction is aligned with the magnetic field, and a high energy state, m = -½, where 
the spin direction is opposite to the magnetic field. These two energy levels can be labelled as 
spin up and spin down. The energy difference between the two levels is defined by Planck’s 
constant (h), frequency of electromagnetic radiation (ν), magnetogyric ratio (γ), and field 
strength (B0) as shown in Equation 2.6.  
Equation 2.6:    Δ𝐸 = ℎ𝜐 =
ℎ𝛾𝐵0
2𝜋
 
When a magnetic field is applied, the spins will precess around the B0 axis at the Larmor 
frequency (ω). This will be dependent on the gyromagnetic ratio (γ) and the strength of the 
magnetic field strength (B0) as shown in Equation 2.7 .13,117  
Equation 2.7:             𝜔 = 𝛾𝐵0 
After a radio frequency (RF) pulse, transitions occur between energy levels. Transitions 
occurring from the low to high energy levels correspond to the absorption of energy. As the 
B
0
 
a) b) c) 
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population is higher in the lower energy level, this is the major transition. The transitions 
which occur in the reverse direction, lead to the emission of energy.  These transitions are 
detected as a signal with the intensity proportional to the population difference.13,117 A 90o 
pulse will position the net magnetisation in the x-y plane where it will precess with the Larmor 
frequency, shown in Figure 2.5(a). The precession will induce an oscillating current in the RF 
coil, which is detected as an NMR signal. The signal will decay with time due to relaxation 
producing an FID, shown in Figure 2.5(b). By using a Fourier transform, a spectrum can be 
created.  
Figure 2.5: Schematic diagram to show (a) the application of a 90˚ pulse which causes the net 
magnetisation to move into the transverse plane and (b) the FID produced due to the precession of 
magnetisation in the transverse plane. 
Multiple nuclear environments in a single sample will result in a number of different 
precession rates which, once Fourier transformed, will produce a spectrum with multiple 
peaks. The difference between the peaks of the sample and that of a reference is called the 
chemical shift. Splitting can occur within a NMR peak due to the influence of neighbouring 
spins on the Larmor frequency. By analysing the position and splitting of the peaks, 
information regarding the structure and chemical environment can be obtained.13,117  
a) b) 
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2.8 Relaxation 
When a RF pulse is turned off, the magnetisation vector moves from its equilibrium 
position. The spin system relaxes due to a loss in energy, which can be described as 
longitudinal or transverse relaxation.117 The longitudinal relaxation time (T1) is associated with 
the net magnetisation returning to its initial position. T1 relaxation is exponential and can be 
calculated using the magnetisation located in the z-direction during thermal equilibrium, using 
Equation 2.8. 
Equation 2.8:    𝑀𝑧 = 𝑀0 (1 − 2𝑒
−𝑡
𝑇1⁄ ) 
One method for measuring T1 is the inversion recovery experiment. In this method a 
number of spectra are recorded using an 180˚ - τ - 90˚ - FID pulse sequence, shown in Figure 
2.6. The 180˚ pulse rotates the magnetisation vector to a negative z-axis position. A range of 
evolution times, τ, are used throughout the experiment. By creating an experiment with 
increasing τ times, the signal will increase and the data can be fit to give a T1 relaxation 
constant.13,117  
 
Figure 2.6: Schematic to show (a) the inversion recovery pulse sequence, (b) graph of signal intensity 
over time.  
Transverse relaxation (T2) describes how rapidly the transverse magnetisation 
components decay. After the 90˚ pulse, the precessing nuclear spins gradually lose their phase 
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coherence and the magnetisation reduces to zero. Again, an exponential relationship is 
observed between the evolution time and the magnetisation in the transverse plane (Mx,y). 
This allows the T2 relaxation constant to be determined, using Equation 2.9.13,117 
Equation 2.9:    𝑀𝑥,𝑦 = 𝑀0𝑒
−2𝑡
𝑇2⁄  
T2* results primarily from inhomogeneity in the magnetic field. The measured T2 
relaxation time is a combination of these field inhomogeneities and molecular interactions 
intrinsic to the sample. To separate the data of interest, the field inhomogeneities are 
eliminated using a CPMG pulse sequence, shown in Figure 2.7. Following excitation by a 90˚ 
pulse, spins begin to dephase during the mixing time τ.  An 180˚ pulse refocuses the signals, 
creating an echo. Multiple 180˚ pulses are used with a constant mixing time and the echoes 
are repeated a defined number of times before data collection. The intensity and decay of 
the acquired echoes can be fit to obtain the intrinsic T2 value. By using a short echo time, 
relative to diffusion of the spins, only the intrinsic T2 is measured.13,117   
Figure 2.7: Schematic to show (a) CPMG pulse sequence (b) a graph of the change in signal intensity 
over time.  
2.9 Magnetic Resonance Imaging  
In MRI, the application of magnetic field gradients causes the magnetic field to no 
longer be uniform. Spins experience position-dependent field strength, which causes 
a) b) 
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precession at varying frequencies, producing a helix of phase. The Larmor frequency (ω) of the 
nuclei becomes spatially encoded with respect to the x, y and z direction (r). The wavelength 
(λ) is determined by the strength (G) and duration (t) of the gradient and the reciprocal space 
vector (k), as given in Equations 2.10 and 2.11.27,118  
Equation 2.10:      𝜔𝑟 = 𝛾𝐵0 + 𝑦𝐺 ∙ 𝑟 
Equation 2.11:                       𝑘 =
1
𝜆
=
𝛾𝐺𝑡
2𝜋
 
2.9.1 Frequency and Phase Encoding  
 K-space is used in order to gain spatial information by increasing the gradient strength 
(phase encoding) or time (frequency encoding). To generate a 2D image, frequency and phase 
encoding gradients are generally used in the x and y direction and slice selection in the z 
direction, in order to determine the slice thickness and z position. When creating a 2D image, 
the NMR signal at each location in a K-space map is collected.27  
During phase encoding, a gradient pulse with a constant duration is used. The gradient 
is switched off before the start of the acquisition. This means that the frequency of the spin 
packets will be identical but their phase will be different. This allows for spatial encoding in 
the phase direction. Here K-space is traversed by varying the gradient strength (Ky).  
During frequency encoding, a magnetic field gradient is applied with constant field 
strength during signal acquisition and the acquisition time is varied (traverse through Kx). Spins 
at different positions will have different frequency dependence and so the signal intensity 
across the spectra is proportional to the number of spins located at each position.27 In order 
to obtain spatial information in the third dimension an additional slice encoding gradient can 
be used which, when used with a soft RF pulse, selectively excites spins in a slice of the 
sample.27  
~ 43 ~ 
 
2.9.2 Resolution and Field of View  
Resolution in an MR image is dependent on K(max), which is ΔK multiplied by the total 
number of data points collected.  The resolution in the frequency encoding direction is 
influenced by the NMR signal linewidth and pixel size, with the linewidth limiting the 
resolution. The field of view is defined by ΔK. If some of the sample is outside of the field of 
view, aliasing will occur leading to image fold-over and artefacts.119  
2.9.3 Spin Echo Imaging Sequence  
A spin echo imaging sequence can be used to produce two dimensional images. A slice-
selective gradient is used in the z-direction in order to spatially encode spin packets. Through 
the use of a soft, frequency selective, 90˚, RF pulse, a narrow band of frequencies is excited 
and this corresponds to the selected slice of the sample. Often sinc or Gaussian functions are 
used for the soft pulse.27,119 Following slice selection, a phase encoding gradient step is used 
to spatially encode spin packets along the y-direction. An 180˚ pulse is required to focus the 
magnetisation, allowing for the production of an echo. The frequency encoding gradient will 
be applied and the resulting data encoded in both the frequency and phase directions. The 
echo time, TE, is defined as the time between the middle of the excitation pulse and the centre 
of the echo, which is at the centre of the positive part of the read gradient. The above 
sequence is repeated with a repetition time of TR. By using a number of varying phase 
encoding gradients, all the required values of Ky will be obtained. The consequent array will 
be  Fourier transformed in order to produce a 2D image.27,119  
The spin echo sequence can be modified using RARE (Rapid Acquisition with Relaxation 
Enhancement), shown in Figure 2.8.120 Here, multiple pulses are used to create many echoes. 
By applying a different phase encoding gradient to each echo, multiple K-space lines can be 
attained from a single excitation. This can dramatically decrease experiment time.120  
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Figure 2.8: A pulse program diagram for imaging sequence with n echoes. 
2.9.4 Image Contrast  
Image contrast occurs due to variations in signal intensity across the pixels which form 
the image. These variations can be attributed to differences in relaxation time, spin density, 
chemical shift, and molecular displacement. By choosing the correct imaging sequence, 
optimal contrast will be observed.  A spin density image can be produced if the echo time is 
short, in comparison to the T2 time, and the repetition time is long in comparison to the T1 
time. By varying the repetition time or the echo time, T1-weighted or T2-weighted images can 
be obtained. A series of T1 or T2 images, with difference signal intensities can be collected and 
the changes in signal intensity can be used to produce maps which give T1 or T2 values at a 
specific position in a 2D image.118  
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Chapter 3: Effect of Peptide Length on Relaxivity and the 
Effectiveness of MRI Contrast Agents 
3.1 Introduction 
The relaxivity of an MRI contrast agent (CA), is dependent on the number of 
coordinated water molecules, the distance between water and Gd(III), the water residence 
time and the rotational correlation time of the complex.46 The majority of CAs used in the clinic 
do not exhibit optimal relaxivity, due to, amongst other things, their small size and rapid 
rotational correlation time.15 
One popular strategy for enhancing relaxivity is to slow down the rotational correlation 
time of the CA through the design of macromolecular Gd(III) complexes. These can be based 
on linear polymers72, nanotubes,121,122 dendrimers,123 carbohydrates,124 viral capsids,125 
liposomes126 and peptides.15,25,122 One approach involves the preparation of Gd(III) peptide 
hybrid complexes, in which a small Gd(III) complex is conjugated to a peptide or protein 
fragment, resulting in an increase in rotational correlation time and an enhancement in 
relaxivity.127,128 An example of this is the small molecule CA [Gd(MS-325)] (gadofosveset 
trisodium), a derivative of [Gd(DTPA)]2-, which is designed to bind to HSA, thereby increasing 
the rotational correlation time.40,46 When conjugated to HSA, the observed relaxivity was 42.0 
mM-1 s-1 (at 20 MHz). This can be compared to the relaxivity of [Gd(MS-325)] in PBS which is 
6.6 mM-1 s-1 under the same conditions.15 This represents a 7 times increase in relaxivity.40 
In other work,129 a Gd(III) binding site was engineered onto the surface of a rat cell 
adhesion protein. The Gd(III) complex showed promising MRI relaxivity with q = 2. 
Additionally, the protein had a slow rotational correlation time of 10 ns, giving a high relaxivity 
for the protein complex.129  
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3.2 Aims 
It has previously been reported that the MB1 series of Gd(III) coiled-coils display 
promising MRI relaxivity,97 and that the introduction of the Gd(III) binding site towards the N-
terminus, Gd(MB1-1)3, yielded the highest relaxivity complex (r1 = 9.9 ± 1.5 mM-1 s-1, r2 = 88.3 
± 16.8 mM-1 s-1 at 7 T) by increasing q to 3.95 This second generation design was adopted for 
subsequent optimisation, specifically to evaluate whether the dependence of relaxivity on 
molecular rotation could be exploited to further modulate the MRI efficiency of the Gd(III) 
complex. A series of three peptides based on the MB1-1 design; MB1-1S, MB1-1 (original 
design95) and MB1-1L, were studied in order to investigate the importance of peptide length 
and rotational correlation time on MRI relaxivity.  
With the Gd(III) binding site located at the N-terminus, the shorter (MB1-1S) and 
longer (MB1-1L) designs were achieved by removal or addition of a heptad at the C-terminus, 
see Figure 3.1 and Table 3.1. By altering the length of the peptide, the role of rotational 
correlation time of Gd(III) coiled-coils on MRI relaxivity could be interrogated. This could 
provide insight into the mechanism of this class of Gd(III) coiled CA.  
Table 3.1: The peptide names and sequences used in this chapter  
Peptide Sequence   
MB1-1S Ac – G IAANEWK DAAIEQK IAAIEQK IAAIEQK G – NH
2
  
MB1-1 Ac – G IAANEWK DAAIEQK IAAIEQK IAAIEQK IAAIEQK G – NH
2
  
MB1-1L Ac – G IAANEWK DAAIEQK IAAIEQK IAAIEQK IAAIEQK IAAIEQK G – NH
2
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Figure 3.1:  Schematic diagram of (a) MB1-1S, (b) MB1-1 and (c) MB1-1L. The peptide backbone is 
represented as a cartoon, binding site (Asn, Asp) and sensitiser (Trp) shown as sticks and Ln(III) as a 
sphere.  
3.3 Results and Discussion  
3.3.1 Secondary Structure  
It was first of interest to investigate how the secondary structure of the peptide was 
affected when the length of the peptide was changed. Secondary peptide structure refers to 
the regular structure of the peptide backbone. This can be defined as α-helical or a β-sheet 
and is stabilised by hydrogen bonding. The secondary structure of MB1-1S, MB1-1 and MB1-
1L was investigated using CD spectroscopy. A 30 µM solution of MB1-1L monomer forms an 
α-helical coiled-coil, represented by the intense minimum at 208 and 222 nm in the CD 
spectrum, see Figure 3.2(c). The intensity at 222 nm (Θ222 = −31992 deg dmol-1 cm2), which is 
an indication of the extent of folding, is consistent with that of a well-folded α-helical coiled-
coil peptide (84 ± 2%).  
~ 48 ~ 
 
In contrast, MB1-1S yielded instead a CD spectrum more consistent with a poorly 
folded, random coil (Θ222 = −5928 deg dmol-1 cm2; 20 ± 1% folded), see Figure 3.2(a). This can 
be compared to the previously investigated MB1-1 which was calculated to be 80 ± 6% folded 
in the absence of metal.95  
 
Figure 3.2: CD profile of 30 μM monomer peptide (a) MB1-1S, (b) MB1-1 and (c) MB1-1L in the 
presence (dashes) and absence (full) of 10 μM GdCl3 ran in 10 mM HEPES buffer pH 7.0.  
The addition of 10 μM GdCl3 into a 30 μM MB1-1L monomer solution led to a very 
small increase in the negative intensity of the minimum at 222 nm (Θ222 =-33757 deg dmol-1 
cm2, 85 ± 2%) A greater change was observed with MB1-1S, with the resulting spectrum 
resembling more of an α-helix (Θ222 = -8470 deg dmol-1 cm2, 33 ± 4%). This can again be 
compared to the previously investigated MB1-1 (83 ± 7%). The addition of a heptad, from five 
to six, has no significant impact on the degree of peptide folding, as determined from the CD 
spectra of MB1-195 and MB1-1L. This observation applies to both the apo state and in the 
metallo complex, with the degree of folding being the same within error. In comparison, MB1-
1S remains poorly folded on addition of 1 equivalent of Gd(III). 
Titrations of aliquots of GdCl3 (1 mM stock) into a 30 μM solution of MB1-1S monomer 
were monitored by CD, with the data shown in Figure 3.3(a). The addition of Gd(III) initially 
led to an increase in the negative minimum at 222 nm which then remained largely unchanged 
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on addition of  higher equivalents. A 1/3 Gd + MB1-1S  1/3 Gd(MB1-1S)3 binding model was 
used to analyse the data, giving an average association constant (log Ka) of 4.4 ± 0.6. This can 
be compared to the previously investigated MB1-1 where log Ka = 4.9 ± 0.6. Due to the 
negligible change in molar ellipticity of MB1-1L on addition of Gd(III), a binding constant could 
not be extrapolated.  
 
Figure 3.3: CD spectra of 100 μM (a) MB1-1S, (b) MB1-1 and (c) MB1-1L in the presence of increasing 
aliquots of Gd(III) in 10 mM HEPES buffer pH 7.0. (d) The normalised fraction folding of MB1-1S, 
analysed using a MB1-1S + 1/3 Gd(III)  1/3 (Gd(MB1-1S)3)  binding model, allowed for the calculation 
of a binding constant.  Error bars are standard deviation for n=3 experiments.  
It was previously reported by Berwick and co-workers that MB1-1 was the most well 
folded of the coiled coils which feature the Asn3Asp3 Gd(III) binding site (metallo 83 ± 7% 
folded)95 and reasoned that the fifth heptad may not be essential. MB1-1S, which contains 
only four heptads, was found to be largely unfolded in the apo state (no more than 20% based 
(d) 
(b) (c) (a) 
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on the CD molar ellipticity at 222 nm), which only increased to 33% on addition of GdCl3, 
suggesting that the 5th heptad is essential for a well folded coiled coil. 
3.3.2 Ln(III) Binding  
TbCl3 titrations were monitored directly by luminescence. Due to Tb(III)’s low-lying 
excited states, which allow for emission in the visible spectrum, it can be used as a model for 
Gd(III) luminescence. A solution of 30 μM MB1-1L monomer was excited at 280 nm, and the 
emission spectrum monitored from 455 - 700 nm. Similar spectra were recorded on addition 
of aliquots of TbCl3 (1 mM stock), and displayed the characteristic Tb(III) emission peaks at 
490, 545, 585, 620, and 650 nm, see Figure 3.4(c). These increased in intensity on addition of 
up to one equivalent of Tb(III) per three strands of MB1-1L.  
The region from 530 – 560 nm was integrated and plotted as a function of Tb(III) 
concentration. A 1/3 Tb + MB1-1L 1/3 Tb(MB1-1L)3 binding model was used to interpret the 
data, giving an association constant (log Ka) of 5.0 ± 0.2. The experiment was repeated with 
MB1-1S giving a log Ka of 4.6 ± 0.2 and can be compared to the previously investigated MB1-
1 for which a log Ka of 5.3 ± 0.1 was calculated, with the spectra shown in Figure 3.4.  
Tb(III) luminescence experiments provide important insight into Ln(III) coordination 
chemistry. For MB1-1 and MB1-1L the data was consistent with one Ln(III) ion per trimer 
saturating the binding site with the same affinity (within error). This suggests binding affinity 
is independent of peptide length. It is important to note that this affinity (log Ka of 5.0) is 
significantly lower than current clinically adopted MRI CAs (log Ka of 18.871), and hence, an 
improvement in Ka would be required prior to translation into a clinical setting.95  
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Figure 3.4: Emission profile of (a) MB1-1S, (b) MB1-1 and (c) MB1-1L recorded in the presence of 
increasing aliquots of Tb(III) in 10 mM HEPES buffer pH 70, using a λexc = 280 nm. The normalised 
integration of the 545 nm peak analysed using a peptide + 1/3 Gd(III)  1/3 (Gd(peptide)3)  binding 
model, allowed for the calculation of a binding constant for (d) MB1-1S (e) MB1-1 and (f) MB1-1L. 
Error bars are standard deviation for n=3 experiments. 
For the metallo MB1-1S system, the lack of substantial folding recorded in the CD 
experiments was accompanied by only a small luminescence enhancement on addition of 
Tb(III). Although this is consistent with some binding, this could be non-specific, including to 
Glu residues intended for salt bridge formation, some of which are located in close proximity 
to the Trp sensitiser. The binding constant is similar to that of the longer peptides, despite the 
fact that MB1-1S is poorly folded.  
(a) (b) (c) 
(d) (e) (f) 
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3.3.3 Peptide Stability  
CD spectroscopy was used to compare the stability of MB1-1S, MB1-1 and MB1-1L, by 
both thermal and chemical denaturation. 30 μM solutions of peptide monomer in the absence 
and presence of 10 μM GdCl3 were subjected to a gradual increase in temperature from 25 to 
85˚C, and the CD signal at 222 nm recorded as an indication of peptide folding, with the data 
shown in Figure 3.5.  
The MB1-1S apo peptide was found to be only 20% folded at 25˚C, which remained 
unchanged over the measured temperature range and is more consistent with the signal 
contribution of an unstructured peptide. The metallo MB1-1S complex was 29% folded at 25˚C 
and decreased in folding to 20% at 85˚C. In contrast, MB1-1L decreased in folding by 
approximately 30% (from 83% to 58% apo and 86% to 58% metallo) when the temperature 
reached 85˚C, but never reached an unfolding baseline. When comparing MB1-1L to MB1-1, 
the thermal unfolding profiles show a gradual decrease in folding over a 60˚C range. 
Importantly both the Gd(MB1-1)3 and Gd(MB1-1L)3 complexes remain largely folded at 
biologically relevant temperatures (37˚C). 
When analysing peptide stability, it can be concluded that MB1-1S has poor stability 
with respect to thermal unfolding studies, which show it to be entirely unfolded even in the 
presence of Gd(III), at 55˚C. In MB1-1S, the binding site is located at the N-terminus. This was 
previously found to be the most tolerated position for the binding site and yielded the most 
folded five heptad coiled coil.95 In MB1-1S, the destabilising effect of the Asn and Asp layers, 
which interrupt two heptads, cannot be overcome by the remaining two intact heptads.  It 
can be concluded that a minimum of five heptads are required for the folding of coiled coils 
which feature a Asn3Asp3 binding site, even in the presence of Ln(III). Intriguingly, all of the 
Ln(III) coiled-coils that have been reported to date consist of five heptads, which may imply 
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that the fifth heptad is required to overcome the destabilising negative charges of the Ln(III) 
binding site.80,81,95,97,114 These findings are somewhat in contrast with other metallo coiled-
coils, including the work of Pecoraro and co-workers who have found that Cys3 binding sites 
for Hg(III) and Cd(III) coordination are well tolerated within coiled coils consisting of four 
heptads, and that metal binding can even induce folding for shorter peptides consisting of 
three heptads.91,130  
 
Figure 3.5: Percentage folded data from CD thermal unfolding of 30 μM (a) MB1-1S, (b) MB1-1 and 
(c) MB1-1L monomer in the absence (dark) and presence (light) of 10 μM GdCl3 in 10 mM HEPES 
buffer pH 7.0.  
Chemical denaturation showed the folding of MB1-1L, and the previously investigated 
MB1-1, to decrease in the presence of 6 M guanadinium hydrochloride (Gua-HCl), when 
monitored by CD, as shown in Figure 3.6. When the Gua-HCl concentration increased, a 
decrease in signal at 222 nm was observed. This occurred in solutions containing 30 μM 
peptide monomer, in both the absence and presence of 10 μM GdCl3. A difference in 
percentage folding between the two peptides was observed at 6 M Gua-HCl with MB1-1 being 
completely unfolded (17%) in the apo and metallo complexes whilst MB1-1L remained 
somewhat folded (38%).  
(a) (b) (c) 
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A two-state equilibrium model between folded trimer and unfolded monomer was 
used to interpret the data. Extrapolation of the data yielded free energies of folding, ΔG°H2O, 
of 18.2 ± 3.5 kcal mol-1 and 21.6 ± 2.5 kcal mol-1 for apo MB1-1 and MB1-1L, and 17.8 ± 1.5 
kcal mol-1 and 21.8 ± 5.6 kcal mol-1 for Gd(MB1-1)3 and Gd(MB1-1L)3, respectively, displaying 
no increase in stability, within the error of the experiment.  
The ΔG°H2O data for MB1-1 and MB1-1L suggests that the additional 6th heptad does 
not induce further coiled coil stability in the apo or metallo systems. However, in the work by 
other groups it has been reported to enhance stability with respect to denaturation, by 5-9 
kcal mol-1.71,109  
 
Figure 3.6: Percentage folded data from CD chemical unfolding of 30 μM MB1-1 (diamond, red) and 
MB1-1L (triangle, blue) monomer in the absence (light) and presence (dark) 10 μM GdCl3, in 10 mM 
HEPES pH 7 buffer. Concentration of Gua-HCl was increased between 0 and 6 M and the signal at 222 
nm monitored. 
3.3.4 Ca(II) Displacement  
Many Ln(III) binding sites evolve from native Ca(II) binding sites and although not 
designed for Ca(II), it was of interest to see if Ca(II) could bind or displace Ln(III) from the site. 
This is of particular significance due to the large quantities of Ca(II) in the body .  
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First a sample of 30 μM peptide monomer was run with integration of the spectra 
giving a base value for 0% Tb(III) binding. 10 μM Tb(III) was added to the above sample and 
left to equilibrate for 20 minutes before measuring. Integration of this spectrum gave a value 
representative of 100% Tb(III) binding. Ca(II) in aliquots of 10 μM, 100 μM, 1 mM and 10 mM 
was added to individual samples and left to equilibrate for 20 minutes. By integrating each 
spectrum and comparing to the 0% and 100% Tb(III) binding controls, the percentage of Tb(III) 
binding could be calculated for each sample. The average of three experiments with standard 
deviation error bars is shown in Figure 3.7. A decrease in Tb(III) binding was observed for all 
three peptides on addition of Ca(II). The largest decrease was observed for MB1-1S, which 
could be due to its unfolded structure and the increased accessibility of the Ln(III) binding site. 
Both MB1-1 and MB1-1L showed a negligible reduction in Tb(III) binding when there was a 1:1 
ratio of Tb(III):Ca(II) and a 10 - 30% reduction after the addition of 100 μM Ca(II) (1:10 ratio). 
This increased to a maximum of 80% displacement on addition of 10 mM Ca(II).  
This amount of displacement could be due to the binding site being positioned at the 
N-terminus of the coiled coil, making it more labile compared to if it was in the middle heptads. 
This could be concerning as it demonstrates that Gd(III) could be displaced by Ca(II) in the 
body, causing the release of highly toxic Gd(III). This, along with the binding constants, shows 
that the stability of the complex needs to be improved before the use of these probes in vivo. 
This could be achieved by cross linking the peptide strands so that Gd(III) is held more tightly 
in place within the Ln(III) binding site.  
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Figure 3.7: Bar chart showing percentage of Tb(III) remaining bound following Ca(II) displacement 
studies with MB1-1S, MB1-1 and MB1-1L. 30 μM peptide monomer and 10 μM Tb(II), in 10 mM 
HEPES buffer pH 7.0, in the presence of 10 μM, 100 μM, 1 mM and 10 mM Ca(II).  
3.3.5 Water Coordination 
The coordination environment of the metallo peptides was characterised further by 
establishing the amount of inner-sphere water coordinated to Tb(III) when bound to MB1-1S, 
MB1-1 and MB1-1L. Tb(III) luminescence decay lifetimes in H2O and D2O were used to probe 
the amount of inner-sphere water coordinated to Tb(III) when bound to MB1-1S and MB1-1L, 
with the data shown in Figure 3.8. The luminescence lifetime decays of MB1-1S and MB1-1L 
at 545 nm were recorded as 1.4 ± 0.2 ms in H2O and 0.7 ± 0.3 ms in D2O for MB1-1S and 1.5 ± 
0.3 ms in H2O and 0.6 ± 0.2 ms in D2O for MB1-1L.  
In order to correct for the contribution of outer sphere water, the Parker-Beeby 
equation116 was applied and it was found that primary water coordination remains largely 
unchanged for the three peptides (q = 3.5 ± 0.5, 3.1 ± 0.295 and 3.7 ± 0.7, for MB1-1S, MB1-1 
and MB1-1L, respectively).  
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 Figure 3.8: Representative decay profiles of Tb(III)  emission at 545 nm for 100 μM peptide 
monomer(a) MB1-1S and (b) MB1-1L on addition of 10 μM of Tb(III) in 10 mM HEPES buffer pH 7.0, 
recorded in both H2O (light) and D2O (dark) fit to a mono-exponential decay allowing for calculation 
of q values. 
The similar hydration states of MB1-1 and MB1-1L are proposed to be due to the fact 
that the addition and removal of a heptad at the C-terminus does not have a significant impact 
on coiled-coil stability, Ln(III) affinity and coordination chemistry, and is unlikely to impact on 
water penetration and coordination. As the additional heptad has been introduced at the C-
terminus, and the Tb(III) binding site is located at the N-terminus, it is unlikely that the binding 
site will be sensitive to subtle structural changes at the C-terminus (c.a. 5 nm away). Despite 
MB1-1S being unfolded in the metallo form, the q value remains the same, within error, as the 
two longer peptides. 
3.3.6 Relaxivity and MRI Contrast Agent Efficiency  
In order to establish if changing the length of the peptide affects relaxivity, the 
longitudinal (T1) and transverse (T2) relaxation times of water protons were investigated at 7 
T and 1 T, in the presence of increasing concentrations of Gd(MB1-1S)3, Gd(MB1-1)3 and 
Gd(MB1-1L)3, with the data shown in Figures 3.9 and 3.10, respectively.  
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An increase in the concentration of the Gd(III) complex leads to a decrease in both the 
T1 and T2 relaxation times for all peptides. The relaxivities were found to be (r1) 11.4 ± 1.5 and 
(r2) 71.0 ± 3.6 mM-1 s-1 for MB1-1S and (r1) 10.9 ± 0.8 and (r2) 81.8 ± 5.4 mM-1 s-1 for MB1-1L 
at 7 T. These can be compared to the values previously reported for MB1-1 (r1) 9.9 ± 1.5 and 
(r2) 88.3 ± 16.8 mM-1 s-1.95 This demonstrated that the change in peptide length is not 
significant enough to cause in a change in relaxivity between MB1-1 and MB1-1L. The relaxivity 
of MB1-1S was lower than the two longer peptides, which may be due to the lack of folding. 
 
Figure 3.9: Relaxivity plots of relaxation rates showing reciprocal of relaxation time as a function of 
Gd(III) concentration for  T1 (left) and T2 (right) for (top) MB1-1S, (middle) MB1-195 and (bottom) 
MB1-1L . All samples recorded at 7 T at 298 K in the presence of 10 mM HEPES buffer pH 7.0, with 
two equivalences of peptide trimer to Gd(III). Error bars show standard deviations from data 
repeated in triplicate. 
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T1 and T2 measurements were conducted at a lower field (1 T), for the two well-folded 
peptides (MB1-1 and MB1-1L), in order to assess if the effect of peptide size had more of an 
impact at lower field strengths. This is because rotational correlation time has previously been 
shown to have a larger impact on r1 at low fields.40 An increase in Gd(III) coiled-coil 
concentration led to relaxivities of (r1) 64.3 ± 3.2 and (r2) 87.6 ± 0.9 mM-1 s-1  for MB1-1, and 
(r1) 67.4 ± 4.2 and (r2) 96.5 ± 3.2 mM-1 s-1 for MB1-1L, with the data shown in Figure 3.10.  
 
Figure 3.10: Relaxivity plots of relaxation rates showing reciprocal of relaxation time as a function of 
Gd(III) concentration for  T1 (left) and T2 (right) for (top) MB1-1 and (bottom) MB1-1L . All samples 
recorded at 1 T at 298 K in the presence of 10 mM HEPES buffer pH 7.0, with two equivalences of 
peptide trimer to Gd(III) Error bars show standard deviation.  
Again little difference is observed between Gd(MB1-1)3 and Gd(MB1-1L)3. When 
comparing relaxivity data at the lower, and more clinically relevant field strength (1 T) with 
the higher field strength (7 T), the most notable difference is that the longitudinal relaxivity 
(r1) significantly increases (MB1-1 = 11.7 ± 1.5 to 64.3 ± 3.2 mM-1 s-1, MB1-1L 10.9 ± 0.8 to 67.4 
± 4.2 mM-1 s-1). It is well understood that r1 typically increases at low fields for large complexes 
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with slow rotational correlation time.40 For example, small and rapidly tumbling Gd(III) 
complexes, such as MS-325, show only a small increase in r1 on lowering the field strength, 
from 5.2 mM-1 s-1 at 9.4 T to 8.3 mM-1 s-1 at 1.4 T. This is in contrast with the slow tumbling 
analogue formed on binding to HSA, where an increase from 7.2 mM-1 s-1 at 9.4 T to 24.3 mM-
1 s-1 at 1.4 T is observed. This is due to molecular tumbling becoming more significant at low 
fields.40 In contrast, r2 remains largely unchanged with changing field strengths, and, if 
anything, increases with increasing field strength.40,46 This is because Gd(III) magnetises 
linearly and the susceptibility effects of Gd(III) are higher with increasing field strength and 
this results in greater r2 at high fields.40  
3.3.7 Prediction of the Rotational Correlation Time  
As part of a collaboration with Dr Smith, School of Maths, University of Birmingham, 
hydrodynamic calculations, based on the equations by Kim and Karrila,131 were performed to 
calculate a theoretical rotational correlation time of MB1-1S, MB1-1 and MB1-1L. This method 
has previously been used to model prolate spheroids and applied to the Olfactory Marker 
Protein, a globular protein, and a bacteriorhodopsin fragment in which all residues experience 
nanosecond timescale motions,132,133 and is described in more detail by Holde et al.134 
Rotational correlation times of 4.6, 6.9 and 10.0 ns were calculated for MB1-1S, MB1-1 and 
MB1-1L, respectively. This shows that the addition of a heptad theoretically increases the 
rotational correlation time by 2-3 ns. Relaxivity will reach a maximum when the correlation 
time is the inverse of the proton Larmor frequency. For a 1.5 T imaging spectrometer, as used 
clinically, the optimum τc is 2.5 ns and the optimum value for τm is about 10 ns.15 When 
comparing to the MB1 peptides, MB1-1L is closest to this optimum value for low field imaging. 
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3.3.8 Prediction of the Water Residence Time  
Calculations derived from the SBM equations were written, as shown in Appendix A9,  
and run in MATLAB135 for the two stable and well folded coiled-coils, MB1-1 and MB1-1L. The 
theoretical longitudinal relaxivity was plotted as a function of water residence time, for both 
low (1 T) and high field strengths (7 T), with the data shown in Figure 3.11. In addition to the 
rotational correlation time, relaxivity is dependent on how the Gd(III) ion interacts with water 
molecules, including the number of bound water molecules, the water residency time and the 
Gd-water distance. 
From the previously described Tb(III) lifetime experiments, it is assumed that Gd(MB1-
1)3 and Gd(MB1-1L)3 coordinate Gd(III) in a very similar fashion, having a very similar (within 
error) number of coordinated water molecules. The two metallo complexes are assumed to 
differ primarily in their rotational correlation time in solution. From the predictive plot shown 
in Figure 3.11, it is observed that when r1 = 11 mM-1 s-1 (7 T) and r1 = 65 mM-1 s-1 (1 T), (an 
average of what was as calculated for Gd(MB1-1)3 and Gd(MB1-1L)3 experimentally) the water 
residency time is either extremely short, or extremely long, being located on either extreme 
of the predictive curves. At 7 T the water residency time is calculated to be either 0.5 ns or 
3000 ns for both Gd(MB1-1)3 and Gd(MB1-1L)3. At 1 T the water residency time is calculated 
to be either 6 ns or 500 ns for both Gd(MB1-1)3 and Gd(MB1-1L)3. The short values (0.5 and 6 
ns) would be consistent with values reported for water coordinated to free Gd(III) in aqueous 
solution (1 ns)17, whereas the longer value is more in line with what has been reported for 
small molecule Gd(III) complexes, such as [Gd(DTPA)]2- (gadopentetic acid/ Magnevist), bound 
to a protein complex (1000 ns).15  
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Figure 3.11: Effect on r1 with changing water residency time τm (ns), for a q=3 system, on r1 at field 
strengths of (a) 1 T and (b) 7 T, with rotational correlation times of  6.9 ns corresponding to MB1-1 
(red) and 10.0 ns corresponding to MB1-1L (blue).  
3.3.9 Experimental Water Residence Time in Gd(MB1-1)3 
Variable temperature 17O NMR is a technique used to provide information regarding 
water residence time and water exchange. The technique works by measuring the exchange 
rate of the oxygen atom of water and can provide information on the chemical exchange 
mechanism. Transverse relaxation rates are measured using a CPMG pulse sequence and the 
relaxation data interpreted using SBM theory and the Swift and Connick Equations.136  
In order to establish which scenario was most likely, as part of a collaboration with Dr. 
Ivanovic-Burmazovic at Friedrich-Alexander-Universität, Germany, 17O NMR was used to 
calculate the water residence time for Gd(MB1-1)3 which was found to be very short (1.56 ns) 
and of the same order of magnitude as that measured for 9-coordinated Gd(III) aqua complex 
(1.02 ns). This is similar to the rapid water residency times (0.5 and 6 ns) predicted in Figure 
3.11.20–22  
When looking at Figure 3.12, based on a fast water residency time of 1.56 ns, it is 
predicted that there will be very little difference in relaxivity of MB1-1 and MB1-1L at either 1 
T or 7 T for the given rotational correlation times. In order to see a difference in relaxivity for 
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MB1-1 and MB1-1L it theoretically would be necessary to redesign the binding site to change 
the water residency time to between 7 – 300 ns.   At a water residency time of 40 ns, it is 
calculated that the highest possible r1 for this class of contrast agent will be observed at 1 T 
and the greatest difference between rotational correlation times of 6.9 and 10 ns will be 
observed at 7 T. Therefore, an analogue of MB1-1 with τm of 40 ns could be designed to 
achieve maximum r1 at 1 T, and a difference in τR at both field strengths would be observed. 
 
Figure 3.12: Effect on r1 with changing water residency time τm (ns), for a q=3 system, on r1 at field 
strengths of (a) 1 T and (b) 7 T, with rotational correlation times of  6.9 ns (red) and 10.0 ns (blue). 
3.4 Conclusions  
This study illustrates a number of key points about the MB1-1 series of Gd(III) coiled-
coils. Firstly, a minimum of 5 heptads is required for successful coiled-coil folding, in the 
presence of a Ln(III) binding site. This is due to the de-stabilising nature of the negatively 
charged site being overcome with increased length. This was not achieved in MB1-1S where 
there were 4 heptads. For peptides consisting of 5 or 6 heptads, Ln(III) binding to a N-terminal 
site caused little change in structure, stability and coordination chemistry, as evident from CD 
and luminescence. This translated through to the MRI studies in which MB1-1 and MB1-1L 
exhibited the same r1 and r2 relaxivities at both 1 and 7 T. This study suggests that when 
considering the SBM equations the rotational correlation time is not the limiting factor for this 
40 ns 
1.56 ns 
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class of contrast agent at the magnetic field strengths used and as q remains constant, the 
water residency time must be limiting.  
Water residency time was calculated using 17O NMR and investigated using 
calculations to determine how relaxivity was affected when using different rotational 
correlation times. It was found that no difference in r1 would be observed between MB1-1 
and MB1-1L when τm = 1.56 ns. By slowing τm to 40 ns it was predicted that a difference would 
be observed between the two peptides and r1 would be at its maximum at 1 T. This could be 
further investigated using the MB1 series of peptides where the Ln(III) binding site is 
translated along the coiled coil, specifically with MB1-4 where q = 2. As the Ln(III) binding site 
is located further into the hydrophobic core, it would be predicted that the water residency 
time will be longer and may fall in the optimum window predicted in Figure 3.12. This will 
provide more information with regards to the importance of water residency time in this class 
of contrast agent and how it can impact relaxivity.    
~ 65 ~ 
 
Chapter 4: Investigation of the Importance of Water 
Coordination to the Exterior of a Coiled-Coil MRI Contrast 
Agent 
4.1 Introduction  
In addition to inner-sphere water mechanisms, secondary sphere water mechanisms 
can contribute to relaxivity. This is defined as water which hydrogen bonds to inner-sphere 
water or the contrast agent (CA).45 This second sphere is defined by the water residence time, 
which must be longer than the diffusional correlation time and can lead to a strong 
enhancement of the relaxivity of the CA.45 Secondary sphere water is governed by the same 
parameters as inner-sphere water, as described by the SBM equations, and has previously 
been investigated using a number of different metal centres.137–140 The three defined 
hydration spheres (inner, secondary and outer) are compared in Figure 4.1. 
 
Figure 4.1: Schematic diagram to show the location of inner, second and outer sphere water 
molecules surrounding an MRI CA. 
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When investigating secondary sphere water for GdCAs there are three distinct features 
that must be considered for optimisation.45 (1) The water residence time (τm) for current MRI 
CAs is two orders of magnitude longer than the optimal value. This is a major challenge for 
achieving high relaxivity.45 (2) The metal to hydrogen distance (rMH) values for inner-sphere 
water molecules show little variation amongst Ln(III) complexes with different charge, 
coordination number and hydration state. The distance of secondary sphere water is more 
varied and has previously been investigated between 3.2 and 4.5 Å. Due to the 1/rMH6 
dependence, control of this parameter is of high importance in order to obtain high 
relaxivities.45 (3) Unlike in the inner-sphere, the number of water molecules located in the 
second sphere can increase without the number of donor atoms of the ligand changing and 
without hindering the stability of the complex.45  
Secondary sphere water plays a small role in the relaxivity of small molecule GdCAs, 
however, it is very important to consider for an accurate interpretation of relaxivity data and 
for a better understanding of the relationship between structure and relaxivity.45 It has 
additionally been found that secondary sphere relaxivity has a direct impact on q = 0 
complexes, such as MB1-2, where the relaxivity cannot be attributed to inner or outer sphere 
mechanisms. Instead it arises from exchangeable water in the second sphere.  
There are a number of examples which highlight the importance of secondary sphere 
water, using a range of metals. Kushnir and Navon investigated water relaxation enhancement 
using Mn(II) bound to a series of macromolecules. They found an additional contribution to 
the inner-sphere r1 mechanism, which dominated when analysed at high fields.137 This 
additional contribution could not be explained by an inner or outer sphere mechanism. It was 
determined that the water molecules were located outside the inner-sphere with an average 
residency time of 0.3 ns, thus being defined as secondary sphere.137 Oakes and Smith 
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investigated the relaxation properties of [Mn(EDTA)(H2O)]2- and found secondary sphere 
contributions to be from four water molecules which were hydrogen bonded to four 
coordinated carboxylate groups. The metal-hydrogen distance was calculated to be 3.7 Å, 
close enough to have a significant impact on the overall relaxivity.138 Merbach and co-workers 
reported a detailed computational and 17O NMR investigation into the structure and dynamics 
of the second hydration sphere around a Cr(III) hexa-aqua ion. Thirteen water molecules were 
found to be located in the second sphere with an average lifetime of 128 ps, resulting in a 
large increase in relaxivity.139,140 
4.2 Aims 
Secondary sphere water coordination was investigated with the MB1 peptide series. 
Through the careful selection of hydrogen bond acceptor groups on the ligand, there is the 
possibility to promote the formation of strong interactions between the CA and water, 
increase the number of water molecules located in the second hydration sphere and shorten 
their average distance from Gd(III), all attributing to an increase in relaxivity.45 A peptide was 
designed, in order to compare to MB1-2,97 with the potential to coordinate more water to its 
exterior. An increase in secondary sphere water coordination to the peptide exterior was 
hypothesised to result in an increase in relaxivity. By using a design where q = 0 any change to 
the relaxivity could be attributed to secondary sphere water interactions on the coiled-coil 
exterior. The peptides discussed in this chapter are the same length as MB1-1 in Chapter 3.  
Table 4.1: Mo1-2 and MB1-297 peptide sequences. Additional lysine and glutamate residues in Mo1-2 
are shown in bold and underlined. 
Peptide  Sequence  
MB1-2 Ac – G – IAAIEQK IAANEWK DAAIEQK IAAIEQK IAAIEQK – G – NH2  
Mo1-2 Ac – G – IKAIEEK IKENEWK DKAIEEK IKAIEEK IKAIEEK – G – NH2 
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Figure 4.2:  Schematic diagram of (a) MB1-2 and (b) Mo1-2. The peptide backbone is 
represented as a cartoon, binding site (Asn, Asp) and sensitiser (Trp) shown as sticks, additional Lys 
residues in Mo1-2 shown as red sticks and Ln(III) as a sphere.  
The new peptide, Mo1-2, has additional lysine (K) residues, which have replaced 
alanine (A) residues, on its exterior in the b position, the sequence is compared to MB1-2 in 
Table 4.1 and the structures are compared in Figure 4.2. Mo1-2 was initially designed in 
collaboration with Muhammed Rassul as part of a PSIBS mini project. Alanine is known to be 
a helix-inducing amino acid, whereas lysine can hydrogen bond to water, has the ability to 
form salt bridges with polar amino acids on the other peptide chains within the coiled coil, 
and induces coiled-coil formation. Water can hydrogen bond to the NH3+ group of the lysine 
side chain, which could result in enhanced water coordination with the peptide, and has the 
potential for increased relaxivity. The glutamine (Q) residue at position f of the heptad was 
replaced with glutamate (E), in order to balance the charge of the lysine residues in the coiled 
coil. Polar residues such as glutamine and glutamate are known to help with solubility and can 
hydrogen bond to water through their polar side chains. The structures of these amino acids 
are shown in Figure 4.3.  
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Figure 4.3: Amino acid substitutions in the newly designed Mo1-2 peptide.  
A further consideration is the longer length of the lysine side chain, compared to that 
of alanine. Lysine has a number of rotamers which will increase the size of the major b axis 
(width), shown in Figure 4.4. This has the potential to reduce the rotational correlation time 
which in turn could increase the relaxivity. However, in this class of CA this would be unlikely 
as the rotational correlation time was concluded to not be a limiting factor in Chapter 3.  
Secondary sphere water coordination in this chapter is described as water coordinated 
to the exterior of the coiled coil. It is important to consider that secondary sphere water can 
also be coordinated to the primary sphere water or within the hydrophobic core of the coiled 
coil. The location of the secondary sphere water coordinated to the exterior of Mo1-2 is much 
further away from Gd(III) than water coordinated to the primary sphere water, or within the 
hydrophobic core, which could mean it results in a smaller increase to relaxivity. The water 
residency time for secondary sphere water coordinated to the coiled-coil will be sufficiently 
faster than water coordinated to primary sphere water within the coiled-coil construct. This 
difference in water residency time will also impact how much the relaxivity will change.   
Glutamate (E) 
Alanine (A) 
  
 Lysine (K) 
Glutamine (Q)  
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Figure 4.4: Introduction of lysine residues into a model of Mo1-2 increase the major b axis 
(shown in black). The peptide backbone is shown as a cartoon with the lysine residues displayed as 
sticks. 
4.3 Results and Discussion 
4.3.1 Secondary Structure  
The secondary structure of Mo1-2 was experimentally determined using CD 
spectroscopy, with data shown in Figure 4.5. A 30 µM solution of Mo1-2 monomer forms a 
partially α-helical peptide, as is evident from the minimum at 208 and 222 nm in the CD 
spectrum. The intensity at 222 nm is consistent with a partially folded α-helical coiled-coil 
peptide (Θ222 = −9184 deg dmol-1 cm2, 27 ± 4%). On addition of 10 µM GdCl3 an increase in the 
intensity of the minimum at 222 nm is observed, with the spectrum now consistent with 
enhanced peptide folding (Θ222 = −22913 deg dmol-1 cm2, 66 ± 8%).  
This is very similar to the behaviour of MB1-2 where the intensity of the apo peptide 
represents some α-helical coiled-coil formation (Θ222 = −7460 deg dmol-1 cm2, 21 ± 3%). On 
addition of 10 µM GdCl3 the spectrum becomes more representative of a well folded coiled-
coil (Θ222 = −21971 deg dmol-1 cm2, 62 ± 3%). It can be concluded that the substitutions made 
to the coiled-coil exterior, caused no substantial change in folding, within the error of the 
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experiment. This is due to the Ln(III) binding site remaining in the same position within the 
hydrophobic core and the isoleucine residues that template the hydrophobic core remaining 
unchanged. A small decrease in folding could have been expected due to the strongly alpha-
helix inducing alanine residues in MB1-2 being replaced with lysine residues, however, no 
change in folding was observed. 
 
Figure 4.5: CD profile of 30 μM monomer peptide in the presence (dashed) and absence (solid line) 
of 10 μM GdCl3 in 10 mM HEPES buffer pH 7.0, for MB1-2 (black line) and Mo1-2 (grey line).  
4.3.2 Calculation of a Binding Constant using CD and Luminescence  
Titrations of aliquots of GdCl3 into a 30 μM solution of Mo1-2 monomer were 
monitored by CD and led to a gradual increase in the signal at 222 nm which plateaued at 
higher equivalences, with the data shown in Figure 4.6. A 1/3 Gd + Mo1-2  1/3 Gd(Mo1-2)3 
binding model was used to interpret the data, giving an average association constant (log Ka) 
of 5.3 ± 0.3, however, it was found that the Mo1-2 data did not fit well to a 1:3 binding model. 
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Figure 4.6: CD titration of 30 μM (a) Mo1-2, (b) MB1-2 with increasing aliquots of GdCl3 in 10 mM 
HEPES buffer pH 7.0. The normalised fraction folding is shown to the right. Models for MB1-2 + 
1/3Gd(III) -> 1/3(Gd(MB1-2)3)  and Mo1-2 + 1/4 Gd(III) -> 1/4 (Gd(Mo1-2)4) were used, allowing the 
calculation of a binding constant.  Error bars are standard deviation for n=3 experiments.  
Because of this, 1:2 and 1:4 binding models were investigated. A binding constant for 
each stoichiometry was predicted, generating a theoretical fit, as shown in Figure 4.7. It was 
shown that the 1:4 prediction was the most similar to the experimental data. A 1:4 binding 
model was used to analyse the experimental data and yielded a log Ka of 4.0 ± 0.3. It was 
unexpected that the new Mo1-2 peptide no longer had a 1:3 stoichiometry as no change to 
the trimeric inducing residues was made.  
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Figure 4.7: (a) Theoretical predictions for a 1:2, 1:3 and 1:4 stoichiometry, generated using ChemEQL 
Software.141 Ln(III) was used with ligands (L) with a -1 charge. An estimated binding constant of log Ka 
= 4.0 was used in the calculation. (b) Overlay of 1:4 predication (green) and experimental CD data 
(grey). 
Tb(III) titrations were monitored directly by luminescence allowing for verification of 
the stoichiometry of Mo1-2, with the data shown in Figure 4.8. A solution of 30 μM Mo1-2 
monomer was excited at 280 nm, and the emission spectrum monitored from 455 - 700 nm, 
with an increase in the intensity of the characteristic Tb(III) emission peaks displayed on the 
addition of Tb(III). The region from 530 – 560 nm was integrated and plotted as a function of 
Tb(III) concentration. A sharp increase followed by a plateau at a 1:4 equivalence was 
observed, representative of saturation of the binding site with Tb(III). A binding model of 1/4 
Tb + Mo1-2 1/4 Tb(Mo1-2)4 was used, giving an association constant (log Ka) of 4.3 ± 0.6. 
This can be compared to MB1-2 where log Ka was calculated to be 5.1 ± 0.2 using CD and 5.5 
± 0.2 using luminescence.  
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Figure 4.8: Emission profile of (a) Mo1-2 and (b) MB1-2 with increasing aliquots of Tb(III) ran in 10 
mM HEPES buffer pH 7.0, using a λexc = 280 nm. The normalised integration of the 545 nm peak is 
shown to the right.  MB1-2 + 1/3 Gd(III)   1/3(Gd(MB1-2)3) and Mo1-2 + 1/4 Tb(III)   1/4(Gd(Mo1-
2)4) binding models allowed for the calculation of a binding constant.  Error bars are standard 
deviation for n=3 experiments.  
4.3.3 Determining the Oligomeric State of Mo1-2 
Due to the discrepancy in fitting the binding curve of Mo1-2, analytical ultra-
centrifugation (AUC) was used to determine the mass and stoichiometry of the metallo 
complex, with the data collected as part of a collaboration with Dr Adams at the University of 
Nottingham and the data shown in Figure 4.9. A weighted average of 11.6 ± 0.2 kDa was 
calculated with a z-average of 14.2 ± 0.7 kDa. This is consistent with a system with a species 
of 8 kDa and 18 kDa, corresponding to a metallo dimer and tetramer in a ratio of 62% dimer 
and 38% tetramer. It is possible that these numbers are underestimates due to the effects of 
non-ideality, but this should not impact the result by a large margin. 
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Figure 4.9: AUC data analysed by MULTISIG. The overall weight and z-averages are given as 11.4 kDa, 
13.5 kDa.  The distribution shows two species, one at 8 kDa and one at 18kDa, which matches closely 
to a dimer-tetramer system.  
Coiled-coil peptide sequences consist of heptad repeats which contain two 
hydrophobic positions (a and d).84 These residues have the ability to determine the 
stoichiometry of the coiled coil.142 Alber and co-workers investigated the change in structure 
of derivatives of the GCN4 leucine zipper when sets of buried residues (a and d position) in 
the  peptide sequence were altered and found that dimer, trimer and tetramer structure could 
be formed.84 The occurrence of isoleucine at the a position and leucine at the d position of 
the heptad repeat was found to favour the formation of a dimer, whereas the reverse 
arrangement resulted in a tetrameric peptide. It was found that an even distribution of 
isoleucine, where it is positioned at both the a and d positions, resulted in a trimer.84,86 In the 
Mo1-2 peptide isoleucine is positioned at the a and d position in four of the heptads with a 
substitution for asparagine in the d position of the second heptad and aspartate in the a site 
of the third heptad in order to form the Ln(III) binding site. From this amino acid configuration 
we would predict the formation of a trimer. The same substitution is made in MB1-2 where a 
trimer is known to form. 
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In addition to leucine and isoleucine, polar residues which are buried in the 
hydrophobic core of a coiled-coil peptide can play a significant role in defining the 
stoichiometry of the coiled coil. Two-stranded coiled-coils such as those in transcription 
regulators,86 often contain at least one asparagine residue at position a, toward the centre of 
the sequence.86,87,142 Polar residues such as glutamine and threonine at positions a and d are 
also shown to favour trimer formation. In the Mo1-2 sequence, glutamine has been replaced 
with glutamate in the f sites. Glutamine is also present in the e position in both Mo1-2 and 
MB1-2. There is one asparagine in the d site of the third heptad which could signify for a 
dimeric structure, however, this same substitution occurs in the MB1-2 peptide where a 
trimer peptide is known to form.97 
The driving force for trimerisation can be described by the optimal organisation of side-
chain–side-chain interactions of the heptad repeat. The motif incorporates networks of 
surface salt bridges and optimal internal hydrophobic packing interactions.87 It was found that 
the same motif is present in intracellular, extracellular, viral and synthetic trimeric coiled coils.  
In MB1-2 and Mo1-2, glutamate is at position e and lysine at position g to promote the 
formation of inter-helical salt bridges, for stabilisation and trimeric formation.  
The characteristic rules of coiled-coil formation developed in the 1990’s have allowed 
for the development of pattern-based methods that predict the occurrence of a specific 
stoichiometry with a high degree of confidence.87 These methods allow the user to input the 
primary structure of a coiled coil. The programme determines the stoichiometry based on the 
location of hydrophobic and hydrophilic amino acids as well as taking into account key 
features of all the amino acids present in the primary structure.  
Investigation into the stoichiometry of coiled-coil peptides has been further 
undertaken by Woolfson and co-workers.143–148 This has included the development of a 
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number of algorithms, e.g. LOGICOIL149 and SOCKET150, which have the ability to identify 
coiled-coil domains in the structures of natural proteins. This has resulted in a database, 
CCPLUS,151 and Periodic Table of Coiled-Coil Structures152 which lists the natural coiled-coil 
domains from the Protein Data Bank. The rules for coiled-coil stoichiometry and folding are 
integrated into the database to provide a guide for de novo coiled-coil designs. 
It was of interest to calculate what stoichiometry the Mo1-2 peptide would be 
predicted to be, using the rules for coiled-coil formation. LOGICOIL149 analysis has the ability 
to determine the contribution of dimer, trimer and tetramer species. The algorithm uses 
information from over 90% of known coiled-coil structures.149 The statistical method used in 
LOGICOIL (Bayesian variable selection) can be easily applied to predict coiled-coil oligomeric 
states, and also has the ability to account for higher order associations such as inter helical 
interactions.149  
Table 4.2: LOGICOIL predictions for MB1-2 and Mo1-2 
Peptide Antiparallel 
dimer 
Parallel dimer Parallel Trimer Parallel Tetramer 
MB1-2 1.01 1.03 1.22 0.49 
Mo1-2 1.01 0.90 1.36 0.81 
 
The results of the LOGICOIL analysis performed for Mo1-2 and MB1-2 are shown in 
Table 4.2. It was predicted that the most probable state of Mo1-2 would be a trimer with the 
second most probable being an antiparallel dimer. In comparison, it was predicted that  MB1-
2 was most likely to be a trimer with the second most probable structure being a parallel 
dimer. 
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Figure 4.10: Parallel dimer, trimer and tetramer helical wheel diagrams for Mo1-2. The binding site 
amino acids are circled in red. Salt bridges are shown by blue dashed lines for the dimer structure 
and the salt bridge between aspartate and lysine is circled in blue. Figures generated using DrawCoil.  
 
The stoichiometry of Mo1-2 was further investigated by drawing helical wheel 
structures, shown in Figure 4.10, it is possible to see the potential for the formation of a Ln(III) 
binding site in a dimer, trimer and tetrameric composition. Salt bridges are shown to form 
between the lysine residues at the g positon and the glutamate residues at the e position in 
the dimer structure. Interestingly a salt bridge is also shown to form between the aspartate 
binding site residue at the a position and a lysine residue in the heptad above in the dimer 
structure. This could mean that the aspartate residue may no longer be involved in binding 
the Ln(III). It would be proposed that more water could coordinate to the Ln(III) in the dimeric 
structure, increasing the q value. This is because only three ligands are forming the Ln(III) 
binding site, one bi-dentate aspartate residues and two mono-dentate asparagine residues. If 
this is the case, it could result in a higher relaxivity. In the tetrameric structure, there are 12 
possible donor atoms for Ln(III) binding. This would be likely to result in q = 0 as there are no 
free coordination sites for water if all peptide ligands are involved in Ln(III) binding.  
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4.3.4 Effect of Oligomeric State on the Rotational Correlation Time  
By looking at the helical wheel diagrams in Figure 4.10 it is possible to see the potential 
for the formation of dimer and tetramer structures, which were shown to be present in the 
AUC analysis. From the LOGICOIL predictions and positions of the amino acids chosen in the 
Mo1-2 peptide we would still expect a trimer to form. This was further investigated using MD 
simulations. Simulations were conducted in triplicate, using AMBER, of Mo1-2 in a dimeric, 
trimeric and tetrameric structure with the 10 ns snapshot output compared in Figure 4.11. 
  
Figure 4.11: Schematic representation of a snapshot of a 10 ns MD simulations of Mo1-2 as a (a) 
dimer, (b) trimer and (c) tetramer. The peptide backbone is shown as a cartoon with the binding site 
amino acids and tryptophan sensitiser shown as sticks. The Gd(III) ion is shown as a grey sphere. 
In the dimer simulation, only the four oxygen donor atoms from the aspartate residues 
are shown to be involved in Ln(III) binding. The Ln(III) is shown to be positioned outside of the 
hydrophobic core. This is different from the helical wheel diagram which showed that the 
aspartate residue would be involved in salt bridge formation rather than Ln(III) binding and 
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could allow for an increase in q. However, the helical wheel diagram is a much simpler 
depiction compared to MD simulations. 
In the trimer, six oxygen atoms from the aspartate residues and three oxygen atoms 
from the asparagine residues are shown to be involved in Ln(III) coordination. This leaves three 
available binding sites for water coordination. 
In the tetramer, the eight oxygen ligands from the four aspartate residues are shown 
to coordinate to the Ln(III) this leaves four coordination sites on the Ln(III) available for a 
water. The asparagine ligands although oriented towards the Ln(III), do not appear to take 
part in Ln(III) coordination.  
 
Figure 4.12: Snapshot of 10 ns MD simulations of Mo1-2 as a (a) dimer, (b) trimer and (c) tetramer. 
The peptide backbone is shown as a cartoon with the binding site amino acids and tryptophan 
sensitiser shown as sticks. The Gd(III) ion is shown as a grey sphere and inner-sphere water shown as 
a red and white sphere. 
(a) (b) (c) 
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When comparing water coordination to the Ln(III) in the MD simulations of the three 
systems, it was found that, after 10 ns, four water molecules were coordinated to the dimer, 
zero to the trimer and one to the tetramer, as shown in Figure 4.12. A q of four for the dimer 
would result in a dramatic increase in relaxivity compared to the trimer species with no inner-
sphere water.  
 
Figure 4.13: Top down and side on view of 2 ns snapshots of the MD simulation of the Mo1-2 dimer. 
The peptide is shown as a cartoon with the binding site and tryptophan residues shown as sticks. The 
Ln(III) is shown as a grey sphere and primary water is shown as red and white spheres. 
Primary water coordination was further investigated for the dimer simulation, with 
snapshots shown in Figure 4.13. When analysing the snapshots taken every two nanoseconds, 
it was observed that at 2 ns the dimer species has q of zero and the Ln(III) is located in the 
centre of the isoleucine core. After 4 ns, the Ln(III) moves to the helical interface of the 
peptide, and locates itself between the two α-helices. Now q increases to five. This remains 
the same until 10 ns where q reduces to four, suggesting an inner-sphere water residency time 
of 6 ns. Throughout the 10 ns simulation, the four oxygen atoms from the two aspartate 
~ 82 ~ 
 
residues are involved in Ln(III) coordination. From 2 ns to 6 ns one oxygen ligand from an 
asparagine residue coordinates to the Ln(III), this dissociates by 8 ns. Also observed over the 
10 ns is distortion of the α-helix. This is most apparent at 4 ns where the peptide structure 
below the lanthanide binding site is no longer α-helical.  
 In the tetramer simulation (a snapshot shown in Figure 4.14) one inner-sphere water 
is coordinated to the Ln(III). This water molecule is present throughout the 10 ns simulation, 
suggesting an inner-sphere water residency time longer than 10 ns. This can be compared to 
the inner-sphere water residency time in MB1-1 which was experimentally determined to be 
1.56 ns using 17O NMR and calculated to be between 0.5 and 6 ns using the SBM equations. 
This could be due to the Ln(III) binding site being located further into the hydrophobic core. 
Additionally, one secondary sphere water molecule was coordinated to the primary sphere 
water which could provide an increase in relaxivity through the secondary sphere mechanism.  
 
Figure 4.14: A snapshot at 10 ns of a hypothetical Mo1-2 tetramer. The peptide is shown as a cartoon 
and mesh, the binding site and tryptophan amino acids are shown as sticks, Ln(III) is shown as a grey 
sphere and the waters of interest are shown as red and white spheres.  
 
To investigate the theoretical impact different peptide oligomers would have on 
relaxivity, due to changes in their dimensions and their rotational correlation times, the width 
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of the coiled coils, from the MD simulations was measured, and found to be 24.1 ± 2.7 Å for 
the dimer, 23.3 ± 2.1 Å for the trimer and 26.7 ± 4.2 Å for the tetramer. The length of the three 
different stoichiometries remained the same (57 Å). The rotational correlation time was then 
calculated for the changing width of the coiled coil using the same calculations as in Chapter 
3, with the results plotted in Figure 4.15. 
It was found that the rotational correlation time increased as the width of the coiled 
coil increased. For the dimer, trimer and tetramer it was found that the change in width had 
very little effect on the rotational correlation time, increasing it from 6 ns to 8 ns. 
  
Figure 4.15: Predicated effect of changing the width of a coiled coil on the rotational correlation 
time. Highlighted area shows the change in width from 24.1 Å to 26.7 Å, corresponding to a change 
in rotational correlation time of 6 to 8 ns, calculated for a peptide length of 57 Å. 
 The calculated rotational correlation times were then used to calculate the r1 relaxivity, 
with the data shown in Figure 4.16. Four different q values were used as it was proposed from 
the MD simulations that q = 4 for the dimer, q = 0 for the trimer and q = 1 for the tetramer. As 
a value of 0 would return a null answer, intermediate values of 0.5 and 2 were also considered. 
It was found that no change in r1 is observed when the rotational correlation time changes 
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between 6 and 8 ns, when calculated for each q value. An increase is observed up to 5 ns, but 
after this there is little change in r1 for all q values.  
These calculations demonstrate that the change in stoichiometry between a dimer, 
trimer and tetramer have very little effect on r1, if q remains the same. This is due to the small 
change in width only causing a change in the major b axis and the length (major a axis) 
remaining the same.  
 
Figure 4.16: Predicted effect of changing the rotational correlation time on r1 relaxivity for a q = 0.5 
(blue), 1.0 (red), 2.0 (green) and 4.0 (yellow). Predictions made at 7 T, τm = 1.56 ns, r = 2.6 nm. 
To further investigate the importance of secondary sphere water coordination, the 
Mo1-2 peptide was characterised using CD, luminescence and MRI in order to determine the 
stability of the complex, quantify the amount of water coordinated to the Ln(III) when bound 
to the binding site and to determine the relaxivity. It was anticipated that this analysis would 
give further insight into the stoichiometry of the peptide as if experimentally q = 1 it would 
indicate the presence of a tetramer species with q values of more than one indicative of the 
presence of a dimer species. 
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4.3.5 Effect of Amino Acid Substitutions on Peptide Stability  
CD spectroscopy was used to determine the chemical and thermal stability of Mo1-2, 
in comparison to MB1-2, with the data shown in Figure 4.17. Samples containing 30 μM of 
Mo1-2 monomer, in the absence and presence of 10 μM GdCl3, were subjected to a gradual 
increase in temperature from 25 to 85˚C, and the CD signal at 222 nm was recorded as a 
measure of folding.  
The apo peptide was 28% folded at 25˚C and decreased to 18% folded at 85˚C. The 
metallo complex was 63% folded at 25˚C and decreased to 28% folded when the temperature 
reached 85˚C. This is shown to be comparable to MB1-2 which in the apo peptide was 19% 
folded at 25˚C and remained the same at 85˚C. The metallo complex was 59% folded at 25˚C 
and decreased to 28% folded when the temperature reached 85˚C.This shows the stability for 
both peptides, in the apo and metallo complexes, is the same within the error of the 
experiment, indicating the change in exterior residues or change in stoichiometry did not 
impact peptide stability.  
 
Figure 4.17: Change in percentage folded of 30 μM (black) MB1-2 and (grey) Mo1-2 monomer in the 
absence (dark) and presence (light) of 10 μM GdCl3 in 10 mM HEPES buffer pH 7.0. % folded based on 
the CD signal at 222 nm.  
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Chemical denaturation showed the folding of Mo1-2 to decrease by 60% in the 
presence of 6 M guanadinium hydrochloride (Gua-HCl), when monitored by CD. A two-state 
equilibrium model between folded and unfolded was used to examine the peptide unfolding 
profiles. Extrapolation of the data gave free energies of folding, ΔG°H2O, of 14.0 ± 2.3 kcal mol-
1 for the apo peptide, and 16.4 ± 0.8 kcal mol-1 for the metallo complex. This can be compared 
to MB1-2 which gave ΔG°H2O, of 12.7 ± 1.5 kcal mol-1 for the apo peptide, and 15.3 ± 2.0 kcal 
mol-1 for the metallo complex. ΔG°H2O for both apo and metallo systems is the same, within 
the error of the experiment, for MB1-2 and Mo1-2. This shows that the modification of the 
exterior of the coiled coil, or the possible change in stoichiometry, has no noticeable influence 
on the stability of the peptide. Despite this, when comparing the trends of Mo1-2 and MB1-2 
they were shown to be different, especially in the metallo system, as shown in Figure 4.18. In 
Gd(Mo1-2)3 a sharp transition followed by a plateau at 3 M is observed. In comparison in 
Gd(MB1-2)3 a slower transition occurs followed by a plateau at 4 M suggesting Gd(MB1-2)3 is 
more stable. It was hypothesised that Mo1-2 would be more stable due to the presence of 
more side chains, lysine and glutamate, with the potential to form stabilising salt bridges 
across the coiled coil but this was not observed in this experiment. 
Figure 4.18: Change in molar ellipticity of 30 μM (a) Mo1-2 and (b) MB1-2 monomer in the absence 
(red) and presence (blue) 10 μM GdCl3, in 10 mM HEPES buffer pH 7.0 as a function of [Gua-HCl] . 
Concentration of Gua-HCl was increased between 0 and 6 M and the signal at 222 nm monitored. 
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4.3.6 Computational Analysis of Water Coordination to the Peptide Exterior 
 
Figure 4.19: Schematic diagram to show the distances from the central Gd(III) to various locations 
within the Mo1-2 coiled coil. (a) Shows the distances of each point in the coiled coil measured from 
the Gd(III) ion and (b) shows how the coiled coil fits within these measurements. 
 In the work by Berwick and co-workers,95,97 the MB1-2 peptide was designed with a 
Ln(III) binding site positioned in the second and third heptads. The complex was reported to 
have q = 0.0 ± 0.1 and a relaxivity of 4.1 ± 1.2 mM-1 s-1 (r1) and 24.4 ± 2.6 mM-1 s-1 (r2) at 7 T.97 
Here, outer sphere water coordination was considered to be the main contributing factor to 
relaxivity. MD simulations and computational analysis were used in order to analyse the 
secondary sphere water contribution to the peptide systems.  
When analysing the 20 ns simulations of Mo1-2, lysine residues were measured to 
extend approximately 9.5 Å from the Gd(III) centre when in the g position (also present in 
MB1-2) and 14.6 Å in the b position (a new feature in Mo1-2), as shown in Figure 4.19. Water 
located around the lysine side chain was analysed in this system at a distance between 10 and 
20 Å from the Gd(III) ion centre. It was calculated that Mo1-2 had 914 ± 24 water molecules 
located in this region compared to MB1-2 where there were 772 ± 25, in the comparable 
simulation. The most dramatic difference between the two peptides was in the region 
between 16.1 and 20 Å, with the number of water molecules at each distance given in Table 
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4.3. When analysing the coiled-coil structure, this region is located directly around the NH3+ 
terminal group of the lysine residues. It is observed that more water is hydrogen bonded to 
the exterior of the peptide in Mo1-2 compared to the surface of MB1-2. The water molecules 
coordinated to the lysine residues of Mo1-2 are shown in Figure 4.20.  
Table 4.3: Average number of water molecules at increasing distances from the coiled-coil peptide, 
calculated for Mo1-2 and MB1-2. Data shown is an average for three simulations and a standard 
deviation error. 
 Distance / Å 
PEPTIDE 2.1 -3 3.1 – 4 4.1 -5 5.1 -6 6.1 -7 7.1 - 10 10.1 – 13 13.1 - 16 16.1 - 20 
Mo1-2 
1.0 ± 
0 
0.6 ± 
0.5 
0.1 ± 
0.8 
0.6 ± 
0.9 
2.3 ± 
1.6 
22.7 ± 
3.4 
93.3 ± 
5.1 
194.7 ± 
7.7 
656.1 ± 
11.7 
MB1-2 
1.0 ± 
0.0 
0.7 ± 
0.5 
2.3 ± 
0.7 
0.3 ± 
0.7 
3.3 ± 
1.6 
27.4 ± 
2.7 
97.8 ± 
5.9 
198.7 ± 
8.5 
475.5 ± 
10.8 
 
 When looking at water closer to the coiled coil, more water is shown to be present in 
the MB1-2 simulation, between 2.1 and 5 Å distance from the Gd(III). This could indicate that 
in Mo1-2 the lysine residues, although polar and with the ability to hydrogen bond with water, 
are pushing the water molecules further away from the peptide and the paramagnetic Gd(III). 
This would increase the average Gd(III) to water distance resulting in a decrease in relaxivity, 
the opposite of the hypothesis. 
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Figure 4.20: Pymol figures showing the coordination of water to lysine residues on the coiled-coil 
exterior. The peptide backbone is shown as a cartoon, the Ln(III) as a grey sphere, lysine residues and 
binding site residues as sticks and secondary sphere water as spheres.   
4.3.7 Water Coordination 
Calculating q from MD simulations can sometimes give different values to those 
obtained experimentally. This has previously been observed in the work by Berwick. 
Therefore, q was experimentally determined for the Mo1-2 system. Tb(III) luminescence 
lifetimes in H2O and D2O were used to probe the amount of inner-sphere water coordinated 
to the Tb(III) when bound to Mo1-2. The lifetime decays at 545 nm were measured as 0.6 ± 
0.1 ms in H2O and 0.4 ± 0.1 ms in D2O with the decay shown in Figure 4.21. In order to correct 
for the contribution of outer sphere water, the Parker-Beeby equation116 was applied and it 
was calculated that less than one (0.6 ± 0.1) water was bound to Tb(III) in the metallo peptide 
complex. This can be compared to MB1-2 where zero waters are coordinated to the Tb(III) (0.0 
± 0.1).97 A value of 0.6 ± 0.1 agrees with the MD simulations of the trimer and tetramer 
complexes where between zero and one water molecule was bound to the Ln(III).  
 
Figure 4.21: Decay profiles of Tb(III)  emission at 545 nm for 100 μM Mo1-2 monomer on addition of 
0.3 equivalences of Tb(III) in 10 mM HEPES buffer pH 7.0, fit to a mono-exponential decay, in H2O 
(dark) and D2O (light) allowing for calculation of q values. 
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4.3.8 Relaxivity and Contrast Agent Efficiency 
To determine the relaxivity of the Gd(Mo1-2)3, the longitudinal (T1) and transverse (T2) 
relaxation times were measured and compared to MB1-2, as shown in Figure 4.22. Double the 
concentration of peptide was used to ensure complete complexation of Gd(III) for if the 
complex was a dimer, trimer or tetramer. The longitudinal (r1) and transverse (r2) relaxivity, 
were found to be (r1) 6.3 ± 2.3 and (r2) 21.6 ± 3.6 mM-1 s-1 respectively, compared to that of 
MB1-2 calculated to be (r1) 4.6 ± 0.9 and (r2) 21.3 ± 1.2 mM-1 s-1 at 7 T.97  
T1 and T2 measurements were recorded at a lower field (1 T) in order to assess if the 
differences between Mo1-2 and MB1-2 were more apparent at lower field strengths (42.6 
MHz (1 T)). This is because, when measuring at a lower field it is more sensitive to changes in 
the rotational correlation time and associated water dynamics.40 This yielded relaxivities of 
(r1) 16.7 and (r2) 20.2 mM-1 s-1 for Mo1-2, and (r1) 17.9 and (r2) 20.7 mM-1 s-1 for MB1-2. Caution 
should be taken when drawing conclusions as only one experiment was performed. An 
increase in r1 was observed when comparing 1 T and 7 T for both peptides. This is due to the 
slow rotational correlation time of the peptides and tumbling becoming more significant at 
low fields.40 No significant differences in the longitudinal or transverse relaxation time were 
observed at either 1 T or 7 T. This means that the difference in q (0.6 vs 0.0) was not significant 
enough to cause an increase in relaxivity and any differences in secondary sphere water 
coordination, or in the stoichiometry of Mo1-2, had no significant effect on relaxivity. 
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Figure 4.22: Relaxivity plots showing reciprocal of relaxation time as a function of Gd(III) 
concentration for  T1 (left) and T2 (right) at 7 T (top) and 1 T (bottom). Data is shown for Mo1-2 (grey) 
and MB1-2 (black).  All samples recorded in the presence of 10 mM HEPES buffer pH 7.0, with an 
excess of peptide monomer compared to Gd(III). Error bars show data repeated in triplicate at 7 T, 
only one experiment was collected at 1 T.  
4.4 Conclusions  
In this chapter the effect of water coordination to the coiled-coil exterior on the 
relaxivity of Gd(III) binding peptides has been investigated. A new peptide, Mo1-2, was 
designed, synthesised and characterised and compared to the previously established MB1-2.  
It was found that the addition of lysine residues on the peptide exterior had no effect 
on the stability of the peptide, despite additional polar groups being added to the peptide 
sequence with the ability to form stabilising interactions and predicted to increase the stability 
of the complex. Additionally, no change in relaxivity was observed, at low or high fields, 
despite more water being predicted to coordinate to the exterior of the peptide via the NH3+ 
groups of lysine. This water was too far from Gd(III) to result in a significant increase in 
relaxivity and no improvement in MRI CA potential was observed. 
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Interestingly, it was found that from CD and luminescence analysis, a 1:4 stoichiometry 
was observed for Mo1-2 compared to 1:3 for MB1-2. This was confirmed using AUC where a 
dimer: tetramer ratio of 62% dimer and 38% tetramer was determined. By analysing MD 
simulations and helical wheel diagrams it was found that both of these oligomers were 
possible due to salt bridging networks and the formation of an isoleucine core, despite the 
theory predicting a trimer. Luminescence lifetime experiments yielded q = 0.6, closer to the 
primary sphere water predictions for the trimer and tetramer species. Given more time, Mo1-
2 would be further analysed using techniques such as Mass Spectrometry, ESR and NMRD in 
order to accurately determine the stoichiometry of the coiled coil.   
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Chapter 5: Investigating the Presence of Water Located in 
the Hydrophobic Core of a Coiled-Coil Peptide 
5.1 Introduction  
When considering the relaxivity potential of MRI contrast agents (CAs), it is essential 
to consider contributions from surrounding water molecules. These can be located in the 
inner-sphere (directly coordinated to Gd(III)), second sphere (coordinated to the primary 
water or CA support), or the outer sphere (water that diffuses close to the CA).19 The 
contribution of the solvent to the relaxation time can be improved by increasing the number 
and lifetime of water molecules located within each hydration sphere.  
In Chapter 4, secondary sphere water was determined to be too far away, when 
coordinated to the exterior of the coiled coil, to impact relaxivity. In this chapter, the 
secondary sphere water located within the hydrophobic core and its effect on relaxivity was 
investigated. It was proposed that a water channel was present in the hydrophobic core of 
MB1-2 which would allow water to be closer to Gd(III) and this would have a greater effect on 
relaxivity. 
In 1996, Hodges and co-workers first proposed that a cavity located within the 
hydrophobic core of a coiled-coil peptide could be used to accommodate water molecules.153 
This would result in a shorter Ln(III) – hydrogen distance (rMH), compared to bulk water, hence 
increasing relaxivity (if the water residency time remained the same).  The presence of a cavity 
was later confirmed by Pecoraro and co-workers in a coiled coil containing a Cd(II) thiolate 
binding site.154,155 Here, a L-leucine amino acid located directly above the cadmium binding 
site in the hydrophobic core of the coiled coil was replaced with a smaller, less sterically 
hindered alanine residue, and led to removal of the cavity and an increase in hydration state 
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(q) of cadmium.156 It was also observed in the work by Pecoraro and co-workers that the 
presence of a cavity can force the metal binding site to adopt an undesirable trigonal 
pyramidal geometry.154  
The presence of cavities within the hydrophobic core of coiled coils can be highly 
destabilising, especially if the peptide is unable to repack its hydrophobic core to compensate 
for the cavity.114 It has been estimated that the introduction of a cavity can destabilise the 
peptide by approximately 2-5 kcal mol-1, depending on the extent of repacking of the 
hydrophobic core.114 Additionally, the presence of disulphide bridges around the cavity site 
was shown to decrease the degree to which the peptide is destabilised.114  
5.2 Aims  
In the work by Berwick and co-workers,95,97 MB1-2 was designed with a Ln(III) binding 
site positioned in the second and third heptads, shown in Figure 5.1, with q = 0.0 ± 0.1 and a 
relaxivity of (r1) 4.1 ± 1.2 mM-1 s-1 and (r2) 24.4 ± 2.6 mM-1 s-1 at 7 T.97 Here, outer sphere water 
coordination was considered to be the main contributing factor to relaxivity. Upon further 
investigation into Berwick’s 10 ns MD simulation of MB1-2 it was found that a water channel 
was present, which ran from the peptide exterior to above the Ln(III) binding site, which could 
allow water to get closer to Gd(III) than previously thought, shortening the Gd(III) - H2O 
distance and increasing relaxivity. This was the first time water had been seen in this type of 
secondary sphere water environment in the MB1 peptides and presented an exciting 
opportunity to investigate the effect of water located in a channel.  
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Figure 5.1: Schematic representation of MB1-2 after 20 ns of MD simulation with the peptide 
backbone shown as a cartoon, the Ln(III) metal as a sphere and binding site amino acids and the 
tryptophan sensitiser displayed as sticks. 
In order to investigate the channel further, a new peptide was designed in which the 
water channel in MB1-2 would be blocked, so that no water could be located within the site. 
The design involved using a D-Isoleucine (D-Ile) to replace the L-isoleucine (L-Ile) residue in 
the a position immediately above the Ln(III) binding site; the isomers are shown in Figure 5.2. 
As the Ile side chain would now point towards the C-terminus, as opposed to towards the N-
terminus for L-Ile, it was proposed that the channel would no longer be able to exist in the 
same position. D-amino acids have previously been used in de novo designed coiled-coils, due 
in part to their side chains having the same structure as their L-analogues.157 Single amino acid 
substitutions have sometimes been shown to cause the formation of hairpin turns or stop the 
formation of an α-helix.157–159 When all the amino acids in a sequence have been changed to 
D-amino acids, a mirror structure has been observed. In other examples, it has previously been 
found that single, double and triple substitutions in α-helicies can be tolerated within a coiled-
coil strucuture.157,160  
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Figure 5.2: The (a) D- and (b) L- stereoisomers of isoleucine. 
5.3 Results and Discussion  
5.3.1 Investigation into Water Location in MB1-2 
Further computational investigations into MB1-2 were completed. The simulation of 
MB1-2 was repeated and extended to 20 ns as it allowed the system to reach equilibrium. This 
was determined by counting the number of water molecules within 5 Å of the peptide 
backbone, with the data shown in Figure 5.3. By analysing the number of water molecules 
within this specified area it was calculated that this plateaued at 18 ns. It was concluded, that 
at this time point, the simulation has reached equilibrium.  
 
Figure 5.3: Quantification of water within 5 Å of Gd(MB1-2)3 peptide measured as a function of time. 
Equilibrium was reached after 18 ns, shown by the plateau of the curve. 
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When analysing the MB1-2 simulation, it was found that a water channel is present 
and remains throughout the simulation. The channel starts at the coiled-coil exterior at a 
distance of 9 Å from the Gd(III) and passes through the hydrophobic core of the peptide to the 
Gd(III) binding site. The channel allows water access in close proximity (defined as within 8 
Å)127 to the Ln(III) binding site, even allowing water molecules to interact directly to the inner-
sphere water, and is predicted to result in an increase in water residence time compared to 
the bulk water. The increase in water residence time allows water to be influenced 
significantly by the paramagnetic Ln(III) before returning to the bulk water and has the 
potential to account for the relaxivity of the Gd(MB1-2)3 complex, as experimentally q = 0. The 
simulations show one water molecule directly coordinated to the Ln(III), at a distance of 2.9 
Å, despite a q = 0 being experimentally determined.97 The water molecule is present after 2 
ns of the simulation and remains coordinated to the Ln(III) throughout the 20 ns, indicating a 
water residence time of at least 18 ns. 
The secondary sphere water molecules are shown to “queue up” in the channel and 
are directly hydrogen bonded to each other and to the inner-sphere water molecule, as shown 
in Figure 5.4(a). The secondary sphere water to Ln(III) distances are measured to be 5.0, 6.5, 
9.2, 10.2 and 13.6 Å. After this distance, no water is directly interacting with water within the 
channel and so can be considered as outer sphere water.  
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Figure 5.4 Schematic representation of Gd(MB1-2)3 20 ns MD simulation snapshot. Secondary sphere 
water molecules are shown located in a channel from the Gd(III) to the exterior of the coiled coil. The 
peptide backbone is shown as a cartoon, the Gd(III) metal as a grey sphere, the binding site amino 
acids and the tryptophan sensitiser displayed as sticks (and pink on the surface) and the secondary 
sphere water molecules are shown as red spheres.(a) Top down view showing secondary sphere 
water channel, (b) side view showing the entrance of the water channel from the coiled-coil exterior, 
(c) cross section view showing secondary sphere water located in the channel, (d) side view showing 
the binding site amino acids, Ln(III) and secondary sphere water.  
5.3.2 Analysing Water Distances and SN1-2 Design 
For water in the secondary sphere, relaxivity can be described by the same 
mechanisms used for inner-sphere water. The equation differs in that each water molecule 
(a) (b) 
(c) (d) 
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will have its own relaxation time and residency time.40 The r’MH  is longer than for primary 
sphere water and the residency time τ’m is shorter.40 
Equation 5.1:    𝑟𝑖
𝑠𝑠 =
𝑞′/[𝐻2𝑂]
𝑇𝑖𝑚
′ +𝜏𝑚
′   𝑖 = 1,2 
By using Equation 5.1, it was calculated that a sharp decrease in r1 is seen when the 
water distance increases from 2 to 8 Å, with water further than 8 Å barely contributing to 
relaxivity, as shown in Figure 5.5. This water is defined as in proximity to Gd(III). When 
considering the coiled coil, the outside of the alpha-helix backbone is approximately 9.2 Å 
from the Ln(III) centre, with the amino acid side chains extending to a maximum of 9.5 Å, 
illustrated in Figure 4.19. This indicates that any water present within the hydrophobic core 
of the coiled coil will have a substantial effect on relaxivity. Water molecules outside of the 
coiled-coil motif and coordinated to the exterior of the coiled coil will not have a significant 
influence on relaxivity. This could explain why no significant difference was observed between 
Mo1-2 and MB1-2 in Chapter 4. 
 
Figure 5.5: A graph to show the change in r1 when the distance between Gd(III) and H2O 
increases (7 T). 
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The contribution of each water molecule located in the channel in the MB1-2 
simulation was calculated using Equation 5.1, with the values given in Table 5.1. A bulk water 
concentration [H2O] of 55.6 mol L-1, τR of 6.6 ns and a τ’m of 1 ns was used in the calculation. 
By adding the contributions of the secondary sphere water together an overall r1 of 4.0 mM-1 
s-1 was calculated, compared to the experimental value of 4.1 ± 1.2 mM-1 s-1, showing all 
relaxivity for MB1-2 could be assigned to secondary sphere effects.  
Table 5.1: Calculated secondary sphere water contributions to r1; calculations are based on Equation 
5.1 with a q’ = 1 at each water distance. Water distances are measured from a 20 ns snapshot of the 
MB1-2 simulation. 
Water distance / Å r1 / mM-1 s-1 
5.0 3.10 
6.5 0.73 
9.2 0.10 
10.2 0.05 
13.6 0.01 
 
The water channel in MB1-2 was found to be highly significant, as all water contributed 
to the relaxivity. It was of interest to examine what would happen if the water channel was 
blocked, as a proof of concept, and to better understand the role of secondary sphere water 
interactions. In order to try and block the water channel a new peptide, SN1-2, was designed. 
In this new peptide, D-Ile replaced the L-Ile located in the a position above the Ln(III) binding 
site, with the peptide sequence given in Table 5.2, where X represents D-Ile and the structure 
compared to MB1-2 in Figure 5.6.  
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Table 5.2: MB1-2 and SN1-2 peptide sequences used to investigate secondary sphere water 
interactions. 
Peptide Sequence 
MB1-2 Ac – G IAAIEQK IAANEWK DAAIEQK IAAIEQK IAAIEQK  G – NH2 
SN1-2 Ac – G IAAIEQK XAANEWK DAAIEQK IAAIEQK IAAIEQK  G – NH2 
  
It was proposed that the insertion of D-Ile above the binding site would block the water 
channel located above the Ln(III) binding site as the D-Ile side chains would point towards the 
C-terminus. This in turn would eliminate water in close proximity to Gd(III). MD simulations of 
SN1-2 were attempted using AMBER, as with previous peptides, in order to compare the 
structure with MB1-2. However, the D-Ile was not well tolerated in the equilibrium step of the 
simulation and the D-Ile would revert back to L-Ile, despite this not being possible physically. 
This was thought to be because of the sterics within the hydrophobic core and the hindrance 
of having a D-isomer surrounded by L-isomers in a tightly packed system. A number of 
techniques were used in order to try and stop this from happening; for example, using a lower 
density of water in the hydration box, manually reverting the amino acid back to the D-isomer 
after each step, and trying to fix the D-isomer in position. None of these techniques gave a 
result that was computationally accurate and could be critically compared to the 20 ns MB1-
2, especially when considering the location of secondary sphere water. Further work could be 
undertaken to better understand the SN1-2 system using MD simulations. MD is only one way 
of analysing a peptide structure and often gives results which are different to those achieved 
using spectroscopic and analytical laboratory techniques. This has previously been observed 
by Berwick and co-workers where they observed q = 1 for MB1-2 using MD simulations and 
experimentally found it to be q = 0. Therefore, in this chapter blocking of the channel was 
quantified using experimental techniques such as determining the amount of inner-sphere 
water, and the water that contributes to q from outer sphere effects. The relaxivity of the new 
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peptide will be compared to MB1-2 and will be lower if the channel is blocked, due to the 
possibility that all of MB1-2 relaxivity being attributed to secondary sphere water 
coordination.  
 
Figure 5.6: Schematic diagram of (a) MB1-2 and (b) SN1-2 with the peptide backbone shown as a 
cartoon, the Ln(III) metal as a sphere and binding site amino acids, Ile layer above the binding site 
and the tryptophan sensitiser displayed as sticks. The substitution for D-Ile is shown in grey in (b).  
When analysing initial MD models of SN1-2 (post minimisation, pre equilibrium), it can 
be observed that the D-Ile substitution would block water access, as shown in Figure 5.7. 
Although further modelling was not possible, this initial structure gave an insight into the 
accessibility of the Ln(III) binding site of SN1-2 when compared to the secondary sphere water 
locations from the 20 ns MB1-2 simulation. D-Ile residues come within 4 Å of the Gd(III) ion 
and water is estimated to be blocked so that it can be no closer than 9 Å from Gd(III). The 
blocking of this water is expected to result in a decrease in relaxivity of  3.83  mM-1 s-1, using 
the data from Table 5.2. 
(b) (a) 
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Figure 5.7: Initial MD model of SN1-2 overlaid with the secondary sphere water locations of MB1-2 
shown as red spheres. (a) The substitution for D-Ile is shown as blue sticks and are shown to block 
the entry of secondary sphere water to the Ln(III)  (b) D-Ile residues are shown as blue spheres and 
are shown to block the channel that was present in MB1-2, so that secondary sphere water cannot 
move in proximity to Ln(III). The peptide backbone is shown as a cartoon, the Ln(III) metal as a sphere 
and binding site amino acids and the tryptophan sensitiser displayed as sticks. 
5.3.3 Secondary Structure  
The secondary structure of SN1-2 was investigated using CD spectroscopy; with the 
spectra shown in Figure 5.8. A 30 µM solution of SN1-2 monomer, yields a CD spectrum 
representative of a poorly folded random coiled coil (Θ222 = −4900 dmol-1 cm2; 13 ± 2% folded). 
The addition of 10 μM GdCl3 to the above sample leads to a spectrum representing enhanced 
coiled-coil folding with minimum at 208 and 222 nm (Θ222 = −10160 dmol-1 cm2; 26 ± 1% 
folded). This can be compared to MB1-2 which is poorly folded in the apo form (21 ± 3% 
folded) and becomes well folded on the addition of 10 μM GdCl3 (62 ± 3% folded).97 
The poorly folded nature of the peptide could be due to the insertion of a D-amino 
acid into the hydrophobic core of the coiled coil. It has previously been shown, in the work of 
Pecoraro, that when a L-amino acid is substituted with a D-amino acid the ellipticity at 222 nm 
is still indicative of a right-handed α-helix, however, it decreases in intensity, suggesting a 
decrease in folding by around 40%.161 This is comparable to the decrease observed for SN1-2 
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compared to MB1-2. Within the hydrophobic core of the coiled coil, the amino acid side chains 
are closely packed and so an amino acid which is the opposite isomer has no room to sit, 
causing steric repulsion.  
 
Figure 5.8: CD profile of 30 μM monomer peptide (blue) SN1-2 and (black) MB1-2 in the presence 
(dashed) and absence (line) of 10 μM GdCl3 ran in 10 mM HEPES buffer pH 7. 
Aliquots of GdCl3 were titrated into a 30 μM solution of SN1-2 monomer and 
monitored by CD, initially leading to a gradual increase in the signal at 222 nm which plateaued 
at higher equivalents, as shown in Figure 5.9. A 1/3 Gd + SN1-2  1/3 Gd(SN1-2)3 binding model 
was used, giving an average association constant (log Ka) of 4.7 ± 0.2. This can be compared to 
MB1-2 where a log Ka of 5.1 ± 0.2 was calculated. The binding constants are the same for SN1-
2 and MB1-2, within the error of the experiment, suggesting that despite SN1-2 being less 
folded, the introduction of D-Ile has little impact on Ln(III) binding. This could be expected as 
there has been no change made to the binding site amino acids and only one substitution to 
the amino acids in the sequence.  
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Figure 5.9: (a) CD spectra of 30 μM SN1-2 in the presence of increasing aliquots of Gd(III) in 10 mM 
HEPES buffer pH 7.0. (b) The normalised fraction folding of SN1-2 and using a peptide + 1/3 Gd(III)  
1/3 (Gd(Peptide)3) model allowed for the calculation of a binding constant. Error bars are standard 
deviation for n=3 experiments. 
5.3.4 Tb(III) Binding and Luminescence 
TbCl3 titrations were monitored directly by luminescence in order to further 
investigate Ln(III) binding, with the spectra shown in Figure 5.10.  A solution of 30 μM SN1-2 
monomer was excited at 280 nm and the emission spectrum monitored from 455 - 700 nm. 
Similar spectra were recorded on addition of aliquots of TbCl3. A 1/3 Tb + SN1-2 1/3 Tb(SN1-
2)3 binding model was used to interpret the data, giving an association constant (log Ka) of 4.7 
± 0.4. This can be compared to the previously investigated MB1-2 for which a log Ka of 5.5 ± 
0.2 was calculated. This shows the same trend as the CD titrations and represents no 
significant difference in Ln(III) binding between the two peptides, despite the fact that SN1-2 
is poorly folded in both the apo and metallo complexes and MB1-2 is well folded on addition 
of Gd(III). 
~ 106 ~ 
 
 
Figure 5.10: (a) Emission profile of SN1-2 with increasing aliquots of Tb(III) ran in 10 mM HEPES pH 7, 
using a λexc = 280 nm. (b) The normalised emission, fitting data for a peptide + 1/3 Gd(III)  
1/3(Gd(Peptide)3) allowing the calculation of a binding constant.  Error bars are standard deviation for 
n=3 experiments. 
5.3.5 Water Coordination 
When calculating water coordination to a Ln(III), two methods can be used. The 
Horrocks-Sudnick equation162,163 calculates the number of water molecules coordinated to the 
Ln(III). The Parker-Beeby equation116 allows for correction to remove any contribution from 
outer sphere water effects. By comparing q calculated from each of these equations, the 
contribution from outer sphere effects can be considered. 
Luminescence lifetime decays in H2O and D2O were measured in order to quantify the 
amount of inner-sphere water coordinated to Tb(III) when bound to SN1-2. The lifetime 
decays at 545 nm were measured as 1.2 ± 0.0 ms in H2O and 2.1 ± 0.1 ms in D2O, with the 
decay curves shown in Figure 5.11. The inner-sphere water coordination was calculated as  q 
= 1.5 ± 0.1 using the Horrocks-Sudnick equation.162,163 
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Figure 5.11: Decay profiles of Tb(III)  emission at 545 nm for 100 μM SN1-2 monomer on addition of 
10 μM of Tb(III) in 10 mM HEPES buffer pH 7.0, fit to a mono-exponential decay for H2O (light) and 
D2O (dark) allowing for calculation of q values. 
In order to correct for contributions from the outer sphere water, the Parker-Beeby 
equation116 was used, giving q = 1.5 ± 0.1. This can be compared to the previously reported 
MB1-2 of q = 0.4 ± 0.1 using the Horrocks-Sudnick equation 0.0 ± 0.1 using the Parker-Beeby 
equation.97 As the Horrocks-Sudnick and Parker-Beeby equations gave the same q for SN1-2, 
it could be considered that all water is inner-sphere and there are no outer sphere 
contributions. The increase in water coordination in SN1-2, compared to MB1-2, could be 
attributed to the lack of folding shown in the CD spectra. Even in the presence of Ln(III), the 
complex was only 26 ± 1% folded. This could mean that the binding site is more accessible to 
water, allowing more water to coordinate to Ln(III) compared to MB1-2; if this was the case 
one may expect q to be even higher.  
5.3.6 Relaxivity and MRI Contrast Agent Efficiency 
The relaxivity of SN1-2 was investigated and the longitudinal (T1) and transverse (T2) 
magnetic resonance relaxation times of protons measured, with the relaxivity plotted in Figure 
5.12. The measurements were made using CPMG and inversion recovery pulse sequences, 
with increasing concentrations of Gd(SN1-2)3 at 300 MHz (7 T). The inverse relaxation times 
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were plotted as a function of Gd(III) concentration and yielded relaxivities of r1 = 9.1 ± 0.9 and 
r2 = 39.7 ± 2.8 mM-1 s-1 compared to 4.6 ± 0.9 and 21.3 ± 1.2 mM-1 s-1 for MB1-2.  
 
Figure 5.12: Relaxivity plot showing reciprocal of relaxation rate as a function of Gd(III) concentration 
for  (a) T1 and (b) T2 for SN1-2.  All samples recorded at 7 T at 298 K in the presence of 10 mM HEPES 
buffer pH 7.0, with two equivalences of peptide trimer per Gd(III). Error bars show standard 
deviation for data repeated in triplicate.  
The increase in r1 and r2 for SN1-2 compared to MB1-2 can be attributed to the increase 
in q from 0.0 ± 0.1 to 1.5 ± 0.1. Due to the lack of folding of SN1-2, which is thought to be 
responsible for the increase in water coordination, it was not possible to answer the 
hypothesis that insertion of a D-Ile above the binding site would block the water channel 
present in MB1-2. Because of this a new peptide was designed which would compensate for 
the destabilising nature of the D-Ile.  
5.3.7 SN1-3L and MB1-3L Peptide Design 
 As shown in Chapter 3, the addition of one heptad to a five heptad trimeric coiled-
coil has no significant effect on peptide folding, water coordination, or relaxivity when the 
binding site is at the N-terminus. A new peptide, SN1-3L, was designed with an additional 
heptad at the N-terminus of the SN1-2 coiled coil. It was hypothesised that the additional 7 
amino acids would “zip up” the top of the peptide, forming a well-folded, stable coiled-coil 
~ 109 ~ 
 
peptide, whilst allowing the D-Ile residue to block the water channel. The addition of a heptad 
results in an increase in the number of stabilising hydrophobic layers and salt bridges. The 
Ln(III) binding site is now in the third and fourth heptad so these two new peptides can also 
be compared to MB1-3 which has 5 heptads with the binding site in the third and fourth 
heptad, with data given in Table 1.3. MB1-3 is less folded than MB1-2 (15 ± 1% apo and 41 ± 
4% metallo) and the binding constant (log Ka = 5.2 ± 0.36), q (0.0 ± 0.1), and relaxivity (r1 = 4.0 
± 1.0 and r2 20.9 ± 1.0 mM-1 s-1) are the same, within error.   
  
Figure 5.13: Effect of water residency time τm (ns), for a q = 1 system, on r1 at field strengths of 7 T 
with rotational correlation times of 6.9 ns (corresponding to SN1-2 (blue)) and 10.0 ns) 
corresponding to SN1-3L (red)).  
 A comparison of the theoretical r1 of SN1-2 and a new 6 heptad peptide (SN1-3L) 
was calculated using the SBM equations,20,21 represented in Figure 5.13. When calculated at 7 
T, using q = 1 and a rotational correlation time of 6.9 ns for SN1-2 and 10.0 ns for SN1-3L, with 
a water residence time of 1 ns, the r1 relaxivity was predicted to be the same for the two 
systems. The water coordination of SN1-2 is 1.5 and q for SN1-3L must be determined before 
accurate comparisons can be made as if q is higher, r1 will also increase. 
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Figure 5.14: Schematic diagram of (a) SN1-3L and (b) MB1-3L with the peptide shown as a cartoon, 
the Ln(III) binding site amino acids as sticks, and metal ion as a sphere. 
In order to reliably determine the influence of D-Ile within the new SN1-3L design, an 
analogous 6 heptad peptide with a L-Ile in place of the D-Ile was also synthesised, shown in 
Figure 5.14 and Table 5.3. This would allow any changes in secondary structure or relaxivity to 
be attributed to the addition of the D-Ile and blocking the channel, instead of due to the 
increase in peptide length, even though the addition of a heptad was shown not to have an 
impact when the binding site was located at the N-terminus.  
Table 5.3: Peptide sequences used to investigate secondary sphere water interactions, where X = D-
Ile and binding site amino acids are in bold. 
Peptide Sequence 
MB1-2 Ac – G IAAIEQK IAANEWK DAAIEQK IAAIEQK IAAIEQK G – NH2 
SN1-2 Ac – G IAAIEQK XAANEWK DAAIEQK IAAIEQK IAAIEQK G – NH2 
SN1-3L Ac – G IAAIEQK IAAIEQK XAANEWK DAAIEQK IAAIEQK IAAIEQK G – NH2 
MB1-3L Ac – G IAAIEQK IAAIEQK IAANEWK DAAIEQK IAAIEQK IAAIEQK G – NH2 
  
5.3.8 Secondary Structure  
The secondary structure of SN1-3L and MB1-3L was investigated using CD 
spectroscopy, with the resulting spectra shown in Figure 5.15. 30 µM monomer solutions 
(b) (a) 
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yielded spectra consistent with a partially folded α-helical coiled-coil for SN1-3L (Θ222 = -8285 
deg dmol-1 cm2, 25 ± 4 %) and a well folded α-helical coiled-coil for MB1-3L (Θ222 = -32696 deg 
dmol-1 cm2, 73 ± 4 %).  The partial folding of SN1-3L is due to the insertion of a D-Ile in the 
hydrophobic core, and was also observed for SN1-2. Due to the extra length of the peptide an 
increase in folding compared to SN1-2 is observed.  
 
Figure 5.15: CD profile of 30 μM monomer peptide (a) MB1-3L and (b) SN1-3L in the presence (red) 
and absence (blue) of 10 μM GdCl3 ran in 10 mM HEPES buffer pH 7.  
The addition of 10 μM GdCl3 to SN1-3L led to an increase in signal at 222 nm, indicating 
the formation of a well folded α-helical coiled-coil (Θ222 = -24498 deg dmol-1 cm2, 64 ± 7 %), as 
shown in Figure 5.15.  MB1-3L formed a well folded structure without the need for Ln(III) 
templating and so a negligible change was observed (Θ222 = -33363 deg dmol-1 cm2, 77 ± 4 %). 
In comparison to SN1-2, SN1-3L is a well folded coiled-coil upon Ln(III) addition and so can be 
used in order to test the proposed hypothesis of blocking the water channel above the Ln(III) 
binding site. Here, the additional heptad provides an increase in folding and compensates for 
the destabilising introduction of D-Ile. 
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Figure 5.16: CD spectra of 30 μM (a) SN1-3L and (b) MB1-3L with increasing aliquots of Gd(III) in 10 
mM HEPES buffer pH 7. (c) The normalised fraction folding is shown for SN1-3L fitting data for a 1/3 
peptide + Gd(III)  1/3(Gd(Peptide)3) allowing the calculation of a binding constant.  Error bars are 
standard deviation for n=3 experiments. 
A titration of GdCl3 into a 30 μM solution of peptide monomer was monitored by CD 
and led to a gradual increase in intensity at 222 nm which plateaued at one equivalence of 
Gd(III) per trimer for SN1-3L, as shown in Figure 5.16. A 1/3 Gd + monomer  1/3 
Gd(monomer)3 binding model was used to interpret the data, giving an average association 
constant (log Ka) of 4.7 ± 0.2 for SN1-3L. In contrast, the analogous titration of GdCl3 into MB1-
3L, showed no significant change in folding, and a binding curve could not be extrapolated. 
The binding constant for SN1-3L was calculated to be the same as that for SN1-2 suggesting 
that the additional heptad did not influence the Ln(III) coordination environment. This would 
be expected as no change has been made to the binding site amino acids and it has been 
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shown previously with MB1-1 and MB1-1L that increasing the length of the peptide from 5 to 
6 heptads has no impact on metal binding. 
5.3.9 Tb(III) Binding and Luminescence 
TbCl3 titrations were monitored by luminescence, using the method previously 
described, with the spectra for SN1-3L and MB1-3L shown in Figure 5.17. Characteristic 
emission spectra were observed for both peptides with signal intensity increasing on addition 
of Tb(III) up to one equivalence of Tb(III) per trimer.  
 
Figure 5.17: Emission profile of (a) SN1-3L and (b) MB1-3L with increasing aliquots of Tb(III) ran in 10 
mM HEPES buffer pH 7, using a λexc = 280 nm.  The normalised fraction folding is shown below. Fitting 
data for a 1/3 peptide + Gd(III)  1/3(Gd(Peptide)3) is shown for (c) SN1-3L and (d) MB1-3L, allowing 
the calculation of a binding constant.  Error bars are standard deviation for n=3 experiments.  
A 1/3 Tb + monomer  1/3 Tb(monomer)3 binding model was used to interpret the 
data, giving an association constant (log Ka) of 4.7 ± 0.5 for SN1-3L and 5.1 ± 0.7 for MB1-3L. 
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The binding constants for SN1-3L and MB1-3L are the same, within the error of the 
experiment, compared to SN1-2, MB1-2 and MB1-3. This suggests that the addition of a 
heptad, to both systems, has caused no change in Ln(III) binding. 
5.3.10 Thermal Stability  
CD spectroscopy was used to compare the stability of the three new peptides, SN1-2, 
SN1-3L and MB1-3L, by thermal denaturation, as shown in Figure 5.18. This was conducted to 
see if the introduction of D-Ile would affect the overall stability of the peptide. It has previously 
been shown that the introduction of a single D-amino acid can decrease stability by 1 kcal mol-
1,161 however removal of a cavity can increase stability by 2-5 kcal mol-1. 30 μM solutions of 
peptide monomer in the absence and presence of 10 μM GdCl3, were subjected to a gradual 
increase in temperature from 25 to 85˚C, and the CD signal at 222 nm recorded as an 
indication of peptide folding. 
 
Figure 5.18: Percentage folded data from CD thermal unfolding of 30 μM (a) SN1-2 (b) SN1-3L and (c) 
MB1-3L monomer in the absence (dark) and presence (light) of 10 μM GdCl3 in 10 mM HEPES buffer 
pH 7.0, based on the CD signal at 222 nm.  
SN1-2 in the apo and metallo complex was found to be 12% and 22% folded at 25˚C, 
respectively, and stayed largely the same over the measured temperature range. In contrast, 
(a) (b) (c) 
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SN1-3L remained at 30% folded in the apo form and decreased in folding from 55% to 42% in 
the metallo complex but did not become completely unfolded as evidenced by the lack of 
baseline for the unfolding transition. MB1-3L decreased from 75% folded at 25˚C to 65% 
folded at 85˚C in the apo system and 80% to 75% in the metallo complex but remained folded 
at physiological temperatures.   
It can be concluded that SN1-2 has poor stability with respect to thermal unfolding 
studies, which show it to be entirely unfolded even in the presence of Gd(III). This is vastly 
different to MB1-2, with the comparable spectra shown in Figure 5.19, suggesting that the 
insertion of D-Ile into a 5 heptad peptide results in a dramatic decrease in stability. The 
stability increases for the longer, more folded metallo complexes and MB1-3L was found to 
be considerably more stable than SN1-3L in both the apo and metallo complex. This suggests 
that the addition of a D-Ile in both the 5 heptad and 6 heptad peptides results in a decrease 
in peptide thermal stability. When comparing the spectra of SN1-2 and SN1-3L, SN1-3L 
appeared to be more stable, despite the fact that the binding constant was calculated to be 
the same and Gd(SN1-3L)3 was well folded at physiological temperatures. It has previously 
been shown that the introduction of a single D-amino acid into a coiled coil consisting of all L-
amino acids does not lead to major distortion of the α-helical backbone.154 The extent to which 
D-amino acids destabilise the α-helix has been shown to be highly dependent on the size of 
the side chain, with b-branched amino acids such as Ile being the most destabilising as they 
are too big to fit into the available space in the hydrophobic core.114,154,155,161 The introduction 
of a single D-amino acid has been shown to destabilise the coiled coil by around 1 kcal mol-
1.161  
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Figure 5.19: Percentage folded data from CD thermal unfolding of 30 μM MB1-2 in the absence 
(dark) and presence (light) of 10 μM GdCl3 in 10 mM HEPES buffer pH 7.0, based on the CD signal at 
222 nm.  
5.3.11 Water Coordination 
 It was of interest to investigate whether the water channel present in MB1-2 had 
been blocked in SN1-3L. It was hypothesised that by adding an extra heptad above the binding 
site, the peptide would be more folded than SN1-2 (as demonstrated by CD) and the D-Ile 
would block the water channel above the Ln(III) binding site. Luminescence lifetime decays 
were performed in H2O and D2O, with the decay shown in Figure 5.20. The lifetime decays at 
545 nm were measured as 2.0 ± 0.0 ms in H2O and 2.2 ± 0.1 ns in D2O for SN1-3L and 1.8 ± 0.3 
ms in H2O and 2.4 ± 0.1 ns in D2O for MB1-3L. This yielded  q = 0.2 ± 0.1 for SN1-3L and q = 0.5 
± 0.3 for MB1-3L, using the Horrocks-Sudnick equation162. When correcting for outer sphere 
water, using the Parker-Beeby equation116, it was calculated that q = 0.1 ± 0.1 for SN1-3L and 
q = 0.2 ± 0.1 for MB1-3L.  
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Figure 5.20: Decay profiles of Tb(III)  emission at 545 nm for 100 mM monomer of (a) SN1-3L (b) 
MB1-3L on addition of 0.3 equivalences of Tb(III) in 10 mM HEPES buffer, pH 7.0, data recorded in 
H2O (light) and D2O (dark) and fit to a mono-exponential decay for allowing for calculation of q 
values. 
 It was calculated that q was the same for SN1-3L and MB1-3L, within the error of 
the experiment, when using both the Horrocks-Sudnick and Parker-Beeby equations. This 
could indicate that the insertion of a D-Ile above the binding site has no effect on the water 
channel present and no effect on secondary sphere water coordination, or that removing the 
channel has no effect on inner-sphere water coordination. Additionally, q is found to be lower 
for the two longer peptides than for SN1-2 which could be attributed to the well folded nature 
of these metallo peptides compared to SN1-2. However, q for SN1-3L and MB1-3L is the same 
as MB1-2. This shows the addition of a heptad had no effect on water coordination, as was 
previously demonstrated with MB1-1 and MB1-1L. This result does not allow conclusions to 
be drawn on the absence or presence of the water channel and so further investigations are 
required. 
5.3.12 Relaxivity and MRI Contrast Agent Efficiency  
 It was hypothesised that the relaxivity of SN1-3L would be the same as that of MB1-
3L due to the same q but any secondary sphere effects may become apparent by an increase 
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in relaxivity for MB1-3L. The r1 and r2 relaxivities were calculated to be (r1) 6.3 ± 0.3 and (r2) 
26.8 ± 2.2 mM-1 s-1 for SN1-3L and (r1) 7.9 ± 1.1 and (r2) 23.2 ± 3.4 mM-1 s-1 for MB1-3L at 7 T, 
with the data shown in Figure 5.21.  
 
Figure 5.21: Relaxivity plot showing reciprocal of relaxation time as a function of Gd(III) 
concentration for  T1 (left) and T2 (right) for (top) MB1-3L  and (bottom) SN1-3L . All samples recorded 
at 7 T at 298 K in the presence of 10 mM HEPES buffer pH 7.0, with two equivalences of peptide 
trimer to Gd(III) Error bars show standard deviation from data repeated in triplicate. 
No significant difference in r1 or r2 was observed between SN1-3L and MB1-3L, which 
would be expected as q is the same, within error, for the two peptides. This meant that any 
differences in secondary sphere effects were not significant enough to be observed by a 
change in relaxivity at 7 T. The relaxivity for both peptides was found to be the same as MB1-
2 and MB1-3, within the error of the experiment, suggesting again that the rotational 
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correlation time has little impact on relaxivity for this class of contrast agent, under these 
experimental conditions. The results of this experiment meant that a conclusion could not be 
made regarding the removal of the water channel.   
5.4 Conclusions  
In this chapter the presence of a water channel observed in the MD simulations of 
MB1-2 was investigated. The MD simulation was extended to 20 ns and repeated in triplicate 
in order to further analyse the MB1-2 structure. It was determined that the relaxivity of MB1-
2 could be attributed to the presence of a water channel located directly above the Ln(III) 
binding site which allowed water molecules to sit in proximity (within 8 Å) to Ln(III). This was 
experimentally investigated through the use of a D-Ile located directly above the Ln(III) binding 
site with the hypothesis that this would block the water channel, limiting the access to water. 
This would be accompanied by a decrease in relaxivity and would provide an important insight 
into the mechanism of relaxivity for when q = 0 and allow for a proof of concept into secondary 
sphere water.   
Three new peptides were synthesised. SN1-2 consisted of 5 heptad repeats with D-Ile 
located above the Ln(III) binding site. The peptide was insufficiently folded resulting in water 
accessing the unstructured metal binding sites and so could not be used for meaningful 
comparison. Two further peptides, MB1-3L and SN1-3L, consisting of 6 heptad repeats, 
showed an increase in peptide folding compared to MB1-2 and SN1-2. SN1-3L had a D-Ile 
above the metal binding site and MB1-3L was used as a control with an L-Ile in the same 
position. Both peptides were well folded and had no water located in the inner-sphere, 
directly coordinated to the Ln(III). Relaxivity data showed SN1-3L and MB1-3L to have the 
same r1 and r2 relaxivity, within error.  
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Through the use of a D-Ile, in SN1-2, the water channel located in MB1-2 appeared to 
be blocked in initial MD simulations. Further work could be completed in order to provide 
further insight into SN1-2 and SN1-3L systems, using MD simulations, to visualise the presence 
or absence of a channel within the hydrophobic core.  
When comparing SN1-3L and MB1-3L experimentally, no significant difference was 
observed in q and there was no change in relaxivity suggesting that the water channel had not 
been blocked and water was still able to be located in proximity to Gd(III). Alternatively, the 
channel had been blocked in both peptides and so the secondary sphere water effects were 
the same in both systems.  
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Chapter 6: Investigating the Introduction of Ln(III) Coiled 
Coils into Biological Systems 
6.1 Introduction  
Magnetic resonance imaging (MRI) is a widely used clinical imaging technique which 
provides contrast without using ionising radiation.164 MRI has major advantages for soft tissue 
imaging as it is non-invasive, non-ionising, can penetrate optically opaque systems and has no 
apparent side effects.33 The ability to capture information from multiple planes deep within a 
patient and excellent soft tissue contrast have contributed to the development of MRI as a 
powerful imaging tool.33 
MRI contrast agents (CA) are used annually in approximately 30 million procedures, 
with more than 300 million procedures performed to date.165 Lauterbur and co-workers were 
the first to demonstrate the effectiveness of using paramagnetic CAs to improve tissue 
contrast in MRI.2 All clinically approved Gd(III) contrast agents (GdCAs) are based on small 
molecules with relaxivity (r1 and r2) of around 4-6 mM-1 s-1.164 The first GdCAs, Magnevist 
[Gd(DTPA)]2- and Dotoram [Gd(DOTA)], were extracellular fluid agents, followed by those 
designed for specific tissue types, for example, liver and gastrointestinal imaging.166  
Most GdCAs are approved at a dose of 0.1 mmol Gd/kg, with kg referring to the weight 
of the patient, and for MR angiography studies double this dose is sometimes used.28,39 Newer 
agents, such as Gadofosvest, are approved at lower doses (0.03 mmol/kg).167 The dose 
administered will impact exposure and elimination times. GdCA kinetics exhibit a distribution 
phase followed by an elimination phase, as shown in Figure 6.1. If the dose is lowered by a 
factor of three, the exposure is reduced, as the area under the curve for plasma elimination 
becomes smaller. If the dose remains the same but the elimination and distribution becomes 
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longer then the area under the curve will be larger and the patient will be exposed to Gd(III) 
for longer.35 This occurs in renally impaired patients, such as those with Nephrogenic Systemic 
Fibrosis (NSF). For clinically approved GDCAs, there is no intracellular distribution around the 
body, apart from sometimes in the liver.36  
 
Figure 6.1: Graph to show the effect of dose and half time on Gd(III) exposure to the patient. The 
dotted line represents compound administered at 0.3 x dose for the same GdCA represented by the 
solid line. The dashed line shows the effect of a 3 x longer half-life, compared to the same dose of the 
solid line, for example in a renally impaired patient. Figure reproduced with permission from Aime, 
S.; Caravan, P. J. Magn. Reson. Imaging 2009, 30 (6), 1259–1267. 
Following the injection of a GdCA into a patient, the compound distributes in the blood 
and extracellular space. The terminal half-life for blood elimination is about 1.5 hours for 
patients with normal renal function.35,36 Preclinical animal studies indicate that GdCAs 
currently on the market are excreted rapidly and intact.35 As GdCAs are exclusively eliminated 
by the kidneys.168 In patients who suffer from renal diseases, for example NSF, the half-life of 
GdCA elimination can increase from hours to days depending on the severity of the 
disease.168,169 This slow removal of Gd(III) can result in deposition of Gd(III) in the brain, skin 
and internal organs.168,170,171 Pharmacokinetic studies in patients with NSF show the complete 
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removal of the GdCA after 7 days. In healthy patients this will have occurred within 12 
hours.35,172,173 
It is still not established if the Gd(III) retained in patients with renal disease is 
coordinated, as part of the CA, or has dissociated from the complex. It could dissociate from 
the CA and be present as an insoluble inorganic deposit such as the carbonate or phosphate 
salt. It could also be present in the binding site of calcium binding proteins.174,175 It has been 
reported that Gd(III) can replace Ca(II) in proteins resulting in inhibition of protein function, 
for example in Ca(II) carrier proteins in cell membranes.35  
Experiments of GdCA stability in human serum showed that 20% of Gd(III) was released 
from Gadoversetamide (Optimark) and Gadodiamide (Omniscan) after 15 days at pH 7.4 and 
37˚C, structures shown in Figure 6.2.176 This suggests that patients suffering from renal disease 
could be exposed to free Gd(III) if Gadoversetamide or Gadodiamide were administered.35  
 
Figure 6.2: Structures of clinical MRI CAs; (a) Gadoversetamide (Optimark) and (b) Gadodiamide 
(Omniscan).   
Metals with a high affinity for a Gd(III) binding site can increase transmetalation, for 
example Zn(II), Cu(II) or Fe(III). It is well established that Gd(III) release increases with 
(a) (b) 
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decreasing pH. Therefore, the rate of Gd(III) release will be enhanced in areas of low pH, for 
example in the renal proximal tubes.  
When comparing small molecule CAs to peptide-based designs, peptides sometimes 
face challenges regarding metal selectivity and pharmacokinetic stability. One peptide-based 
MRI CA (ProCA32) is highly selective, has high relaxivities (both r1 and r2) and has the 
appropriate liver retention time and distribution for MR imaging.164 ProCA32 was developed 
by converting a natural Ca(II) binding protein, parvalbumin, into a Gd(III) binding protein which 
is also PEGylated. This is the first of its kind to report an increase in relaxivity (r1 of 33.4 mM−1 
s−1 and r2 44.6 mM−1 s−1 of at 37 °C and 1.4 T) without compromising metal binding stability, 
selectivity and pharmacokinetics, with the Gd(III) binding affinity comparable to that of 
DTPA.164   
6.2 Aims 
 In this chapter two peptides, MB1-1 and MB1-2, were investigated for their potential 
use in biological systems. As the peptides have different positions of the Ln(III) binding site 
and different amounts of inner-sphere water coordination, q = 3 and 0 respectively, it was of 
interest to investigate how this would affect the extent of transmetalation. Transmetalation, 
in MB1-1 and MB1-2, was investigated using a number of biologically relevant metals and  
under physiological buffer conditions. Finally, two cell lines were treated with Gd(MB1-1)3 at 
MRI relevant concentrations in order to assess the toxicity of the metallo complex.  
6.3 Results and Discussion 
6.3.1 Displacement of Ln(III) with Medically Relevant Metals 
NSF, a disease which results in renal failure, can be linked to the use of GdCA.37,177 One 
hypothesis to explain this is the dissociation of Gd(III) from its support. Many studies have 
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been performed in vivo and in vitro in an attempt to determine the extent and mechanism of 
dissociation. It has been determined that there are three dissociation mechanisms between 
Gd(III) and its chelate with dechelation and transmetalation being the most common.30,34  
 (1) Dechelation due to: 
𝐺𝑑𝐿3 ⇆ 𝐺𝑑
3+ + 3𝐿  
 (2) Transmetalation of Gd(III) by an endogenous metal, especially, Ca(II), Cu(II) and Zn(II) 
corresponding to the reaction: 
𝐺𝑑𝐿3 +  𝑀
2+ ⇆ 𝐺𝑑3+ + 𝑀𝐿3
− 
(3) Ligand exchange via the reaction: 
𝐺𝑑𝐿3 + 3𝐿
∗  ⇆ 𝐺𝑑𝐿3
∗ + 3𝐿 
It has been previously reported that a Gd/phosphate ratio of 1:100 will result in 
phosphate-induced gadolinium release by ligand exchange when using Gadodiamide 
(Omniscan),34 structure shown in Figure 6.2(b). The presence of cations such as Ca(II), Cu(II) 
and Zn(II) has been shown to accelerate the release kinetics of gadolinium, either by catalysing 
ligand exchange or by inducing transmetalation.34  
By comparing MB1-1 and MB1-2, the effect of Ln(III) binding site position, and q value, 
on transmetalation could be investigated. It was hypothesised that MB1-2 would have less 
transmetalation due to the Ln(III) binding site sitting deeper into the hydrophobic core and 
being less accessible to competing metals.  
Luminescence was used to determine the extent of transmetalation with Na+, K+, Ca2+ 
and Zn2+. In each experiment, the sample was excited at 280 nm and the emission spectrum 
monitored from 455 - 700 nm. The spectra were then integrated between 530 – 560 nm. Tb(III) 
was used as a model for Gd(III), as described in previous experiments. 
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First a sample of 30 μM peptide monomer was run with integration of the spectra 
giving a base value for 0% Tb(III) binding. 10 μM Tb(III) was added to the above sample and 
left to equilibrate for 20 minutes before measuring. Integration of this spectrum gave a value 
for 100% Tb(III) binding. Each metal (NaCl, KCl, CaCl2 and ZnCl2) was added to individual 
samples and left to equilibrate for 20 minutes, in aliquots of 10 μM, 100 μM, 1 mM and 10 
mM. By integrating each spectra and comparing to the 0% and 100% Tb(III) binding controls, 
the percentage of Tb(III) binding could be calculated for each sample. The average of three 
experiments with standard deviation error bars is shown in Figure 6.3.  
It can be observed that the singly charged metals (Na(I) and K(I)), shown in Figure 6.3(a) 
and 6.3(b), result in very little transmetalation in either the MB1-1 or the MB1-2 system, even 
at 1000 equivalences of metal compared to Tb(III) concentration. In comparison, a 
displacement of approximately 20% was observed with Ca(II) and Zn(II) in the MB1-1 system 
at 100 μM, shown in Figure 6.3(c) and 6.3(d). This increased to 30% and 90% transmetalation 
for 1 mM and 10 mM Zn(II) and 30% and 60% transmetalation for Ca(II), respectively. In 
comparison, little transmetalation occurred in MB1-2 with 20-40% displacement occurring at 
10 mM and little change at lower concentrations.  
The Asn3Asp3 Ln(III) binding site, located in the hydrophobic core of the coiled coil is 
designed to accommodate metals with a 3+ charge, in part due to the 3 charge associated 
with the binding site residues. The size and number of ligands makes the site ideal for Ln(III) 
binding. In MB1-1, the binding site sits at the top of the coiled coil and can be thought of as 
more accessible and more dynamic than the MB1-2 site which is located a heptad further into 
the hydrophobic core of the coiled coil. On addition of the biologically relevant metals 
described above, an increase in transmetalation was observed in the MB1-1 system, 
illustrated by a decrease in Tb(III) emission. This could be due to the positioning of the MB1-1 
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site as it is easier to access and is more dynamic. As it is positioned at the top of the coiled coil 
it has the ability to bind a metal using only some of the potential ligands whilst still maintaining 
a folded coiled-coil structure. Despite the charge of the binding site not being overcome by 
the biologically relevant metals, it was observed that the binding site will still accommodate 
the biological metal in preference to Tb(III) at high concentrations.  
In comparison, there is less transmetalation occurring in the MB1-2 system (maximum 
of 40%) independent of which metal is used. This could be due to the binding site now being 
buried in the hydrophobic core of the coiled coil making it less accessible to competing metals. 
Furthermore, the apo-MB1-2 system is unfolded and the peptide requires Ln(III) binding to 
form a well folded coiled coil.  
In both systems, as the destabilising charge of the binding site is not overcome by the 
metals used, it is less favourable for them to bind compared with Tb(III). When comparing the 
metals used in this study, it is observed that the 2+ metals have a higher potential for 
transmetalation compared to the 1+ metals. As the metal ions used are of a similar size, this is 
due to more of the destabilising charge of the binding site being overcome more by the 2+ 
metal ions, compared to the singly charged metals.  
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Figure 6.3: Graph to show the % of Tb(III) binding after the addition of physiological metals (a) Na(I), 
(b) K(I), (c) Ca(II), and (d) Zn(II) for MB1-1 (grey) and MB1-2 (hatched), 10 μM Tb(III), in HEPES buffer 
pH 7.0. 
(a) 
(b) 
(c) 
(d) 
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6.3.2 Lanthanide Binding under Physiological Conditions 
The experiment shown in Figure 6.3 was conducted at pH 7.0 at micro- and milli-molar 
concentrations. This gave results which can only be compared to other laboratory experiments 
and cannot be compared to physiological-type systems. Therefore, Tb(III) binding was 
investigated under physiological-type conditions, using PBS, as a prediction of the extent of 
dechelation and transmetalation that could occur in vivo. 
 
 Figure 6.4: Emission profiles of 30 μM (a) MB1-1 and (b) MB1-2 in the absence (blue) and presence 
(red) of 10 μM Tb(III). Top spectra show experiment in PBS. Bottom spectra show experiments in 10 
mM HEPES buffer pH 7.0.  
Samples of 30 μM peptide monomer prepared in either HEPES buffer pH 7.0 or PBS 
were analysed before and after the addition of 10 μM Tb(III) (with an equilibration time of 20 
minutes). As observed in Figure 6.4(a) and (b), no Tb(III) binding was observed in the presence 
of PBS for MB1-1 or MB1-2. In the analogous experiment, using HEPES buffer at pH 7.0, the 
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characteristic emission peaks are observed. A control experiment of 10 μM Tb(III) in either 
HEPES buffer pH 7.0 or PBS was also ran, as shown in Figure 6.5 (a) and (b). Here the 
characteristic peaks were observed but at much lower intensity compared to the peptide 
spectra due to no sensitisation taking place. Here the characteristic Tb(III) emission peaks are 
observed in both samples. This suggests that the Tb(MB1-1)3 and Tb(MB1-2)3 complexes are 
unable to form in the presence of PBS. This could be due to the PBS having a higher affinity 
for Tb(III) compared to the coiled-coil peptides and with the high concentration of PBS driving 
the formation of Tb-Phosphate complexes. It has previously been observed that a 1:100 ratio 
of Ln(III) to phosphate will result in phosphate induced Gd(III) release.34 As Tb(III) is unable to 
bind to the coiled-coil peptide, no sensitisation of Tb(III) takes place and the emission peaks 
are not observed.  
 
Figure 6.5: Emission profiles of 10 μM Tb(III) in (a) 10 mM HEPES buffer pH 7 and (b) PBS. 
In order to investigate this further, Tb(III) binding was investigated using the individual 
components of PBS at their relevant concentrations and pH. Samples of 30 μM peptide 
monomer in HEPES buffer pH 7.0 were run, with integration of the spectra giving a value for 
0% Tb(III) binding. 10 μM Tb(III) was added to each sample and left to equilibrate for 20 
minutes. Integration of the spectra gave a value for 100% Tb(III) binding. Aliquots of the 
components of PBS (137 mM NaCl, 2.4 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) were added 
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to separate samples of both MB1-1 and MB1-2 and left to equilibrate for 20 minutes. The 
samples were run and the integration of the spectra compared to the 0% and 100% values in 
order to give the percentage Tb(III) binding of the sample, with the data shown in Figure 6.6.  
When analysing the MB1-1 system, it was found that a 70% decrease in Tb(III) binding 
was observed with NaCl and a 20% decrease in Tb(III) binding was observed with KCl. On 
addition of KH2PO4 and Na2HPO4, no Tb(III) remained bound to the peptide complex. This is 
predicted to be due to the high concentration of phosphate present in the sample, compared 
to the concentration of peptide, which drives the formation of Tb(III) phosphate complexes, 
due to phosphate induced Tb(III) release from the Ln(III) binding site. Tb(III) phosphate 
complexes also have a higher association constant (log Ka = 6.4) compared to the Tb(MB1-1)3 
complex. Additionally the low pH of KH2PO4 (4.9) and high pH of Na2HPO4 (9.3) could 
destabilise the metallo complex by interfering with the hydrogen bonding network which 
stabilises the secondary and tertiary structure of the folded coiled coil.  
The same is observed for the MB1-2 system. Transmetalation has less impact on the 
Tb(MB1-2)3 system due to the binding site being located in the second and third heptad of the 
coiled coil, making it less accessible to competing ions. Despite this, on addition of KH2PO4 and 
Na2HPO4 all Tb(III) has dechelated from the peptide system and no binding was observed. This 
shows that the presence of phosphate is highly destabilising for the Tb(peptide)3 complex.  
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Figure 6.6: A graph to show the % Tb(III) binding in samples containing 30 μM (blue) MB1-1 and (red) 
MB1-2 in the respective components of PBS.  
6.3.3 Initial Cell Toxicity Testing  
In order to continue investigating the behaviour of MB1-1 in physiological systems, 
preliminary cell studies were undertaken. Cell health can be monitored using a number of 
different techniques.178 Plasma membrane integrity, DNA synthesis, enzyme activity, ATP 
presence and cellular reducing conditions are well known indicators of cell viability.137,179,180  
Cell testing was conducted as part of a collaboration with Dr De Cogan at the University 
of Birmingham Medical School. Apo-MB1-1 and Gd(MB1-1)3 were used for the cell studies as 
it is the peptide complex with the highest relaxivity (both r1 and r2). It was previously observed 
that Tb(III) transmetalation and ligand exchange occurred in mock physiological conditions. 
Therefore, Gd(III) transmetalation may be observed in the in vivo cell studies with cell death 
occurring if Gd(III) is released.  
An initial investigation was undertaken using Hela cells. Cells were seeded with 
increasing concentrations of MB1-1 (0.02, 0.04 and 0.06 mM) and a 0.01 mM Gd(MB1-1)3 
complex was used, the same concentration of Gd(III) as in CA used in the clinic. A blank 
containing no peptide or GdCl3 and a 0.01 mM Gd(III) control were also investigated.  
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24 hours after seeding, the number of cells was counted using a haemocytometer with 
the processed data shown in Figure 6.7. No significant decrease in cell number was observed 
for the three apo-peptide concentrations and the Gd(MB1-1)3 compared to the blank. A 
significant decrease in cell number was observed with the Gd(III) control, showing cell death 
occurred when in the presence of free Gd(III). This experiment showed that at a clinically 
relevant concentration of 0.01 mM, the Gd(MB1-1)3 complex displayed no toxic effect in the 
HeLa cell line after 24 hours. This could imply that the Gd(III) remains complexed and is not 
free in solution. In healthy patients complete GdCA removal will occur within 12 hours 
suggesting at a concentration of 0.01 mM, Gd(MB1-1)3 would display no toxic effects in a 
healthy patient. This is not the same as what was observed in the transmetalation studies 
where Gd(III) was shown to no longer be complexed. Because of this, further cell studies were 
undertaken.  
 
Figure 6.7: HeLa cells incubated with varying concentrations of MB1-1 and one metallo peptide 
complex after 24 hours incubation time. A blank and a Gd(III) control were also used. Error bars show 
standard deviation for the experiment.  
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6.3.4 Investigation of MB1-1 in Cancerous Brain Cells  
 Hela cells are often used for preliminary cell work as they are easy to cultivate and 
difficult to infect. It was next of interest to investigate brain cells as a more relevant model for 
MRI use in the human body. Gd(MB1-1)3 is non-targeting so a specific tissue type for this CA 
could not be selected. One of the most common uses of clinical MRI is imaging the brain, and 
monitoring cancerous brain tissue.138–140 Therefore, brain cells were chosen for the next stage 
of the biological experiments. Brain cells differ from other cells in a number of ways, most 
importantly in their function. Neurons produce electrical impulses to transfer information. 
Glial cells work to support neurons by protecting them with a buffer and nutritional support.  
 Cancerous human brain cells were incubated with increasing concentrations of MB1-1 
and Gd(MB1-1)3, with the processed data shown in Figure 6.8. A Gd(III) control of 0.03 mM is 
shown in black and shows a significant decrease in cell number over the seven days, indicating 
cell death when in the presence of free Gd(III). The blank control is shown in grey and shows 
little decrease in cell number over time. 
 After one day of incubation, the apo peptide samples showed little difference in cell 
number compared to the blank control, within the error of the experiment. The 0.02 mM 
Gd(MB1-1)3 sample showed the same as the blank control, representing no cell death due to 
the peptide complex. The 0.04 mM Gd(MB1-1)3 sample showed an increase in cell number, 
however, this was not thought to be significant.  
 After three days, the apo peptide samples and the 0.02 mM Gd(MB1-1)3 sample 
showed no significant difference to the blank control, representative of no cell death due to 
addition of the peptide complex. The 0.04 mM Gd(MB1-1)3 sample was significantly lower and 
closer to that of the Gd(III) control. This could mean that Gd(III) has dissociated from the 
peptide and is in the toxic, aqueous form.    
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 After seven days of incubation only the lowest peptide concentration of 0.02 mM was 
shown to be statistically the same as the blank control. The higher concentrations of peptide, 
0.04 and 0.06 mM, showed a significant decrease in cell number, attributed to cell death, and 
were closer in cell number to the toxic Gd(III) control. Both Gd(MB1-1)3 samples showed a 
reduction in cell number, similar to that of the Gd(III) control. 
This experiment shows the metallo complex to be toxic to the human brain cancer cells 
after seven days of incubation. This is most likely due to the transmetalation of Gd(III) by 
biological metals and phosphate in the cell media, as predicted in the initial cell studies using 
PBS. The apo peptide was also shown to contribute to cell death after seven days, even though 
no Gd(III) was present in the sample. This result comes from only one set of experiments and 
so further investigations into the toxicity of both the apo and metallo complexes should be 
completed to provide a better understanding of the system. 
 
Figure 6.8: Human brain cancer cells incubated with varying concentrations of MB1-1 (blue) and 
Gd(MB1-1)3 (green) monitored over 1,3 and 7 days. A blank control is shown in black and a Gd(III) 
control shown in grey.  Error bars show standard deviation for the experiment. 
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6.4 Conclusions  
 In this chapter, Gd(MB1-1)3 and Gd(MB1-2)3 were subjected to transmetalation 
studies using biologically relevant metals. It was observed that the Ln(III) located within the 
binding site in the hydrophobic core of the coiled coil was displaced by Ca(II), Zn(II), K(I) and 
Na(I). Transmetalation was more apparent in the MB1-1 system as the binding site is more 
accessible and dynamic at the top of the coiled coil. The metals with a 2+ charge were shown 
to cause more transmetalation compared to the metals with a 1+ charge. This is thought to be 
due to the higher charge being closer to that required to neutralise the 3- charge of the coiled 
coil. 
 PBS was used as a preliminary test to mimic a biological system and no Tb(MB1-1)3 or 
Tb(MB1-2)3 formation was observed. This could be due to the binding affinity of Tb(III) binding 
to phosphate being higher than that of the peptide complex, or that the phosphate ligand 
disrupts the coordination of the binding site so that Tb(III) can no longer bind. Phosphate was 
also been seen to induce Ln(III) release from the binding site. This was observed when 
investigating Tb(peptide)3 binding in the presence of Na2HPO4 and KH2PO4 and it was found 
that no Tb(peptide)3 was present in the sample. 
 Finally, preliminary cell studies were under taken. It was found that MB1-1 and 
Tb(MB1-1)3 did not display any toxic effect after 24 hours in initial studies using Hela cells. 
When human brain cells were used, a decrease in cell number was observed for the apo and 
metallo peptide complexes after seven days. From this preliminary biological study, it can be 
concluded that currently the Gd(MB1-1)3 system is far from suitable for progression to clinical 
trials. The binding constant is very low for an MRI CA and a significant amount of 
transmetalation occurs when in the presence of biological metals and phosphate. Most 
importantly, a dramatic reduction in cell number was observed when human brain cells were 
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incubated with the metallo complex. Future work for this CA must focus on enhancing metal 
binding and decreasing the potential for transmetalation.  
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Chapter 7: Concluding Remarks and Future Work 
7.1 Conclusions 
In this thesis the MB1 series of peptides has been interrogated to better understand 
the mechanism by which contrast is achieved and thereby offering the opportunity to 
generate new systems with enhanced relaxivity. The SBM equations20,21 were used as a 
guideline for optimisation of the CA. Rotational correlation time, inner-sphere water residency 
time and secondary sphere water dynamics were investigated. Primary sphere water 
coordination has previously been investigated by Berwick where they found that an increase 
in q results in an increase in relaxivity in this class of contrast agent.95  
Rotational correlation time was explored using a series of three peptides of differing 
lengths (MB1-1S, MB1-1 and MB1-1L). It was found that, when using the MB1-1 peptide 
sequence, a minimum of five heptads are required for adequate peptide folding and stability. 
The increase from five to six heptads had little effect on peptide folding, q or relaxivity, 
indicating that the rotational correlation time is not the dominating factor for this series of 
peptide-based CAs. It was also found that water residence time has a large impact on the 
predicted relaxivity of Gd(MB1-1)3 and could be limiting the effect of changing the rotational 
correlation time. The water residency time is currently very fast for Gd(MB1-1)3 but by slowing 
this to approximately 40 ns an increase in relaxivity would be observed and any changes in 
rotational correlation time would have a more significant impact.  
The effect of water coordination to the coiled-coil exterior on the relaxivity of Gd(III) 
binding peptides was investigated through the design of Mo1-2. It was found that the addition 
of lysine residues on the peptide exterior had no effect on the folding or stability of the 
peptide. Additionally, no change in relaxivity was observed, at low or high fields. Secondary 
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sphere water coordinated to the peptide exterior was too far from Gd(III) to impact relaxivity. 
Interestingly, tetramer and dimer stoichiometries were observed for Mo1-2, confirmed using 
AUC and further analysed using MD.  Luminescence lifetime experiments yielded q = 0.6, 
agreeing with trimer and tetramer stoichiometries.  
Secondary sphere water coordination and dynamics were further examined in Chapter 
5. By using MD simulations, it was found that a water channel was present in the hydrophobic 
core of Gd(MB1-2)3 allowing water to come within close proximity (8 Å) to the Ln(III). It was 
hypothesised that by using D-Ile the channel would be blocked and no water would be located 
in the second sphere and the relaxivity would decrease. This was investigated as a proof of 
concept and to better understand the importance of secondary sphere water interactions. 
SN1-2 was designed, based on MB1-2, with D-Ile above the Ln(III) binding site. Gd(SN1-2)3 was 
unfolded and so could not be used to test the hypothesis. Two peptides consisting of 6 
heptads, MB1-3L and SN1-3L were analysed and were both well folded on addition of Gd(III). 
The relaxivity of both peptides was shown to be the same as MB1-2. This was concluded to be 
because that the water channel had not been blocked and water was still able to be located 
in proximity to Gd(III), or because, the channel had been blocked in both SN1-3L and MB1-3L 
and so the secondary sphere water effects were the same in both systems. 
Finally, transmetalation studies were conducted with MB1-1 and MB1-2. It was found 
that less transmetalation occurred when the Ln(III) binding site was located further into the 
hydrophobic core due to poor accessibility. Two cell lines were subsequently incubated with 
MB1-1 and Gd(MB1-1)3. It was found that the cell number decreased substantially after three 
and seven days when treated with Gd(MB1-1)3. Because of this, improvements to metal 
stability and transmetalation would need to be made before the peptide could progress 
further in biological studies.  
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Overall it can be concluded that rotational correlation time and secondary sphere 
water interactions are not the limiting factor for the relaxivity of this class of contrast agent 
under these experimental conditions. Inner-sphere water coordination has previously been 
shown to have a significant impact on relaxivity, through translating the Ln(III) binding site 
along the coiled coil. Further investigations into changing the water residency time may also 
prove the preliminary conclusion that it has a significant impact on relaxivity for this class of 
contrast agent. 
7.2 Future Work 
7.2.1 Use of Alternative Lanthanides for MRI PARACEST  
 CEST and PARACEST imaging are methods being used more and more in clinical MRI 
imaging.181,182 Both of these methods use lanthanides, but not Gd(III), in order to reduce the 
signal of bulk water, providing negative contrast.182,183 By applying a pre-saturation pulse at 
the resonance frequency of an exchanging proton site, the saturated spin is transferred to 
bulk water by chemical exchange.184 This is dependent on the number of exchanging protons, 
the water exchange rate, and the properties of the chosen lanthanide. Most commonly Dy(III), 
Tb(III), Yb(III) and Eu(III) are used.185,186 The MB1-1 and MB1-2 peptides display enhanced 
folding in the presence of Ln(III) in a 1:3 metal to peptide monomer concentration, as 
displayed in Figure 7.1. Initial T1 and T2 measurements using these Ln(III) showed little promise 
with r1 = 0 mM-1 s-1 and r2 of between 5 and 20 mM-1 s-1 in both MB1-1 and MB1-2, with the 
r2 data shown in Figure 7.2. It would next be of interest to determine the CEST and PARACEST 
potential of these systems.  
 
(a)      (b) 
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Figure 7.1: CD profile of 30 μM monomer (a) MB1-1 and (b) MB1-2 in the absence (black) and 
presence of 10 μM Ln(III) in 10 mM HEPES buffer pH 7.0. 
 
Figure 7.2: Processed preliminary data to compare the r2 data for (blue) MB1-1 and (red) MB1-2 with 
a series of Ln(III). 
7.2.2 Mn(II) MRI Contrast Agents  
Due to the toxicity of Gd(III) in current MRI CAs, and reports of metal pooling in the 
brain, research has become more focussed on the use on Manganese.40,66–70 Mn(II) has all the 
attractive attributes of Gd(III); long electronic relaxation time, high spin quantum number, fast 
water exchange, but with increased stability.66 The MB1-1 and MB1-2 peptides have shown 
promising binding potential with Mn(II), however, the binding constant was found to be  lower 
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than that with Gd(III) (log Ka = 2.5 ± 0.4) with 1000 μM required to cause a change in peptide 
folding with a 30 μM monomer peptide solution, with the CD spectra shown in Figure 7.3.  
 
Figure 7.3: CD profile of 30 μM monomer peptide (a) MB1-2 and (b) MB1-1 in the presence (black) 
and absence (grey) of 1000 μM Mn(III) in 10 mM HEPES buffer pH 7.0. 
7.2.3 Improvement in Binding Constant 
 As shown in the initial cell studies conducted with MB1-1, the stability of the metallo 
peptide needs to be greatly improved before translating to further cell studies. Once 
improved, the peptide complex could be adapted to MRI biological concentrations in order to 
perform further in vivo studies. The stability and binding constant could be increased by 
crosslinking the peptide strands of the coiled coil through Lys residues at the peptide termini 
in order to trap Gd(III) within the hydrophobic core of the coiled coil.  
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Chapter 8: Materials and Methods 
8.1 Materials  
Fluorenylmethoxycarbonyl (Fmoc) protected amino acids, dimethylformamide (DMF), 
N,N,N’,N’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) 
synthesis grade N,N-dimethylformamide (DMF) and 20% piperidine in DMF premix,  were 
purchased from Pepceuticals Ltd. Rink amide 4-methylhydrylamine (MBHA) resin, 
diisopropylethylamine (DIPEA), N-methylpyrrolidone (NMP), 20% piperidine in DMF, 
hydroxybenzotriazole (HoBT), N,N-diisopropylethylamine (DIPEA) and dichloromethane 
(DCM) and trifluoroacetic acid (TFA) were purchased from AGTC Bioproducts Ltd. 
Triisopropylsilane (TIPS), xylenol orange sodium salt, and trifluoroacetic acid (TFA) were 
purchased from Acros Organics. Diethyl ether, acetic anhydride, acetic acid, GdCl3·6H2O and 
TbCl3·6H2O were obtained from Sigma Aldrich. Urea (>99% purity), guanadinium 
hydrochloride, glacial acetic acid, HPLC grade water and acetonitrile, sodium hydroxide, 
sodium chloride, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), glacial 
acetic acid and ethylenediaminetetraacetic acid (EDTA) were purchased from Fisher Scientific 
Ltd. D2O (99.9% purity) was purchased from VWR. All water except that used for HPLC was 
ultrapure grade obtained from a Millipore Elix-Gradient A10 system. 
8.2 Peptide Synthesis and Purification 
All peptides reported were synthesised on a CEM Liberty Blue automated peptide 
synthesiser on a 0.25 mmol scale using a rink amide MBHA resin (0.368 g, 0.68 meqg-1) using 
standard Fmoc-amino acid solid-phase synthesis protocols.99  
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An inert N2 atmosphere was used for all automated synthesis and DMF was used as 
the main solvent. All Fmoc amino acids (0.2 M) used in the automated synthesis were 
dissolved in DMF. 
The resin was swollen in DMF (10 ml) for 20 minutes before being loaded onto the 
synthesiser. Deprotection of Fmoc group from each amino acid was performed using 20% 
piperidine in DMF with 0.1 M HoBT. An initial deprotection step (10 mL, 60 W, 75˚C, 30 s) was 
followed by a main deprotection (10 mL, 60 W, 75˚C, 180 s). Coupling to the next Fmoc amino 
acid was achieved using 0.5 M HBTU in DMF (activator) and 2 M DIPEA (34.8 mL) in NMP 
(activator base), in a 1:5:5:10 molar ratio of resin : amino acid : activator : activator base, using 
standard microwave conditions.  
After each deprotection step, the reaction vessel was washed with DMF (3 x 5 min, 5 
sec drain time). After the first amino acid coupling the reaction vessel was washed with DMF 
(1 x 5 mL, 5 sec drain time). This was followed by (2 x 5 mL, 5 sec drain time) after the second 
coupling in addition to the two standard manifold washes (2 x 4 mL DMF, 5 sec drain time) 
A single coupling programme was used apart from for the final two heptads which 
were double coupled (30 W, 75˚C, 600 sec) and both of the terminal Glycine residues were 
double coupled using a 10 min coupling (30 W, 75˚C, 600 sec).  
After all couplings and the final N-terminal deprotection, the resin was washed and 
transferred to a 50 mL falcon tube and swollen in DMF (15 mL) for 20 mins. The resulting 
peptide was acetylated whilst still on the resin using 20% acetic anhydride (4 mL), 20% DIPEA 
(4 mL) in DMF (20 mL) for 30 minutes, whilst being stirred. The peptide on resin was washed 
with DCM (15 mL) and diethyl ether (15 mL) and air dried for one hour.  
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Cleavage occurred under a nitrogen atmosphere, with stirring, using a TFA cocktail 
which contained 2.5% TIPS (0.5 mL), 2.5% H2O (0.5 mL) and 95 % TFA (19 mL) for three hours. 
The resin was removed, filtered and washed with TFA (10 mL). The filtrate was reduced in 
volume (to approx. 10 mL) by blowing N2 over the solution and the peptide was precipitated 
out using a 10 times excess of cold diethyl ether and stored in the freezer for one hour. 
The crude peptide was collected by centrifugation (Eppendorf centrifuge 5702 with 
rotor A-4-38 and rotational speed of 4400 rpm, 10 minutes) and the diethyl ether removed. 
The peptide was dissolved in 50% water, 50% acetonitrile solution and filtered (33 mm with 
0.45 µm pore size).  
The crude peptides were purified by preparative reverse phase HPLC using a 
Phenomenex Synergi C18 column. A linear gradient from 20% to 70% MeCN (+ 0.05% TFA) and 
water (+ 0.05% TFA) over 40 minutes was used with a flow rate of 10 mL /min. Detection 
wavelengths of 210 nm and 280 nm were used.  
The pure peptide was reduced under vacuum and characterised using analytical RP-
HPLC with a Phenomenex Synergi C18 column (1.00 ml/min flow rate), and by MALDI-TOF 
mass spectrometry (MALDI Micro MX Mass Spectrometer) with a 0.04 M sinapinic acid matrix. 
Peptide yields were calculated to be between 12-25%. The peptide spectra are shown in the 
Appendix.  
8.3 Sample Preparation and Concentration Determination 
Stock solutions of GdCl3 and TbCl3 (1 mM) were freshly prepared in deionized water 
and their concentrations determined, in triplicate, using a xylenol orange and EDTA titration, 
as reported by Fedeli and co-workers.187  
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Peptide stock solutions were freshly prepared and concentrations determined in 
triplicate on a Shimadzu 1800 UV spectrometer. Spectra were recorded in single beam mode 
with a medium speed (slit width 1.0 nm, data interval 1.0 nm, scan range 420-260 nm) in a 1 
cm, 700 µl quartz cuvette. The stock concentration of peptide (~1 mg per 100 μL ultrapure 
water) was calculated using the tryptophan absorbance at 280 nm (ε280 = 5690 M-1cm-1). A 5 
μL aliquot of peptide stock was added to 695 μL of 6 M urea so that the peptide was fully 
unfolded. A blank containing 695 μL of 6 M urea and 5 μL ultrapure water was prepared as a 
baseline. All solutions were centrifuged (Eppendorf MiniSpin, 45˚ fixed-angle rotor F-45-12-
11, rotational speed of 13,400 rpm, 3 minutes) and left to equilibrate for 10 min before 
recording. The corrected absorbance was calculated by subtracting the baseline at 400 nm 
from the Trp peak at 280 nm. The concentration of peptide monomer was calculated using 
Equation 2.2  
LnCl3 concentrations were determined in triplicate using a xyenol orange indicator and 
EDTA titration with standard Ln3+ solutions, following a standard procedure reported by Fedeli 
and coworkers.187  
8.4 Circular Dichroism (CD) Spectroscopy 
CD spectra of 30 μM peptide monomer solutions were recorded in the absence and 
presence of 10 μM GdCl3, in 10 mM HEPES buffer pH 7.0, in a 1 mm path length, 300 μL, quartz 
cuvette on a Jasco J-715 spectropolarimeter. The optical chamber was purged and kept under 
inert N2 during the experiments. Scans were recorded from 300 – 200 nm with a 200 nm/min 
scan rate and a 1 nm bandwidth and 1 sec response. Baseline correction was applied for all 
samples. All samples were left to equilibrate for 10 minutes before recording.  
The observed ellipticity in millidegrees was converted into molar ellipticity, (Θ), which 
is reported in units of deg dmol-1 cm2. The percentage folding of the peptide sample was 
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calculated using the theoretical maximum ellipticity value of each peptide at 222 nm, based 
on previous methods.110 The values reported are based on an average of three repeats, and 
the standard deviations reported accordingly.  
The fraction folded, f, is related to the observed ellipticity, Θobs, molar ellipticity of the 
apo peptide, Θapo, and the molar ellipticity of the metallo peptide, Θmet at 222 nm, as given in 
Equation 8.1. 
Equation 8.1:    𝑓 =
Θ𝑜𝑏𝑠−Θ𝑎𝑝𝑜
Θ𝑚𝑒𝑡−Θ𝑎𝑝𝑜
 
Gd(III) titrations were performed on addition of aliquots of a 1 mM stock solution of 
GdCl3in HEPES buffer pH 7.0. Each sample was left to equilibrate for 10 minutes. The resulting 
data was fit using DynaFIT Software (Biokin Ltd, Massachusetts) to a 1/3 M+L 1/3(ML3) 
binding model, to determine the binding constant. Titrations were carried out in triplicate with 
the standard deviation error reported.  
Chemical unfolding data was recorded of a 30 μM peptide monomer solution in 10 mM 
HEPES buffer pH 7.0, in the absence and presence of 10 μM GdCl3, by monitoring the molar 
ellipticity at 222 nm as a function of increasing Gua-HCl concentration (from 0 to 7 M) in a 1 
mm pathlength quartz cuvette. The Gibbs free energy was calculated by fitting to a two-state 
equilibrium model, folded to three monomers, using a nonlinear least squares fitting. The 
script was adapted from previous work by Buer et al,188written in MATLAB, and shown in 
Appendix A10.  
Thermal unfolding spectra were collected using a Jasco Peltier Temperature accessory 
from 25 – 85 ˚C, using a temperature gradient of 0.7 ˚C min-1, in a 1 cm cuvette, monitoring 
the signal at 222 nm. 
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Thank you to Professor Hannon, School of Chemistry, University of Birmingham, for 
use of the instrument. 
8.5 Luminescence 
Luminescence spectra were recorded using a 1 cm path length quartz cuvette and an 
Edinburgh Instruments Fluorescence FLS90 system fitted with a 450 W Xenon arc lamp and a 
Hamamatsu R928 photomultiplier tube. The emission monochromator was fitted with two 
interchangeable gratings blazed at 500 nm and 1200 nm and the data was collected using F900 
spectrometer analysis software.  
30 μM peptide monomer solutions in 10 mM HEPES buffer pH 7.0 were analysed on 
the addition of aliquots of a 1 mM stock solution of TbCl3 in 10 mM HEPES buffer pH 7.0. 
Solutions were excited at 280 nm and emission scanned from 455-750 nm using a 455 nm long 
pass filters. Spectra were corrected for instrument response (grating/PMT) in all cases. The 
change in emission intensity was calculated by integrating the Tb(III) peak at 545 nm and 
normalizing it using the apo peptide spectrum. All experiments were repeated in triplicate to 
calculate an average and standard deviation error.  
Tb(III) luminescence titrations were analysed using Equation 8.2 where f is the 
normalised emission intensity, related to the observed emission intensity, I, emission intensity 
of the apo peptide, Ia, and the emission intensity of the metallo peptide, Im, integrated 
between 530-560 nm. 
Equation 8.2:    𝑓 =
𝐼−𝐼𝑎
𝐼𝑚−𝐼𝑎
 
A binding constant was determined using DynaFIT Software (Biokin Ltd, 
Massachusetts) and a 1/3 M + L3 1/3 (ML3) binding model. Titrations were carried out in 
triplicate with the standard deviation error reported.  
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Tb(III) lifetimes in D2O and H2O were experimentally determined for Tb(peptide)3 by 
analysing solutions of 10 μM TbCl3 and 100 μM MB1-1L in 10 mM HEPES buffer pH 7.0, using 
a μF flash lamp light source (50 Hz), collecting over a 10 ms range, with a lamp trigger delay of 
0.1 ms. Data was fit to mono-exponential decay kinetics using the Kaleidagraph software 
package and the Marquardt-Levenburg linear least squares algorithm, where I and I0 are the 
emission intensity at time t and t=0 and τ is the lifetime, as given in Equation 8.3. By using the 
observed lifetime, the number of coordinated water molecules can be calculated using the 
Horrocks-Sudnik equation, or the Parker-Beeby equation which allows for outer sphere water 
effects to be taken into account.116,162 Data was collected in triplicate with standard deviation 
errors given. 
Equation 8.3:    𝐼𝑡 =  𝐼0𝑒𝑥𝑝
(−𝑡/𝜏) 
Thank you to Professor Pikramenou, School of Chemistry, University of Birmingham, 
for use of the instrument. 
8.6 NMR Spectroscopy 
High field NMR relaxation data was collected using a Bruker DMX 300 spectrometer, 
with a 7 T vertical wide-bore superconducting magnet, which operates at a proton resonance 
frequency of 300.13 MHz, using a 25 mm 1H radio frequency (RF) coil. The 90˚ and 180˚ pulses 
were optimised for each sample (approximately 8 μs and 14 μs respectively). The 
spectrometer was controlled using a Linux workstation operating XWIN-NMR, version 3.5, and 
ParaVision version 3.0 software. An imaging method was used to collect T1 and T2 data with 
all experiments recorded at 293 ± 0.3 K. T1 and T2 maps of water protons in phantom samples 
(consisting of 6 x 3 mm NMR tubes positioned in a Teflon sample holder) were acquired using 
a Rapid Acquisition with Relaxation Enhancement (RARE) spin-echo imaging sequence. 
Horizontal images were acquired with a 10 mm slice thickness, using a 25 by 25 mm field of 
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view, 64 x 64 pixel matrix. A spectral width of 10,000 Hz, receiver gain of 45.2, repetition time 
of 15 s and an echo time of 2.2 ms were used with 2 signal averages. An excitation pulse and 
refocusing pulse of 512 μs were also used. T1 relaxation maps were produced from a series of 
33 spin echo images with varying T1 inversion recovery delays from 5 x10-3 - 11 s and RARE 
factor of 8. T2 relaxation maps were produced from 121 echo images with echo times from 10 
– 1280 ms and a RARE factor of 1. All experiments were collected in triplicate to calculate an 
average and standard deviation error. Experiments were analysed using Prospa Software 
(Magritek, Wellington, New Zealand) and  Kaleidagraph Software (Synergy Software, 
Pennsylvania, USA), where the relaxation time for each concentration was taken from the 
average value from the pixels within the sample.  The relaxivity for each sample was calculated 
from the gradient of a plot of r1 or r2 Vs GdCl3 concentration.  
Low field relaxivity data was collected at the University of Durham as part of a RSC 
sponsored collaboration. A Spinsolve Carbon benchtop NMR (Magritek, Wellington, New 
Zealand), fitted with a 1 T permanent magnet, and functioning at a proton resonance 
frequency of 43 MHz with a 5 mm RF coil was used. The data was collected using automated 
90˚ and 180˚ radio frequency pulses. T1 relaxation data was collected using two scans with a 
3.2 s acquisition time. A repetition time of 15 s was selected with a maximum inversion time 
of 10 s, with the experiment being made up of 21 data points. T2 relaxation data was collected 
using 4 scans with a 3.2 s acquisition time. An experiment repetition time of 7 s was used with 
a 2 ms echo time and a maximum total echo time of 2 s made up of 10 data points. All 
experiments were repeated in triplicate in order to calculate an average and standard 
deviation error. 
Metallo-peptide samples were made in a 1:2 Gd(III):trimer ratio, in 10 mM HEPES 
buffer pH 7.0, to ensure >99% complexation of Gd(III). Gd(peptide)3 solutions containing 2.5, 
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5, 7.5, 10, 15, 20, 30 and 40 μM GdCl3 and 2 equivalents of peptide trimer (0.5:1 GdCl3:peptide 
trimer), were prepared in 10 mM HEPES buffer pH 7.0. A measurement of each peptide 
concentration was repeated in triplicate in order to calculate an average and standard 
deviation error. 10 mM pH 7.0 HEPES and 0.1 mM GdCl3 in 10 mM HEPES pH 7.0 samples were 
used as controls.  
8.7 Molecular Dynamics Simulations  
All peptide models were built using Insight II (Biosym/MSI, San Diego California).97 The 
peptides were solvated using a TIP3P water solvent model with a water box 15 Å larger than 
the peptide in all directions. No counter ions were required as the metallo peptide is neutral. 
Minimisation and MD simulations were performed using AMBER v8.9189 with a ff03 force field. 
Gd(III) ions were input as spheres with a charge of +3 and Van der Waals parameters (MOD4 
RE format in Amber), radius = 1.7131 Å (radius) and well depth = 0.4598. The first step of the 
simulation involved a minimisation step where the peptide was subjected to 100,000 cycles 
of conjugate gradient minimisation. Secondly a 500 ps equilibrium step took place at 300 K, 
with constant volume and periodic boundary conditions. Data gathering ran for 20 ns at 300 
K, with constant volume and periodic boundary conditions, taking snapshots every 10 ps.  
MD simulations were initially analysed using Visual Molecular Dynamics software190 
and viewed using PyMol.191 Further analysis was completed using the Ptraj command in 
AMBER. This allowed for in depth analysis into individual water molecules, their distance from 
Gd(III) and their movements during the simulation. Analysis into water within the primary and 
secondary water spheres could also be conducted.  
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8.8 Cell Culture  
Toxicity experiments were performed as part of a collaboration with Dr De Cogan at 
the University of Birmingham Medical School.  
All cell culture techniques were performed under a sterile tissue culture hood (Gelaire 
BSB 4a laminar flow hood; Gelaire Pty Ltd, Australia). Cancer cell lines were cultured at 37˚C 
in a humidified CO2 incubator (MCO-17AIC; SANYO, Osaka, Japan (UK)) at 5% CO2. All solutions 
and equipment were bought sterile or sterilized by autoclave when required. 
HeLa carcinoma cells (PHE) (Purchased from Public Health England Culture Collections 
(PHECC), London UK) and human astrocytoma cells (human patient, University of Birmingham 
Medical School) were cultured at 37˚C in 5% (v/v) CO2 atmosphere in T75 culture flasks 
(Invitrogen, UK) containing Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Aldrich, UK) 
supplemented with 10% Fetal Bovine Serum (FBS) (Sigma Aldrich, UK) and 1% penicillin and 
streptomycin (Sigma Aldrich, UK). 
Adherent cells were grown to confluence and passaged using a standard trypsin-EDTA 
(0.25%:0.2%) protocol (Invitrogen, UK). This protocol consisted of removal of the cell culture 
media by aspiration, washing of the cell monolayer with PBS, removal of PBS and the addition 
of 1-2 mL trypsin into the container. The culture was then incubated for 2-5 mins at 37 celsius 
in 5% (v/v) CO2 until cells are rounded and in suspension. The trypsin reaction was halted by 
the addition of fresh media and cells were diluted as necessary for experiments. Suspension 
cells were maintained at 2x105 cells/mL and passaged by media splitting. 
 A 48 well plate was prepared using 10,000 cells per well (~100 μL), cell media (150 μL) 
containing DMEM supplemented with 10% FBS, 1% penicillin and 1% streptomycin, and 
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varying concentrations of apo and metallo MB1-1, as shown in Table 8.1. A blank and 0.03 mM 
GdCl3 control were also used. 
 After an incubation period of 24 hours, 3 days or 7 days, a 50 μL sample was taken 
from each cell and the number of cells calculated using a haemocytometer. By counting the 
number of cells in each well, a mean and standard deviation for each concentration could be 
calculated. This process was repeated at each time point. 
Table 8.1: Cell tray set up form MB1-1 cell culture experiments. 
BLANK 0.02 mM 
(MB1-1)3 
0.02 mM 
Gd(MB1-1)3 
0.04 mM 
(MB1-1)3 
0.04 mM 
Gd(MB1-1)3 
0.06 mM 
(MB1-1)3 
0.06 mM 
Gd(MB1-1)3 
0.03 mM 
GdCl3 
BLANK 0.02 mM 
Apo 
0.02 mM 
Metallo 
0.04 mM 
Apo 
0.04 mM 
Metallo 
0.06 mM 
Apo 
0.06 mM 
Metallo 
0.03 mM 
Gd(III) 
BLANK 0.02 mM 
Apo 
0.02 mM 
Metallo 
0.04 mM 
Apo 
0.04 mM 
Metallo 
0.06 mM 
Apo 
0.06 mM 
Metallo 
0.03 mM 
Gd(III) 
BLANK 0.02 mM 
Apo 
0.02 mM 
Metallo 
0.04 mM 
Apo 
0.04 mM 
Metallo 
0.06 mM 
Apo 
0.06 mM 
Metallo 
0.03 mM 
Gd(III) 
BLANK 0.02 mM 
Apo 
0.02 mM 
Metallo 
0.04 mM 
Apo 
0.04 mM 
Metallo 
0.06 mM 
Apo 
0.06 mM 
Metallo 
0.03 mM 
Gd(III) 
BLANK 0.02 mM 
Apo 
0.02 mM 
Metallo 
0.04 mM 
Apo 
0.04 mM 
Metallo 
0.06 mM 
Apo 
0.06 mM 
Metallo 
0.03 mM 
Gd(III) 
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Table A1: Molecular weights of each peptide and MALDI (M+H)+ Ion Mass 
Peptide 
Name 
Sequence Molecular Weight 
(Calculated) 
Observed MALDI 
(M+H)+ Ion Mass 
MB1-1S Ac – G – IAANEWK DAAIEQK 
IAAIEQK IAAIEQK – G – NH2 
 
3250 3250 
MB1-1 Ac – G – IAANEWK DAAIEQK 
IAAIEQK IAAIEQK IAAIEQK – G – 
NH2 
4004 4005 
MB1-1L Ac – G – IAANEWK DAAIEQK 
IAAIEQK IAAIEQK IAAIEQK 
IAAIEQK – G – NH2 
4758 4755 
MB1-2 Ac – G – IAAIEQK IAANEWK 
DAAIEQK IAAIEQK IAAIEQK – G 
– NH2 
4004 4005 
Mo1-2 Ac – G – IKAIEEK IKENEWK 
DKAIEEK IKAIEEK IKAIEEK – G – 
NH2 
4351 4352 
SN1-2 Ac – G – IAAIEQK XAANEWK 
DAAIEQK IAAIEQK IAAIEQK – G 
– NH2 (X = D-Ile) 
4004 4003 
SN1-3L Ac – G – IAAIEQK IAAIEQK 
XAANEWK DAAIEQK IAAIEQK 
IAAIEQK – G – NH2 (X = D-Ile) 
4758 4758 
MB1-3L Ac – G – IAAIEQK IAAIEQK 
IAANEWK DAAIEQK IAAIEQK 
IAAIEQK – G – NH2 
4758 4759 
 
Impurities of higher mass than the peptide (M+H)+ peak are thought to be due to salt adducts.  
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Appendix A10: MATLAB Script for Relaxivity Calculations 
% This code is to determine r1 using a range of MRI constants and variables 
% You can change the variables below to make the calculation specific for your CA 
% This can be used for inner-sphere or secondary sphere calculations by changing r6 
 
%% Variables 
% q = number of coordinated waters 
q = 3; 
% H2O = concentration of water (Constant) 
H2O = 55.6; 
% m = water residence time 
tm = 1.56E-09;  
%u = permittivity of vacuum (Constant) 
u = 8.854e-21; 
%YH = magnetogyric ratio 
YH = 2.678e8;  
%g = g-factor 
g = 2; 
% uB = Bohr magneton (Constant) 
uB = 9.274e-21;  
% s = spin quantum number 
s = 7/2; 
%r6 = ion-proton distance 
r = 2.6e-9;  
%WH = Larmor frequency of proton 
WH = 2.98e8;  
%tR = rotational correlation time  
tR = 6.8e-9; %MB1-1S 
%tR = 8.4e-9; %MB1-1 
%tR = 10e-9; %MB1-1L 
 
%% Calculation  
%tC = total rotational correlation time 
tC = 1./ (1/tR + 1./tm); 
 
T1m = 1./ ((2/15)*(u/(4*pi)).*((YH^2 * g^2 * uB^2 * s*(s+1))/(r^6)).* ((3.*tC)/(1+ WH^2 .* tC.^2)));   
 
%R1 = (q ./ H2O) ./ (T1m + tm); 
 
%r1 = R1 / 1000 
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Appendix A11: MATLAB Script for Calculating ΔG 
% This code is to determine deltaG using Gua-HCl unfolding data.  
% This code will produce a curve of the data and fit the data to give a curve and a value for deltaG 
 
%% Change these parameters 
n = 3; % monomer to n-mer folding 
P = 30e-6; % free monomer concentration in M 
T0 = 298.15; % temperature in K 
 
% Save data in two columns (Concentration of Gua-HCl, Ellipticity) 
 
%% 
R = 8.3145; % Ideal gas constant  
data = [Gua-HCl, Ellipticity] 
%data = uiimport; 
%data = data.data; 
Den = data (:,1); 
Theta_Obsd = data(:,2);  
 
K = @(b, Den) exp(-(b(1).*ones(length(Den),1)-b(2).*Den)./(R*T0));  
 
U = @(b, Den) arrayfun(@(k) fzero(@(x) n*x^n+k*x-k*P, [0 P]), K(b, Den)); 
 
f = @(b, Den) (b(3).*ones(length(Den),1)+b(5).*Den).*U(b, Den)./P + 
(b(4).*ones(length(Den),1)+b(6).*Den).*(P.*ones(length(Den),1)-U(b,Den))./P; 
 
%%Initial Values Module 
beta0 = zeros(6,1); 
beta0(3) = max(Theta_Obsd)+1; 
beta0(4) = min(Theta_Obsd)-1; 
Utest = P.*(Theta_Obsd - (beta0(4).*ones(length(Theta_Obsd),1)))./(beta0(3)-beta0(4)); 
Ktest = n.*(Utest).^n./(P.*ones(length(Utest),1)-Utest); 
DGtest = -R.*T0.*log(Ktest); 
 
TestMat = ones(length(DGtest),2); 
for i = 1:length(DGtest) 
    TestMat(i,1) = 1; 
    TestMat(i,2) = -Den(i); 
end 
 
ParaEst = linsolve(TestMat,DGtest); 
beta0(1) = ParaEst(1); 
beta0(2) = ParaEst(2); 
 
[beta, r, J, COVB, mse, emi] = nlinfit(Den, Theta_Obsd, f, beta0);  
 
% ci = nlparco(beta,r,'covar',COVB); 
ci = nlparci(beta,r,'covar',COVB); 
 
 
